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Abstract 
 
Transhydrogenase is an enzyme located in the cytoplasmic membrane of bacteria or 
the inner membrane of animal mitochondria. Using the energy of the proton 
electrochemical gradient (∆p), transhydrogenase translocates protons across the 
membrane whilst undergoing its redox reaction, in which hydride ion equivalents are 
transferred from NADH to NADP
+
 producing NAD
+
 and NADPH. Transhydrogenase 
comprises three components; dI binds NAD(H), dIII binds NADP(H) and dII spans 
the membrane. Transhydrogenase is thought to function by way of a binding-change 
mechanism, which involves “open” and “occluded” conformations of the enzyme. In 
the open conformation, nucleotides can readily bind and dissociate from the enzyme 
but the hydride transfer reaction is blocked. In the occluded conformation, hydride 
transfer is permitted but the binding and release of nucleotides is blocked. Hydride 
transfer and proton translocation are coupled. The coupling is not well understood due 
to the lack of structural information about the membrane-spanning dII component. 
However, it is believed to involve conformational changes of the enzyme, particularly 
the dII and dIII components, resulting in the switch between the open and occluded 
conformations.  
Enzyme assays and tryptophan fluorescence experiments using apo-dIII in 
complex with dI revealed two features:  
Firstly, the binding of NADP(H) to dIII is very slow and is probably limited 
by the conversion from the occluded to the open conformation. Since the switch 
between the occluded and open conformations is thought to be central in the coupling 
  
of hydride transfer and proton translocation, the results presented here give an insight 
into the binding-change mechanism of transhydrogenase. 
Secondly, NAD(H) is able to slowly bind into the NADP(H)-binding site of 
dIII (the “wrong” site). This brought into question the specificity of the dIII 
component of transhydrogenase for NADP(H). The significance and likelihood of 
NAD(H) binding to dIII in the intact enzyme in the living cell are discussed.  
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CHAPTER 1 
 
Introduction 
2 
 
1.1 Preliminary comments. 
 
Transhydrogenase is a protein located in energy-transducing membranes; these 
include the cytoplasmic membrane of bacteria and the inner membrane of 
mitochondria. It is driven by the energy of the proton electrochemical gradient, ∆p, 
which is generated by the action of the respiratory chain. Transhydrogenase catalyses 
the reduction of NADP
+
 by NADH to produce NAD
+
 and NADPH (equation 1). 
During this hydride transfer reaction protons are translocated inwards across the 
membrane from the p-phase to the n-phase. One proton is translocated across the 
membrane per hydride transferred, i.e. the H
+
/H
-
 ratio is 1 (Bizouarn et al. 1996b). 
The reaction is reversible, although under most physiological conditions it is thought 
to operate in the forward direction (left to right). 
 
NADH  +  NADP
+
  +  H
+
p    NAD
+
  +  NADPH  +  H
+
n    equation 1 
 
H
+
n and H
+
p denote protons present in the n and p aqueous phases respectively. The 
n-phase represents the inside of the cell in bacteria or the matrix of mitochondria. The 
p-phase represents the outside of the cell in bacteria or the cytoplasmic side of the 
membrane in mitochondria. 
 In the presence of ∆p the rate of the forward reaction is increased 
approximately 10 fold. The equilibrium is also shifted towards  the formation of 
NADPH such that the mass action ratio in the presence of ∆p is 500 and in the 
absence of ∆p is 1 (Rydstrom et al. 1970). 
 
 
3 
 
1.2 An overview of respiratory and photosynthetic electron transfer. 
 
During metabolism, glucose is converted to pyruvate by glycolysis. The pyruvate then 
enters the tricarboxylic acid cycle producing NADH, which can donate reducing 
equivalents to the electron transport chain. The electron transport chain is located in 
an “energy-transducing membrane” (Figure 1.1).  
 
 
    
 
 
 
 
Figure 1.1 The chemiosmotic proton circuit. 
The electron transport chain pumps protons across the membrane building up a proton electrochemical 
gradient, ∆p. ATP-synthase and transhydrogenase use the energy of ∆p to drive their reactions. Whilst 
translocating protons across the membrane, ATP-synthase produces ATP from ADP and Pi, and 
transhydrogenase transfers a hydride ion from NADH to NADP+ producing NAD+ and NADPH. 
 
 
The electron transport chain comprises a set of proton pumping complexes such as the 
NADH dehydrogenase complex (complex I), the cytochrome bc1 complex (complex 
III) and the cytochrome oxidase complex (complex IV). Typically, the reduction of 
electron 
transport 
chain 
ATP-synthase transhydrogenase 
H
+ 
H
+ 
H
+ 
NADH + NADP
+ 
NAD
+
 + NADPH ADP + Pi
 
ATP
 
membrane
 
inside  
(n-phase)
 
outside 
(p-phase)
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complex I by NADH initiates electron transfer through the complexes to oxygen. 
During electron flow, protons are pumped across the membrane into the p-phase by 
complexes I and III creating a proton electrochemical gradient, ∆p. In photosynthetic 
bacteria, such as Rhodospirillum rubrum, a reaction centre uses light energy to drive 
cyclic electron transfer through a cytochrome bc1 complex and hence to pump protons 
across the membrane. 
ATP-synthase uses the energy of ∆p, to translocate protons back across the 
membrane to the n-phase and synthesise ATP from ADP and inorganic phosphate 
(Mitchell 1966). Transhydrogenase also translocates protons back across the 
membrane to the n-phase using the energy of ∆p to drive NADP+ reduction by 
NADH. 
 
1.3 The function of transhydrogenase. 
 
Transhydrogenase catalyses the hydride transfer reaction (shown by equation 1) 
involving the nicotinamide nucleotides NAD(H) and NADP(H). These two 
nucleotides play very different roles in metabolism; NAD(H) being mostly involved 
in catabolism and NADP(H) being mostly involved in anabolism. Since 
transhydrogenase involves both nucleotides, it is clear that the enzyme has a role in 
regulating the relative cellular concentrations of NAD(H) and NADP(H) (Kaplan 
1985). The crucial function of transhydrogenase may be to produce NADPH. NADPH 
is required by the cell for various processes and is an important molecule in 
anabolism. It is required for biosynthetic reactions in the cell (Hanson et al. 1980); 
examples of metabolic processes requiring NADPH are fatty acid and amino acid 
biosynthesis (Ambartsoumian et al. 1994). NADPH also plays an important role in 
protecting the cell against oxidative stress via the reduction of glutathione (Oshino et 
5 
 
al. 1977; Hoek et al. 1988; Arkblad 2005). The enzyme glutathione reductase uses the 
reducing power of NADPH to break a disulphide bond in oxidised glutathione 
(GSSG). The resulting reduced form of glutathione (GSH) is a cellular antioxidant 
and acts as a scavenger for reactive oxygen species (Hickman et al. 2002). 
Transhydrogenase is also believed to have a role in the regulation of the tricarboxylic 
acid cycle (Sazanov et al. 1994). 
Other enzymes, including those involved in the pentose phosphate pathway, 
are also involved in the production of NADPH, and can contribute to NADPH 
production for biosynthesis (Hanson et al. 1980). In Escherichia coli, 
transhydrogenase produces ~40% of the NADPH needed for biosynthesis (Sauer et al. 
2004). Deletion of the transhydrogenase gene from Caenorhabditis elegans did not 
lead to any effect on the life span of the organism (Pestov 2009). However, an 
increased sensitivity to oxidative stress was reported (Arkblad 2005).  
Experiments using mice lacking a functional transhydrogenase (Toye et al. 
2005; Freeman et al. 2006a; Freeman et al. 2006b) have showed increased glucose 
intolerance, and had impaired insulin secretion from their pancreatic β-cells in a 
glucose tolerance test compared to wild-type mice. Other evidence has shown that 
oxidative stress is a key factor in the progression of type-II diabetes (Kaneto et al. 
2005; Lowell et al. 2005).  
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1.4 The polypeptide arrangement and architecture of transhydrogenase from 
different species.  
 
Although the distribution of transhydrogenase is patchy among species (Jackson et al. 
2009), the size and architecture of the enzyme is species independent. However, the 
polypeptide arrangements differ between species (Figure 1.2).  
 
 
 
 
                
 
 
Figure 1.2 The polypeptide arrangement of transhydrogenase from different species.  
The number of polypeptides that comprise transhydrogenase varies between species. However, in each 
species there is a region that comprises the hydrophilic dI and dIII components (white) and the 
membrane-spanning dII component (blue).  
 
 
In mitochondria, transhydrogenase consists of a single polypeptide that is ~1000 
amino acid residues in length (Hojeberg et al. 1977; Anderson et al. 1978). Two of 
these polypeptides form the dimeric intact enzyme. There are two types of 
polypeptide arrangement in bacterial species. Transhydrogenase from E. coli consists 
PntAB PntB PntAA 
β α 
H. sapiens 
E. coli 
R. rubrum 
dI dII dIII 
En. histolytica 
linker peptide 
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of two polypeptides, α (502 residues) and β (462 residues) (Clarke et al. 1986). The 
intact enzyme consists of two α and two β polypeptides (α2β2). Transhydrogenase 
from Rhodospirillum rubrum consists of three polypeptides, PntAA (384 residues), 
PntAB (139 residues) and PntB (464 residues) (Williams et al. 1994; Yamaguchi et 
al. 1994). The PntB polypeptide is similar to the β polypeptide of E. coli. Again, the 
intact enzyme consists of 2 of each polypeptide ((PntAA)2(PntAB)2(PntB)2). 
Transhydrogenase, in some protozoan parasites, for example Entamoeba histolytica, 
exists as a single polypeptide with a different topology to that found in mammalian 
mitochondria. The N-terminus of the polypeptide corresponds to the N-terminus of 
PntB from bacteria. This is joined at the C-terminus to the equivalent of the PntA 
polypeptide by a 40-residue linker (Weston et al. 2001; Weston et al. 2002).  
Transhydrogenase has three structural components: dI, dII and dIII (Figure 
1.3). The dI component binds NADH, the dIII component binds NADP
+
 and the dII 
component spans the membrane and translocates protons across the membrane. 
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Figure 1.3 Cartoon of the architecture of the components of transhydrogenase.  
Despite different polypeptide arrangements, the architecture of transhydrogenase is similar for all 
species. The dII component (brown) spans the membrane and is involved in proton translocation, the dI 
component (blue) binds NAD(H) and the dIII component (green) binds NADP(H). The redox reactions 
associated with the dI and dIII components are shown. 
 
 
1.5 The chemical structure of the nicotinamide nucleotide substrates. 
 
The physiological substrates for transhydrogenase are NAD(H) and NADP(H). These 
nicotinamide nucleotides have five functional chemical groups; a nicotinamide ring, 
two ribose groups, an adenine ring and a pyrophosphate group (Figure 1.4). Although 
the groups themselves are essentially rigid, rotation of the bonds between the groups 
NADH 
dIII dIII 
dI dI 
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NAD+ 
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NADPH 
H+ 
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(p-phase)
 
9 
 
allows the nucleotides to adopt different conformations. When bound to proteins, the 
nucleotides adopt a conformation specified by the binding-site. 
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Figure 1.4 The chemical structure of nicotinamide nucleotides. 
NAD(H) and NADP(H) are the physiological nucleotides for the dI and dIII components of 
transhydrogenase, respectively. They comprise 5 different moieties, the nicotinamide ring, the adenine 
ring, two ribose groups and a pyrophosphate group. NAD(H) and NADP(H) differ by a group at the C2 
position of the adenine ribose (R). This group is a hydroxyl for NAD(H) and a phosphate for 
NADP(H). This figure was produced using ACD/ChemSketch freeware. 
 
 
 
 
nicotinamide adenine 
pyrophosphate ribose ribose 
R = H in NAD+  
 
R = PO3 in NADP
+ 
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1.6 The stereospecificity of the hydride transfer reaction of transhydrogenase. 
 
Hydride transfer between NADH and NADP
+
 occurs between the C4 carbon atoms of 
the respective dihydronicotinamide and nicotinamide rings
 
(Figure 1.5). The 
nicotinamide group of the oxidised form of the nucleotides holds a positive charge, 
whereas the reduced form does not. The reduced form has two pro-chiral hydrogen 
atoms at position C4. The positions of these hydrogen atoms are termed pro-R or 
pro-S depending on whether they are on the re face or the si face of the nicotinamide 
ring, respectively. During the hydride transfer reaction, a hydride ion can be 
transferred from either the pro-R or pro-S position. The hydride ion transferred is 
dictated by the binding-site of the enzyme. Usually, an enzyme binds the nucleotide in 
a particular orientation, either a syn or an anti conformation. These nucleotide 
conformations differ by a 180° rotation around the glycosidic bond between the 
nicotinamide ring and the adjacent ribose. Most enzymes that bind the nucleotide in 
the anti conformation will transfer the hydride ion in the pro-R position; these are 
grouped as A-specific enzymes. Similarly, most enzymes that bind the nucleotide in 
the syn conformation will transfer the hydride ion in the pro-S position; these are B-
specific enzymes (Nambiar et al. 1983; Garcia et al. 1995). 
The hydride transfer reaction of transhydrogenase is stereospecific, such that 
the hydride ion is transferred from the C4 pro-R position of the NADH 
dihydronicotinamide ring to the C4 pro-S position of the NADP
+ 
nicotinamide ring 
(Lee et al. 1965). 
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Figure 1.5 The stereospecificity of the hydride transfer reaction. 
The forward hydride transfer reaction of transhydrogenase is stereospecific such that the pro-R hydride 
ion at position C4 of NADH is transferred to the C4 pro-S position of NADP+. Shown, is the 
nicotinamide group of NADH and its conversion to NAD+ during hydride transfer. The 
dihydronicotinamide ring of NADH is uncharged, whereas the nicotinamide ring of NAD+ carries a net 
positive charge. This figure was produced using ACD/ChemSketch freeware. 
 
 
1.7 Isolated recombinant forms of the dI and dIII components. 
 
Recombinant dI and dIII from various species have been isolated and purified as 
soluble proteins (Diggle et al. 1995b; Diggle et al. 1996; Fjellstrom et al. 1997; 
Yamaguchi et al. 1997). The dI component of transhydrogenase contains the 
NAD
+
/NADH binding site and, when isolated, exists as a dimer (Diggle et al. 1995b; 
Venning et al. 2001). The molecular weight of a dI monomer from R. rubrum is 
~40 KDa (Venning et al. 1997). In transhydrogenase from R. rubrum, the dI 
component is a separate polypeptide. In chromatophores, dI can be washed away fully 
inactivating the enzyme (Cunningham et al. 1992; Williams et al. 1994). When 
+H- 
Pro-S Pro-R 
-H- 
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recombinant isolated dI is added to the chromatophores (now dI depleted), full 
activity is restored (Diggle et al. 1995b). This shows that recombinant dI retains full 
activity. The binding affinity of dI (from both R. rubrum and E. coli) for NAD(H) is 
similar in the isolated form of the protein and in the intact enzyme (Kd for 
NADH ≈ 20 µM; Kd for NAD
+
 ≈ 300 µM) (Diggle et al. 1995a; Diggle et al. 1995b; 
Bizouarn et al. 1996a; Venning et al. 2001; Bizouarn et al. 2005).  
 In all species, the dIII component is present on the same polypeptide as at least 
part of dII. Therefore, to isolate dIII from R. rubrum, a plasmid was engineered where 
a start codon was inserted at the beginning of the dIII gene (Williams et al. 1994; 
Diggle et al. 1996). The molecular weight of a dIII monomer is ~21 KDa (Venning et 
al. 1997). Isolated dIII binds NADP(H) extremely tightly compared to the intact 
enzyme, and is believed to be locked predominantly in an occluded conformation, 
from which nucleotides dissociate extremely slowly. Throughout purification in the 
absence of added NADP(H), dIII remains almost fully occupied (Diggle et al. 1996). 
However, the protocol for the purification of isolated dIII used in this work included 
4 µM NADP
+
 in all buffers to ensure full occupancy of the protein. Since nucleotide 
binding to isolated dIII is so tight, measuring binding affinities for NADP(H) has been 
extremely difficult. However, first-order rate constants for NADP
+
 and NADPH 
release were measured using two independent methods. Values were 0.018 s
-1
 and 
0.03 s
-1
 for NADP
+
 release and 0.00045 s
-1 
and 0.0006 s
-1
 for NADPH release (Diggle 
et al. 1996; Rodrigues et al. 2001). Within error, these results are in agreement and 
show that isolated dIII binds NADPH with a higher affinity than NADP
+
. 
 When isolated dI and dIII are mixed they spontaneously form a complex 
comprising a dI dimer and a dIII monomer (dI2dIII). The dI dimer and the dIII 
component are tightly bound with a Kd of ≤60 nM (Venning et al. 2001). This dI2dIII 
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complex is catalytically active; it can catalyse hydride transfer without proton 
translocation (Yamaguchi et al. 1995; Diggle et al. 1996). This proves that hydride 
transfer involves only the dI and dIII components and not the membrane-spanning dII 
component. The dIII component, in dI2dIII complexes, is predominantly locked in its 
occluded conformation and binds NADP(H) with an even higher affinity (~5 fold) 
than isolated dIII (Venning et al. 2001). In the complexes, the two dI components 
have different binding affinities for NAD(H). The first dI component binds NADH 
with a similar affinity as isolated dI and the other binds NADH much more weakly 
with a Kd of ~300 µM (Venning et al. 2001). The dI component with the weaker 
affinity for NADH is associated with the single dIII component. 
 There is more information on the structure of transhydrogenase from R. 
rubrum than on the enzyme from other species. Due to its polypeptide arrangement 
(see Figure 1.2), R. rubrum transhydrogenase can be separated into a soluble fraction 
and an insoluble fraction (Fisher et al. 1971); this makes it a useful experimental 
system. The dI2dIII complex formed from reconstituted isolated R. rubrum dI2 and 
dIII, is tightly bound with a Kd of ≤60 nM (Venning et al. 2001). The reconstitution of 
isolated E. coli dI2 and dIII also form a dI2dIII complex. However, the binding is 
much weaker (Fjellstrom et al. 1999b). Experiments showed that hybrid complexes of 
E. coli dIII and R. rubrum dI associate more tightly than do complexes of E. coli dIII 
and E. coli dI, and that their catalytic properties are similar to those of the R. rubrum 
heterotrimer. Thus, E. coli dIII is often used in complex with R. rubrum dI 
experimentally (for examples see Fjellstrom et al. 1999a; Bergkvist et al. 2000; 
Pedersen et al. 2003). The dI component from R. rubrum also makes catalytically 
active, stable complexes with dIII from Homo sapiens (Peake et al. 1999b), Bos 
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taurus (Yamaguchi et al. 1995), En. histolytica (Weston et al. 2002) and 
Mycobacterium tuberculosis (Wilson et al. 2006). 
 
1.8 In vitro reactions catalysed by the R. rubrum dI2dIII complex of 
transhydrogenase. 
 
In the living cell, transhydrogenase catalyses a forward reaction (equation 1 from left 
to right) and a reverse reaction (equation 1 from right to left); these are the reduction 
of NADP
+
 by NADH and the reduction of NAD
+
 by NADPH, respectively. These two 
reactions are coupled to proton translocation across the membrane through dII. In 
vitro, dI2dIII complexes, formed when isolated dI and dIII are reconstituted, catalyse 
the forward and reverse reactions without proton translocation. These reactions do not 
result in a net absorbance change because the maximum absorption wavelength is 
similar for both NADPH and NADH (340 nm). Thus, the forward and reverse 
reactions catalysed by dI2dIII complexes are routinely measured using nucleotide 
analogues with distinct maximum absorption wavelengths. A commonly used NADP
+
 
analogue is thio-nicotinamide dinucleotide phosphate (thio-NADP
+
), which in its 
reduced form has a maximum absorption wavelength of 395 nm. A useful analogue of 
NAD
+
 or NADH is 3-acetylpyridine adenine dinucleotide (AcPdAD
+
 in its oxidised 
form and AcPdADH in its reduced form), which in its reduced form has a maximum 
absorption wavelength of 375 nm. In vitro, dI2dIII complexes also catalyse an 
unphysiological “cyclic” reaction; in which nucleotide analogues are also used. 
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1.8.1 The forward reaction catalysed by R. rubrum dI2dIII complexes. 
 
The forward transhydrogenation reaction is routinely measured as either the reduction 
of thio-NADP
+
 by NADH or the reduction of NADP
+
 by AcPdADH. In the latter 
reaction, the on-enzyme rate of AcPdADH oxidation was identical to the rate of 
NADP
+
 reduction, showing that the reaction is direct and does not involve reduced-
enzyme intermediates (Venning et al. 1999). In the experiments of Venning et al., 
upon rapid mixing under stopped-flow conditions, dI and dIII quickly bound to form 
dI2dIII complexes. NADP
+
 was already bound to dIII, and AcPdADH bound rapidly 
to dI after mixing. An initial rapid single turnover burst was observed, which was due 
to hydride transfer producing NADPH bound to dIII and AcPdAD
+
 bound to dI. After 
this initial single turnover burst, the reaction proceeded at an extremely slow steady-
state rate. This is because the product NADPH dissociates very slowly from dIII in 
dI2dIII complexes before fresh NADP
+
 can bind. Thus NADPH release from dIII is 
the rate limiting step of the steady-state reaction.  
 
1.8.2 The reverse reaction catalysed by R. rubrum dI2dIII complexes. 
 
The reverse reaction is routinely measured as the reduction of AcPdAD
+
 by NADPH. 
The on-enzyme rate of AcPdAD
+
 reduction was shown to be identical to the rate of 
NADPH oxidation in this reaction. Again, this shows that the reaction is direct and 
involves no reduced-enzyme intermediates (Venning et al. 1997). In the experiments 
of Venning et al., under stopped-flow conditions dI and dIII were mixed and quickly 
bound to form dI2dIII complexes. The isolated dIII was pre-treated such that it was 
fully occupied by NADPH, and after mixing, AcPdAD
+
 rapidly bound to dI. This 
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resulted in a rapid single turnover burst of hydride transfer between the bound 
nucleotides producing NADP
+
 bound to dIII and AcPdADH bound to dI. Following 
the initial burst, the reaction proceeded at an extremely slow steady-state rate. This is 
because after the first round of hydride transfer, NADP
+
 slowly dissociates from dIII 
in dI2dIII complexes before fresh NADPH can bind. Thus, NADP
+
 release is the rate 
limiting step of the steady-state reaction. 
 
1.8.3 The cyclic reaction catalysed by R. rubrum dI2dIII complexes. 
 
Although the cyclic reaction is a wholly unphysiological reaction, it is a useful system 
for studies on the transhydrogenase mechanism. The reaction is defined as the 
combined reduction of NADP
+
 by NADH and oxidation of NADPH by AcPdAD
+
, 
when both take place without either the NADP
+
 or the NADPH dissociating from the 
enzyme (Whitehead et al. 2009) (Figure 1.6). The net reaction is the reduction of 
AcPdAD
+
 by NADH, and is not accompanied by proton translocation through dII 
(Hutton et al. 1994; Bizouarn et al. 1997). The rate of the cyclic reaction in dI2dIII 
complexes proceeds at least 1000 fold faster than the steady-state rates of the forward 
and reverse reactions (the rate of the cyclic reaction is typically ~2710 mol AcPdAD
+
 
reduced mol
-1
 dIII min
-1
). This is because the very slow dissociation of NADP
+
 and 
NADPH from the protein is not necessary for cyclic reaction turnover; NADP(H) 
remains tightly bound to dIII throughout. In dI2dIII complexes, hydride transfer 
between bound nucleotides (Venning et al. 1997; Pinheiro et al. 2001), AcPdAD
+
 
binding and AcPdADH release, and NADH binding and NAD
+
 release to/from dI 
(Venning et al. 1999; Venning et al. 2000) are all fast processes. However, NADP(H) 
dissociation from dIII is very slow (Diggle et al. 1996; Fjellstrom et al. 1999b). This 
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results in very slow steady-state rates of the forward and reverse reactions and a rapid 
cyclic reaction in dI2dIII complexes. 
 
 
 
Figure 1.6 Scheme of the cyclic reaction. 
In this scheme, the dotted lines indicate interactions between dI and dIII, and between the protein 
components and bound nucleotides. The dashed arrows show the two hydride transfer steps in the 
cyclic reaction. Only one of the two dI subunits is depicted.  
               Overall, the cyclic reaction is defined as the combined reduction of NADP+ by NADH and 
oxidation of NADPH by AcPdAD+, without NADP+ or NADPH dissociating from the enzyme 
(Whitehead et al. 2009). When dI and dIII are mixed they spontaneously form a dI2dIII complex. 
Purified under conditions described in Section 2.2.2, dIII contains tightly bound NADP+. Once added, 
NADH rapidly binds to dI and reduces the NADP+ bound to dIII. The resulting NAD+ dissociates from 
dI whilst the NADPH remains tightly bound to dIII. AcPdAD+ then binds to dI and is reduced by the 
NADPH on dIII. The resulting AcPdADH dissociates from dI whilst NADP+ remains tightly bound to 
dIII. Another molecule of NADH binds to dI and the cycle is repeated.  
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In the intact enzyme, NADP(H) binding to, and release from, dIII are coupled 
to proton translocation through dII via long-distance conformational changes (see 
Jackson 2003) and are much faster (~1000 fold) than in dI2dIII complexes. This 
results in much faster rates of the forward and reverse reactions in the intact enzyme. 
In the presence of the membrane-spanning dII component, NADP(H) dissociation is 
much faster and is driven by ∆p. Depending on pH, the rates of the forward, reverse 
and cyclic reactions in the intact enzyme are similar (Bizouarn et al. 1997). 
During the cyclic reaction, hydride ion equivalents are transferred first from 
the C4 pro-R position of the dihydronicotinamide ring of NADH to the C4 pro-S 
position of the nicotinamide ring of NADP
+
, and then from the C4 pro-S position of 
the NADPH to the C4 pro-R position of AcPdAD
+
. Overall this leads to the 
experimentally observed hydride transfer from the C4 pro-R position of NADH to the  
C4 pro-R position of AcPdAD
+
 (Stilwell et al. 1997).  
 
1.9 The structure of the membrane-spanning dII component of 
transhydrogenase. 
 
Unfortunately, as yet no crystal structures of transhydrogenase have been solved that 
include the dII components. A high-resolution structure of the intact enzyme is 
extremely sought after; it will offer a better understanding of the role of dII in the 
coupling between proton translocation and hydride transfer. The dII component is 
central in the coupling mechanism. Other methods of structure determination, for 
example sequence analysis and cysteine labelling, have given some indication of the 
membrane topology of the dII component (Meuller et al. 1999; Studley et al. 1999). 
The dII component comprises 14 transmembrane helices in mammalian 
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transhydrogenase (Yamaguchi et al. 1988; Yamaguchi et al. 1991), 13 in E. coli 
transhydrogenase (Meuller et al. 1999) and 12 in R. Rubrum transhydrogenase 
(Yamaguchi et al. 1993; Jackson et al. 2002) (Figure 1.7). Transmembrane helices 1-4 
are associated with the α-subunit in E. coli dII, and the remaining nine are associated 
with the β-subunit. It is supposed that located within these helices is a channel, 
through which the proton is translocated.  
Mutagenesis experiments have identified residues in the dII component 
thought to be important for proton translocation (Hu et al. 1999; Bragg 2001; 
Yamaguchi et al. 2003; Whitehead et al. 2009). When the highly conserved residues 
βHis91, βSer139, βAsn222 and βGly252 (E. coli numbering) in dII were mutated in 
intact transhydrogenase from E. coli, the resulting mutant transhydrogenases behaved 
very similarly to dI2dIII complexes lacking the dII component (Bragg 2001; 
Yamaguchi et al. 2003). There was a loss of proton pumping ability, and the rate of 
the reverse reaction was significantly inhibited. Furthermore, the release of NADP(H) 
from the dIII component of the mutant protein was extremely slow. Thus, the 
mutations were concluded to lock dIII in its occluded conformation by blocking 
proton translocation. The residues βHis91, βSer139, βAsn222 and βGly252 are 
present on helices 9, 10, 13 and 14, respectively. Therefore, a model was proposed in 
which a helix bundle involving these four helices form the proton channel. The 
residues identified in these mutagenesis experiments are thought to form a hydrogen 
bonding network to enable the conductance of a proton through the channel.  
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Figure 1.7 Model for the transmembrane dII component of transhydrogenase. 
Taken from (Jackson et al. 2005). Transmembrane helices are numbered (H1-H14) according to 
mammalian transhydrogenase (Yamaguchi et al. 1988). The numbers on the rows underneath are of the 
N- and C-terminal residues of the transmembrane helices of E. coli transhydrogenase (Meuller et al. 
1999); helices H1-H4 are present in the α subunit and helices H6-H14 are present in the β subunit. 
Helices in black appear to be transmembrane in all species and helices in red do not. Residues in blue 
are invariant and residues in green are highly conserved. 
 
 
1.10 High-resolution structures of the hydrophilic components of 
transhydrogenase. 
 
The crystal structure of the intact enzyme has not yet been solved. However, the 
hydrophilic components of transhydrogenase, dI and dIII, can be isolated and high 
resolution structures are available of dI from E. coli (Johansson et al. 2005) and R. 
H1     H2     H3    H4      H5         H6     H7     H8     H9    H10  H11   H12   H13   H14 
403    424   452    478                     4       32      56      84     125    161    186    216    240 
421    445   472    498                    25      52      75     104    144    181    207    236    260 
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rubrum (Buckley et al. 2000; Prasad et al. 2002) and of dIII from R. rubrum (Jeeves 
et al. 2000; Sundaresan et al. 2003), B. taurus (Prasad et al. 1999) and  H. sapiens 
(White et al. 2000). When isolated dI and dIII are reconstituted, they form a dI2dIII 
complex. The crystal structure of this complex has been solved (Cotton et al. 2001; 
Mather et al. 2004; Bhakta et al. 2007) and its asymmetry described. For a more 
complete list of published crystal structures available for transhydrogenase, see Table 
6.1. 
 
1.10.1 The structure of the dI component of transhydrogenase. 
 
The crystal structure of dI has been solved bound to NADH, NAD
+
 or in its apo-
protein form (Buckley et al. 2000; Prasad et al. 2002; Johansson et al. 2005) (Figure 
1.8). As in solution, crystallised dI is dimeric. Each dI monomer comprises two 
domains, dI.1 and dI.2. Both domains comprise a Rossmann fold; that is a parallel, 
twisted six-stranded β-sheet flanked by α-helices and loops. This fold is typical for 
nicotinamide nucleotide-binding proteins (Rossmann et al. 1974; Eventoff et al. 
1975). The domains dI.1 and dI.2 are separated by a deep cleft containing the 
NAD(H)-binding site, and are connected by two long α-helices. There is also a β-
hairpin that protrudes from the dI.2 part of one monomer to the other. 
Crystal structures (Buckley et al. 2000; Prasad et al. 2002) and NMR 
experiments (Diggle et al. 1995a; Quirk et al. 1999) have shown the so-called mobile 
loop of dI that is thought to close over NAD(H) when bound. The mobile loop has 
been compared to loop E of dIII (see Section 1.10.2.2). It contains a tyrosine residue, 
Tyr235, in a G-Y-A motif that forms hydrogen bonds with an arginine residue, 
Arg127. This arginine residue interacts with the nicotinamide ring and the 
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pyrophosphate of NAD(H). This set of interactions is very similar to those in loop E 
of dIII involving the nucleotide NADP(H) and the residues Tyr171 and Arg90.   
The nicotinamide group of NAD(H) bound to dI can adopt either a “distal” or 
“proximal” position relative to the nicotinamide group of NADP(H) in dIII. There is a 
loop in dI called the “RQD-loop”; site-directed mutagenesis experiments have 
identified residues within this loop in R. rubrum dI that are thought to be important 
for stabilising the (dihydro)nicotinamide ring of NAD(H) in the proximal position for 
hydride transfer (van Boxel et al. 2003; Brondijk et al. 2006). The residue Gln132 
forms hydrogen bonds with the carboxamide group of the NAD(H) 
(dihydro)nicotinamide as well as the hydroxyl group of the NADP(H) ribose. This 
residue is thought to maintain the proximal position of NADH by acting as a 
molecular tether, holding the two nucleotides in a position that allows hydride transfer 
(van Boxel et al. 2003). Crystal structures show hydrogen bonding between the side 
chain of Arg127 and the residues Asp135 and Ser138. It is proposed that these 
hydrogen bonds and the movement of the Arg127 side chain stabilise the 
(dihydro)nicotinamide ring of the bound NAD(H) in a proximal position (Brondijk et 
al. 2006). The mutation of all four of these residues (Gln132, Arg127, Asp135 and 
Ser138) results in pronounced inhibition of hydride transfer. 
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Figure 1.8 Crystal structure of the dI component from R. rubrum transhydrogenase.  
When isolated in solution or crystallised, dI exists as a dimer. One monomer is shown in yellow and the 
other in blue. Each monomer comprises two domains, dI.1 and dI.2, which are separated by a cleft that 
houses the NAD+-binding site. This figure was produced in Pymol using PDB ID 1F8G. 
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1.10.2 The structure of the dIII component of transhydrogenase. 
 
Crystal structures (Prasad et al. 1999; White et al. 2000; Sundaresan et al. 2003; 
Mather et al. 2004) show that dIII comprises two βαβαβ motifs with the form and 
connectivity of a Rossmann fold. However, in transhydrogenase dIII the NADP(H) is 
bound in a “flipped” orientation compared to other NADP(H)-binding proteins, such 
that the adenosine group is positioned over the second βαβαβ motif and the 
nicotinamide group is positioned over the first. The dinucleotide binding site is 
located in a crevice formed by the βαβαβ motifs and is surrounded by loops including 
helix D/loop D and loop E (Figure 1.9).  
The loop between the first β-sheet and helix contains a GXGXXA fingerprint 
motif (where X is any amino acid) that interacts with the pyrophosphate group of 
NADP
+
. This feature is common to nicotinamide-binding proteins having a Rossmann 
fold (Bellamacina 1996) (see Section 1.12). NMR experiments, in which NADP
+
 was 
replaced by NADPH, showed chemical shift changes in the NADP(H)-binding site, 
helix D/loop D and loop E (Quirk et al. 1999). Helix D/loop D and loop E appear to 
be important structural elements of dIII, and probably contribute significantly to the 
mechanism of coupling to proton translocation in the intact enzyme. 
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Figure 1.9 Crystal structure of the dIII component from R. rubrum transhydrogenase.  
When isolated, dIII exists as a monomer (panel A). It is comprised of a parallel β-sheet (yellow) 
flanked by α-helices (red) and loops (green). The NADP+-binding site is located in a crevice formed by 
loops, including helix D/loop D (blue) and loop E (magenta). In crystal structures of R. rubrum dIII 
(Sundaresan et al. 2003) Loop D can be seen in either an “up” or a “down” position (panel B). This 
figure was produced in Pymol using PDB ID 1PNO. 
 
 
B. 
A. 
helix D/loop D 
Loop E 
Loop D down Loop D up 
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1.10.2.1 Helix D/loop D of dIII. 
 
Helix D/loop D interacts with the pyrophosphate group and the ribose rings of 
NADP(H) as well as loop E of dIII. In crystal structures of dIII from B. taurus and H. 
sapiens with bound NADP
+, helix D/loop D is in an “up” position and the si face of 
the nicotinamide ring is exposed to solvent. In the crystal structure of isolated dIII 
from R. rubrum, helix D/loop D is shown to undergo a conformational change 
(Sundaresan et al. 2003). This conformational change was independent of the redox 
state of the bound nucleotide. In both the NADP
+
-bound form and the NADPH-bound 
form helix D/loop D can be seen in either an “up” position or a “down” position 
(Figure 1.9B), suggesting that the mechanism of transhydrogenase involves four states 
with respect to helix D/loop D; NADP
+
-loop D up, NADP
+
-loop D down, NADPH-
loop D up, NADPH-loop D down. When helix D/loop D adopted the up position, the 
si face of the nicotinamide ring was exposed to the solvent. When down, helix D/loop 
D shielded the si face of the nicotinamide ring from the solvent and NADP(H) formed 
close interactions with conserved residues Ser144, Pro145 and Ile146. It should be 
noted that in all four states there was no conformational change of loop E and it 
remained in an occluded conformation. From these structures of R. rubrum dIII 
(Sundaresan et al. 2003), the authors concluded that helix D/loop D would block 
hydride transfer when in the “down” position. However, previous experiments and 
analysis of crystal structures suggest that helix D/loop D has a role involved with 
information transmission between dIII and dI by regulating the opening and closing of 
the dI cleft (Cotton et al. 2001; Jackson et al. 2002; Mather et al. 2004).  
The highly conserved residue, Asp132 of helix D/loop D interacts with both 
loop E of dIII and the RQD-loop of dI. Mutagenesis experiments of this residue 
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showed a significant decrease in affinity for NADP(H) as well as dI, and a loss of 
proton pumping ability (Meuller et al. 1996; Fjellstrom et al. 1999a). It was 
concluded that Asp132 was essential for catalytic and proton pumping activity, and is 
likely to contribute to the coupling of hydride transfer to proton translocation.  
 
1.10.2.2 Loop E of dIII. 
 
In all structures of isolated dIII (Prasad et al. 1999; White et al. 2000; Sundaresan et 
al. 2003; Mather et al. 2004), loop E is in an occluded conformation. When occluded, 
loop E acts as a “lid” and is closed over the bound nucleotide. Fluorescence resonance 
energy transfer experiments show that the loop E lid prevents the release of the 
nucleotide when occluded, and retracts to form the open conformation of the protein 
and allow nucleotide dissociation (Rodrigues et al. 2002). A structure showing the 
open conformation of loop E would be highly desirable to further understand the role 
of loop E in the coupling between hydride transfer and proton translocation.  
Loop E contains residues that are present in the NADP(H) binding site  and 
interact with NADP(H) when bound. Among these residues is a conserved G-Y-A 
motif, where Tyr171 interacts with the nicotinamide ring of NADP(H) and with the 
invariant residue Arg90. The mutagenesis of the equivalent of Tyr171 in E. coli dIII 
caused a significant decrease in the affinity for NADP(H) (Olausson et al. 1993; 
Johansson et al. 2002). Arg90 interacts with the nicotinamide ring and forms 
hydrogen bonds with the pyrophosphate of NADP(H). There is a similar set of 
interactions involving the mobile loop of dI and NAD(H) (see Section 1.10.1). 
Loop E of dIII also contains a highly conserved K-R-S motif. In R. rubrum 
transhydrogenase this motif consists of the residues Lys164, Arg165 and Ser166, 
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(Figure 1.10). Of this K-R-S motif, the peptide backbone and the three side-chains 
form seven hydrogen bonds with the 2’-phosphate group of NADP(H); the side-chain 
guanidinium of Arg165 also stacks with the adenosine ring of NADP(H) (Figure 
1.11). 
 
R. rubrum       153-DVEKAGTVLFIKRSMA-SGYAGVENE-177 
E. coli   413-EVWKAQNVIVFKRSMN-TGYAGVQNP-437 
H. sapiens       EVWKSKQVIVMKRSLG-VGYAAVDNP     
    B. taurus       EVWKSKQVIVMKRSLG-VGYAAVDNP 
 
 
Figure 1.10 Sequence of fragments from different species showing of the highly conserved K-R-S 
motif of loop E. 
The K-R-S motif is highlighted in grey. Transhydrogenase from R. rubrum and E. coli are numbered by 
different conventions; residue numbers are indicated. 
 
 
 
Figure legend over page 
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Figure 1.11 Hydrogen bonding interactions between the 2’-phosphate group of NADP(H) and the 
K-R-S motif of loop E.  
Crystal structure of R. rubrum wild-type dIII (PDB ID 1PNO) showing the K-R-S motif and its 
interactions with the 2’-phosphate of NADP(H). Hydrogen bonds are shown as dashed green lines. This 
figure was produced using Swiss-PDB Viewer and Povray. 
 
 
The residues of the K-R-S motif have been targeted in mutagenesis studies 
using dIII from E. coli (Fjellstrom et al. 1999a; Hu et al. 1999; Bergkvist et al. 2000). 
The equivalent arginine and lysine residues in E. coli transhydrogenase, βArg425 and 
βLys424, were mutated to cysteine residues (Bergkvist et al. 2000). The cyclic 
reaction was measured in dI2dIII complexes using mutated and wild-type dIII from E. 
coli reconstituted with wild-type dI from R. rubrum. Under the conditions used for the 
purification of dIII the wild-type protein had 92% occupancy with either NADP
+
 or 
NADPH bound in its binding site; 8% of the protein was in its apo-protein form. 
Under the same conditions, the βR425C mutant was present only in its apo-form. The 
rate of the cyclic reaction (AcPdAD
+
 reduction by NADH in the presence of NADP
+
) 
was 12% compared to that of wild-type dIII. The rate of the reverse reaction (the 
reduction of AcPdAD
+
 by NADPH) had an increased rate of 425% compared to that 
of wild-type dIII. Since NADP
+
 release from dIII is the rate limiting step of the 
reverse reaction, this result shows that the rate of NADP
+
 dissociation from βR425C 
in dI2dIII complexes is faster than from wild-type dIII in dI2dIII complexes. The 
NADP(H)-content determination and the enzyme assays are evidence that the βR425C 
mutant has a significantly weakened affinity for NADP(H) compared to wild-type 
dIII. The βK424C mutant also had a decreased NADP(H) content compared to wild-
type dIII, with 63% of it being in its apo-form. The rate of the cyclic reaction was 
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45% compared to that with wild-type dIII. The rate of the reverse reaction, as with the 
βR425C mutant, was 425% of that with wild-type dIII, showing that the βK424C 
mutant also had a weakened affinity for NADP(H). 
In mutagenesis studies of the intact enzyme with functional dII components 
from E. coli transhydrogenase, βLys424 and βArg425 were substituted with other 
residues (Hu et al. 1999). Mutants of these two residues (βK424R, βK424G, βR425K, 
βR425E, βR425G) showed significantly decreased rates of reverse and cyclic 
transhydrogenation. The apparent Km was estimated by measuring the rate of the 
cyclic reaction as a function of NADP
+
 and NADPH concentrations for the βK424R 
mutant, and was found to be >1000 fold higher than that of the wild-type protein. This 
led to the conclusion that the βK424R mutant had a significantly decreased affinity 
for NADP(H) compared to wild-type dIII.   
The enzyme human aldose reductase also has equivalent K-R-S residues 
(Lys262, Ser263, and Arg268) in its NADP(H)-binding site (Wilson et al. 1992; 
Harrison et al. 1994). Although the residues are not consecutive, there are similarities 
with transhydrogenase dIII since the lysine and serine residues form hydrogen bonds 
with the 2’-phosphate of NADP(H). Furthermore, the NADP(H)-binding site involves 
a “holding” loop that is closed over the bound NADPH. This loop is believed to 
undergo a conformational change to allow the release of the bound nucleotide, 
providing another parallel with nucleotide release from transhydrogenase. The R268A 
mutant of aldose reductase was produced and the crystal structure of the apo-protein 
was solved (Bohren et al. 2005). The mutation caused a significant decrease in 
affinity for NADP(H) and the holding loop was displaced to adopt a more open 
conformation compared to the wild-type NADPH-bound structure.  
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1.10.3 The structure of the asymmetric dI2dIII complex. 
 
When isolated dI and dIII are reconstituted, they spontaneously form a dI2dIII 
asymmetric complex, which lacks the second dIII component known to be present in 
the intact enzyme (Figure 1.12). This has been shown both in solution (Venning et al. 
2001) and in the crystalline state (Cotton et al. 2001; Mather et al. 2004; Bhakta et al. 
2007). Isolated dI forms a dimer in solution; both dI monomers are present in the 
asymmetric structure. The absence of the second dIII component is possibly due to 
isolated dIII being locked predominantly in an occluded conformation. 
Transhydrogenase is thought to have an alternating-site mechanism (see Figure 1.13), 
where, at any time, one side of the enzyme (i.e. one dI1dII1dIII1 monomer) is in an 
occluded conformation while the other side is in an open conformation.  For the 
second dIII monomer to bind to the dI2dIII complex, it would thus need to be in the 
open conformation. The production of isolated dIII in its open state has not yet been 
achieved. Modelling studies have shown that a second dIII component (in its isolated, 
occluded form) would not be able to bind to the dI2dIII complex due to side-chain 
clashing between the two dIII components (Cotton et al. 2001). However, NMR 
experiments have shown that dIII can bind to the dI2dIII complex, but with a very low 
affinity (Quirk et al. 1999). 
The first structure of the asymmetric complex to be solved (Cotton et al. 2001) 
was associated with the nucleotides NAD
+
 and NADP
+
. Good electron density was 
observed for NADP
+
 bound to the dIII component, but only for NAD
+
 in one of the dI 
monomers. The electron density of NAD
+
 for the dI monomer associated with dIII 
was very weak. Higher concentrations of NAD(H) were used in the crystallisation 
conditions and the structures were solved for both the NAD
+
/NADP
+
-bound and the 
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NADH/NADPH-bound complexes (Mather et al. 2004). In these structures, both dI 
components show electron density for bound NAD(H) as well as for the NADP(H) 
bound to dIII. They represent catalytically “dead-end” complexes, since both 
nucleotides were either in their oxidised or their reduced form. If crystallisation 
experiments had been performed with the dI2dIII complex and the physiological 
nucleotides, NADP
+
 and NADH, hydride transfer would have occurred. Attempts 
were made to crystallise the asymmetric complex allowing equilibrium to be reached 
by hydride transfer during crystallisation but with doubtful success (Sundaresan et al. 
2005). The unit cell in those experiments contained several undefined complexes, 
which had either NADH and NADPH bound (dead-end complexes) or indiscernible 
nucleotide content. Catalytically inactive nucleotide analogues 1, 4, 5, 6-
tetrahydronicotinamide adenine dinucleotide (H2NADH) and 1, 4, 5, 6-
tetrahydronicotinamide adenine dinucleotide phosphate (H2NADPH) were used to 
form complexes with one oxidised and one reduced nucleotide bound (Bhakta et al. 
2007). In the complex containing bound H2NADH and NADP
+
, the charge-
distribution on the nucleotides is similar to that with the physiological nucleotides 
(NADH and NADP
+
) bound. Thus, the complex was thought more closely to 
resemble the ground state of the intact enzyme than the earlier dead-end complexes. 
In the cyrstal structure of the dI2dIII complex with bound H2NADH and NADP
+
, 
H2NADH is bound to dI in a proximal position relative to the NADP
+
 on dIII. Located 
at the interface of dI and dIII, the hydride transfer site showed the 
dihydronicotinamide ring of the H2NADH and the nicotinamide ring of the NADP
+
 
aligned such that the C4 atoms were 3.4 Å apart and apposed to one another. When 
NADH was modelled into the structure replacing H2NADH, the pro-R hydrogen of 
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the C4 was in a position to transfer to the si face of NADP
+
. This is in agreement with 
the stereospecificity of hydride transfer in transhydrogenase described in Section 1.6. 
The folds of the individual components of the asymmetric complex (dIII and 
dI2) are very similar to those observed in the isolated proteins. Each dI component 
comprises two domains; dI.1 and dI.2. The dI.1 domains are located on the outside of 
the complex and the dI.2  domains form a rigid core. The dIII component is in its 
occluded conformation with loop E closed over the bound nucleotide. Helix D/loop D 
is in the up position; modelling of dIII with helix D/loop D in the down position 
resulted in steric clashing between helix D/loop D and the RQD-loop of dI 
(Sundaresan et al. 2003). This is consistent with the involvement of helix D/loop D in 
a mechanism to transmit conformational change information from dIII to dI.  
In the dI2dIII complex the dIII component makes extensive contacts with dI, 
mainly with the dI.2 domain. In the intact enzyme it is unlikely that dI interacts with 
the membrane-spanning dII components. Since nucleotide-binding to dIII is thought 
to be coupled to proton translocation, extensive contacts are expected between the dIII 
and dII components. 
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Figure 1.12 Crystal structure of the dI2dIII asymmetric complex of R. rubrum transhydrogenase.  
When reconstituted, dI and dIII form an asymmetric complex comprising two dI components (marine 
blue and yellow) and one dIII component (green). Loop E (magenta), helix D/loop D (deep blue), the 
expected positions of the two transmembrane dII components and the second dIII component are 
shown. This figure was produced using Pymol and PDB ID 2OO5. 
dI.1 
dI.2 
dII 
NADP+ 
NADH 
(analogue) 
dIII 
membrane 
inside 
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1.11 The binding-change alternating-site mechanism of transhydrogenase. 
 
During one turnover of the forward reaction of transhydrogenase (left to right in 
equation 1) one hydride ion is transferred from NADH to NADP
+
 whilst one proton is 
translocated across the membrane (Bizouarn et al. 1996b). Analysis of the forward, 
reverse and cyclic reactions and of the rates of NADP(H) binding and release in intact 
transhydrogenase and in dI2dIII complexes led to the proposal of a binding-change 
mechanism for transhydrogenase (Hutton et al. 1994). This predicts that dIII can 
adopt either an open conformation or an occluded conformation. The crystal structure 
of reconstituted dI and dIII showed that the dI2dIII complex is asymmetric (Cotton et 
al. 2001) indicating that, in the intact enzyme the two dI1dII1dIII1 monomers occupy 
different conformations, and that these alternate during turnover (Jackson et al. 2002). 
That is, at any time, one dI1dII1dIII1 monomer is in the occluded conformation and the 
other monomer is in the open conformation (Figure 1.13). It was proposed that, in the 
open conformation, the substrate nucleotides (NADH and NADP
+
) are able to bind to 
or dissociate from the enzyme but that hydride transfer is blocked. Once the substrates 
are bound, the enzyme switches to the occluded conformation. In the occluded 
conformation the binding and dissociation of nucleotides are prevented but the 
dihydronicotinamide ring of NADH and the nicotinamide ring of NADP
+
 are bought 
together permitting fast hydride transfer (kapp ≈ 21000 s
-1
 (Pinheiro et al. 2001)). The 
hydride transfer reaction is direct and does not involve reduced-enzyme intermediates 
(Venning et al. 1997; Venning et al. 1999). The dihydronicotinamide ring of NADH 
and the nicotinamide ring of NADP
+
 are highly reactive moieties (Van Eikeren et al. 
1977). Thus, it is essential to keep the two rings apart during nucleotide binding in the 
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open state. Otherwise, uncontrolled hydride transfer would occur uncoupled from 
proton translocation.  
 
 
 
 
 
 
Figure 1.13 Model for the alternating-site mechanism of transhydrogenase. 
Taken from (Jackson 2003). At any time, one side of transhydrogenase (i.e. one dI1dII1dIII1 monomer) 
will be in an open conformation while the other side is in an occluded conformation. In the open 
conformation the distance between the nicotinamide and dihydronicotinamide rings is too great for 
hydride transfer to occur. The two rings are brought together in the occluded conformation to permit 
hydride transfer. The switch between the open and occluded conformations is a result of a 
protonation/deprotonation event that is coupled to proton translocation through dII. 
 
 
For hydride transfer to occur, the enzyme must adopt an occluded state and 
bring together the dihydronicotinamide and nicotinamide rings of NADH and NADP
+
, 
respectively. Crystal structures of isolated dI (Buckley et al. 2000; Prasad et al. 2002; 
Johansson et al. 2005) indicated that the nicotinamide ring of the bound NAD(H) was 
able to move significant distances within the protein. Structures of the asymmetric 
dI2dIII complex (Cotton et al. 2001; Mather et al. 2004; Bhakta et al. 2007) confirm 
this and explain its significance. The NADH can adopt a distal position when bound 
protonation/deprotonation 
protonation/deprotonation 
open occluded occluded open 
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to dI, in which its dihydronicotinamide ring is 6.5 Å from the nicotinamide ring of 
NADP
+
 bound to dIII; the rings are too far apart for hydride transfer. The NADH can 
also adopt a proximal position in which the dihydronicotinamide ring is closer to the 
nicotinamide ring of NADP
+
 such that they are now a distance of 3.6 Å from each 
other. At this distance van der Waals contacts are formed and hydride transfer 
becomes possible. Analysis suggested that in the open conformation, the nicotinamide 
and dihydronicotinamide rings occupy the distal position, and in the occluded 
conformation they interconvert between the distal and proximal positions (van Boxel 
et al. 2003). 
The switch from the open to the occluded conformation, and thus hydride 
transfer, is coupled to proton translocation through the dII component. The interface 
between the two substrates, NADH and NADP
+
, where hydride transfer takes place is 
a distance of ~30 Å from the dII component. Thus, the coupling is likely to involve a 
long distance conformational change. NMR experiments have shown that this 
conformational change is likely to involve interactions between dII and helix D/loop 
D and loop E of the dIII component (Quirk et al. 1999; Jeeves et al. 2000) (see 
Section 1.10.2). It is an essential feature of the binding-change mechanism that the 
redox state of the nucleotide bound to dIII (i.e. NADP
+
 or NADPH) determines which 
side of the membrane-spanning dII component protons have access to. When NADP
+
 
is bound to dIII, protons in the p-phase (outside) are able to access the proton 
translocating machinery of dII, and when NADPH is bound to dIII, protons in the n-
phase (inside) are able access dII (Jackson et al. 2002). 
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1.12 The specificity of nicotinamide nucleotide-binding proteins. 
 
The nicotinamide nucleotides NAD(H) and NADP(H) differ only by a phosphate 
group on the 2’-hydroxyl group of the adenosine ribose (see Figure 1.4). However, the 
two nucleotides play very different roles in the cell. NAD
+
 usually serves as an 
oxidant during the reactions of catabolism (glycolysis, fatty acid oxidation and the 
tricarboxylic acid cycle). Conversely, NADPH is usually used as a reductant, in 
biosynthetic reactions or in glutathione reduction. That the two nucleotides are 
structurally similar yet play such different roles in the cell, means that proteins must 
have mechanisms to distinguish between them.  
 The specificity of nicotinamide nucleotide-binding proteins has been widely 
researched (reviewed in Wierenga et al. 1985; Baker et al. 1992; Bellamacina 1996; 
Carugo et al. 1997). A common fold for nicotinamide nucleotide-binding proteins is 
the Rossmann fold (Rossmann et al. 1974; Eventoff et al. 1975), in which βαβ motifs 
(numbers of strands and helices can differ) form a crevice that houses the nucleotide-
binding site. Common features of this fold have been identified as being important for 
the specific binding of either NAD(H) or NADP(H). In NAD(H)-binding proteins, at 
the C-terminal of the second β-strand, an aspartate or glutamate residue is often 
located that hydrogen bonds with the 2’-hydroxyl group of the adenosine ribose. The 
bulky 2’-phosphate group which replaces the 2’-hydroxyl group in NADP(H) cannot 
readily fit into this binding pocket. In NADP(H)-binding proteins there is often a 
cluster of positively charged residues that interact with the negatively charged 2’-
phosphate group of NADP(H). This cluster frequently includes an arginine residue 
that hydrogen bonds to the 2’-phosphate group and stacks with the adenine ring. The 
specificity of the NAD(H)-binding protein dihydrolipoamide dehydrogenase from E. 
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coli was changed to favour NADP(H)-binding (Bocanegra et al. 1993) by replacing a 
glutamate residue that hydrogen bonds to the 2’-hydroxyl of the adenine ribose group 
of NAD(H) in the wild-type enzyme with a valine, and introducing four positively 
charged residues (two arginines, a lysine and a histidine) into the binding site. The 
removal of the glutamate residue eliminated potential hydrogen bonds to the 2’-
hydroxyl group of the adenine ribose of NAD(H), and the introduced positively 
charged residues provided potential interactions with the 2’-phosphate group of 
NADP(H), thus switching the specificity of the enzyme from NAD(H) to NADP(H). 
Another feature seen in NAD(H)-binding proteins is a GXGXXG fingerprint 
motif (Wierenga et al. 1985), present in a loop located in the nucleotide-binding site 
between the first β-strand and α-helix of the βαβ motif. The first glycine residue of the 
GXGXXG motif is highly conserved and allows for a tight turn of the main chain. 
This turn positions the second glycine residue, whose small side chain is required for 
the close proximity of the pyrophosphate of the nucleotide with the amino acid 
residues that interact with it. The third glycine residue is required to provide the close 
interaction between the β-strands and the α-helix of the βαβ motif. In NADP(H)-
binding proteins this is often replaced by a GXGXXA fingerprint motif (Hanukoglu et 
al. 1989) and is thought to be significant for the specificity of nucleotide-binding 
proteins. Mutation of the alanine residue for a glycine residue in E. coli glutathione 
reductase resulted in a specificity switch from NADP(H) to NAD(H) (Scrutton et al. 
1990). 
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1.12.1 Structural description of the specificity of transhydrogenase. 
 
For transhydrogenase to function efficiently dI must be specific for NAD(H) and dIII 
must be specific for NADP(H).  
Crystal structures of the dI component of transhydrogenase (Buckley et al. 
2000; Prasad et al. 2002; Johansson et al. 2005) show features that have been 
identified as important for nucleotide specificity in NAD(H)-binding proteins. Firstly, 
the NAD(H)-binding site of dI includes a loop between the first β-strand and α-helix 
of the Rossmann fold which contains a highly conserved GXGXXG fingerprint motif 
that interacts with the pyrophosphate group of the nucleotide. An invariant aspartate 
residue, Asp202, is also present in the NAD(H)-binding site, which, in the crystal 
structures is shown to form hydrogen bonds with the 2’-hydroxyl group of the 
adenosine ribose of NAD(H). 
Crystal structures of the dIII component of transhydrogenase (Prasad et al. 
1999; White et al. 2000; Sundaresan et al. 2003) also revealed features identified as 
important for nucleotide specificity. Thus, the NADP(H)-binding site of dIII contains 
positively charged residues that interact with the 2’-phosphate group of NADP(H). 
These include a highly conserved K-R-S motif (Lys164, Arg165, Ser166), in which 
all three residues form hydrogen bonds with the 2’-phosphate group of NADP(H) and 
the guanidinium of Arg165 stacks with the adenine ring (see Figure 1.11). The dIII 
component also includes a loop between the first β-strand and α-helix of the 
Rossmann fold which contains a highly conserved GXGXXA fingerprint motif that 
interacts with the pyrophosphate group of the nucleotide. Since the NADP(H) bound 
to dIII has a flipped conformation compared to other NADP(H)-binding proteins, the 
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specificity of dIII for NADP(H) is probably predominantly due to the positively 
charged residues that interact with the 2’-phosphate group of NADP(H). 
 
1.12.2 Review of previous work that has brought into question the specificity of 
the dIII component for NADP(H). 
 
Previous work has caused the specificity of the dIII component of transhydrogenase to 
be questioned. In 1994 the cyclic reaction (the reduction of AcPdAD
+
 by NADH in 
the presence of NADP(H) (Figure 1.6)) was reported (Hutton et al. 1994). As well as 
this cyclic reaction, a low rate of AcPdAD
+
 reduction by NADH in intact E. coli 
transhydrogenase was noted in the absence of NADP(H). It was suggested that this 
was due to low levels of contaminating NADP(H) in the NADH and AcPdAD
+
 stock 
solutions.  
A higher rate of AcPdAD
+
 reduction by NADH in the absence of NADP(H) in 
intact E. coli transhydrogenase was reported (Bragg 1996). This was considered too 
high to be due to contaminating NADP(H). Bragg suggested that the rate of AcPdAD
+
 
reduction by NADH in the absence of NADP
+
 was due to AcPdAD
+
 binding in the 
NADP(H)-binding site on dIII, where it would be directly reduced by NADH bound 
to dI. In the presence of NADP
+
, the rate of AcPdAD
+
 reduction by NADH increased 
significantly. The promotion of the reaction by NADP
+
 was attributed to either the 
displacement of AcPdAD
+
 by NADP
+
, or to a second binding site on dIII, in which 
NADP
+
 would bind and induce a conformational change that favours the direct 
reduction of AcPdAD
+
 by NADH. 
Stilwell et al. also reported a low rate of AcPdAD
+
 reduction by NADH in the 
absence of NADP(H), again in intact E. coli transhydrogenase (Stilwell et al. 1997). 
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At pH 6.0, the rate was only a few per cent of that in the presence of NADP
+
. Effort 
was made to ensure that there was no contaminating NADP(H) in the stock solutions 
of NADH and AcPdAD
+
. The enzyme was also washed extensively in an attempt to 
remove all bound NADP(H). The conclusion drawn was that either NADP(H) 
remained tightly bound to dIII throughout the washes and was able to contribute to the 
reduction of AcPdAD
+
 by NADH or that NADH or AcPdAD
+
 bound in the 
NADP(H)-binding site. Zhang et al. (Zhang et al. 1997) also found, independently, 
that intact E. coli transhydrogenase catalyses the reduction of AcPdAD
+
 by NADH in 
the absence of NADP(H). They came to the same conclusion as Stilwell et al., that 
NADH or AcPdAD
+
 could be binding into the NADP(H)-binding site. The 
explanations put forward by both groups did not require a second binding site on dIII 
as had been suggested by Bragg (Bragg 1996). 
Crystal structures of transhydrogenase dIII were then solved (Prasad et al. 
1999; White et al. 2000; Sundaresan et al. 2003) and indicated only one nucleotide 
binding site rendering unlikely the explanation, put forward by Bragg, of two 
nucleotide-binding sites on dIII. 
In dI2dIII complexes, the cyclic reaction is mechanistically significant because 
of its high rate compared to the forward and reverse reactions. The forward and 
reverse reactions are limited by the very slow dissociation of NADP
+
 and NADPH 
from dIII. Within the definition of the cyclic reaction (proposed by Whitehead et al. 
2009), the alternate reduction of NADP
+
 by NADH and AcPdAD
+
 by NADPH take 
place while NADP
+
 and NADPH remain tightly bound in the dIII site. An interesting 
set of experiments was performed by Pedersen et al. (Pedersen et al. 2003), in which 
alkaline phosphatase was used to convert most of the NADP(H) in the dIII solution 
into NAD(H), thus eventually removing most of the NADP(H) (bound to dIII or 
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unbound). Experiments were conducted using hybrid dI2dIII complexes formed of 
reconstituted E. coli dIII and R. rubrum dI. Remarkably, complexes of dI2dIII 
containing phosphatase-treated apo-dIII catalysed AcPdAD
+
 reduction by NADH in 
the absence of NADP(H) with a rate of ~75% of that using NADP(H)-bound dIII. 
Addition of NADP
+
 to the assay buffer restored full cyclic activity to the phosphatase-
treated dIII. It was concluded that for the reaction to proceed, either NADH or 
AcPdAD
+
 must be binding into the NADP(H)-binding site on dIII (the “wrong” site) 
in an orientation that allows hydride transfer with either NADH or AcPdAD
+
 bound to 
dI.  
 
1.13 Objectives of this work. 
 
Since NADP(H) binds so tightly to isolated dIII and to dIII in dI2dIII complexes, it 
has been difficult to determine the nature of nucleotide binding to the protein. 
However, this work describes two separate techniques for the removal of bound 
NADP(H) and the production of apo-dIII. Firstly, the technique was adapted from 
Pedersen et al. (Pedersen et al. 2003) using alkaline phosphatase to cleave the 2’-
phosphate from NADP(H). Secondly, a mutant dIII was isolated in which the arginine 
residue from the highly conserved K-R-S motif in the NADP(H)-binding site was 
substituted by an alanine residue. This mutation eliminates hydrogen bonds between 
the 2’-phosphate of NADP(H) and the protein, and results in a significantly decreased 
nucleotide affinity. The production of apo-dIII has enabled us more thoroughly to 
investigate nucleotide-binding to dIII.  
 In light of the work presented here, we now have a better understanding of the 
nucleotide-binding properties of dIII in dI2dIII complexes. Studies on the kinetics of 
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nucleotide-binding show a very slow rate of nucleotide association with dIII and 
provide insight into the mechanism of intact transhydrogenase. NADH is found to 
bind into the NADP(H)-binding site of dIII with a surprisingly high affinity calling 
the nucleotide specificity of the enzyme into question. The metabolic significance of 
this is discussed. 
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CHAPTER 2 
 
Materials and Methods
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2.1 Over-expression of the dI and dIII components of transhydrogenase. 
 
2.1.1 LB (Luria-Bertani) medium. 
 
LB media was used for the growth of E. coli (except for the preparation of competent 
cells). It contained 10 g tryptone, 5 g yeast-extract and 10 g NaCl per litre at pH 7.0 
(Sambrook et al. 1989). Before use, the medium was sterilised by autoclaving at 
121˚C for 20 minutes. To prepare LB agar plates, 1.2 g bacterial agar was added per 
100 mL media before autoclaving. Ampicillin was added at a final concentration of 
100 µg mL
-1
 when required. The stock solution of ampicillin was sterilised by passage 
through a 0.45 µm syringe filter prior to use. After the plates had been poured they 
were either used immediately or stored at 4˚C.  
 
2.1.2 TYM medium. 
 
TYM medium was used during the preparation of competent E. coli cells. It contained 
20 g tryptone, 5 g yeast-extract, 1 g NaCl and 2.5 g MgSO4 per litre at pH 7.0. The 
medium was sterilised before use by autoclaving at 121˚C for 20 minutes.  To prepare 
TYM agar plates, 1.2 g bacterial agar was added per 100 mL media before 
autoclaving. The plates were poured and either used immediately or stored at 4˚C.   
 
2.1.3 Preparation of E. coli competent cells. 
 
Competent E. coli BL21(DE3) and E. coli C600 cells were prepared using the 
following method. The cells were grown on TYM agar overnight at 37˚C. A single 
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colony was used to inoculate a 5 mL culture of fresh TYM media and was grown in a 
shaking incubator overnight at 37˚C.  Following this, 200 µL was used to inoculate a 
100 mL culture of fresh TYM medium and was grown for ~3 hours, until the optical 
density reached between 0.5 and 0.9 at 650 nm measured on a Unicam Helios γ 
spectrophotometer. This culture was then incubated on ice for 5 minutes and the cells 
harvested by centrifugation at 10,000 g for 15 minutes at 4˚C. The cells were re-
suspended in 20 mL TfbI buffer (see below) and centrifuged again at 10,000 g for 
15 minutes at 4˚C. The collected cells were re-suspended in 4 mL TfbII buffer (see 
below) and kept on ice for 2 minutes. The cells were then dispensed into sterile 
Eppendorf tubes in 200 µL aliquots and snap frozen in liquid nitrogen. Finally, the 
cells were stored at -80˚C. 
 
TfbI buffer 
30 mM potassium acetate 
50 mM MnCl2 
100 mM RbCl 
10 mM CaCl2 
15% glycerol (v/v) 
The TfbI buffer was adjusted to pH 5.8 with HCl and sterilised by passage through a 
0.45 µm syringe filter prior to use. 
 
TfbII buffer 
10 mM MOPS 
10 mM RbCl 
75 mM CaCl2 
15% glycerol (v/v) 
The TfbII buffer was adjusted to pH 7.0 with KOH and sterilised by passage through 
a 0.45 µm syringe filter prior to use. 
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2.1.4 Site-directed mutagenesis of R. rubrum dI and dIII. 
 
The plasmids used in this work are listed in Table 2.1. 
 
pLH1 
The mutant plasmid pLH1 harbours a gene which encodes the R165A mutant of dIII 
from R. rubrum transhydrogenase. It was produced and sequenced by Yorkshire 
Bioscience Ltd. using an undisclosed method. 
 
pLH2  
The mutant plasmid pLH2 harbours a gene which encodes the E155W.R165A double 
mutant of the dIII component from R. rubrum transhydrogenase. It was produced 
using the Stratagene Quikchange kit following the manufacturer’s instructions. The 
template plasmid used was pLH1, (see above) at a concentration of approximately 
100 ng. The mutagenic primers were supplied by Alta Bioscience and had the 
following sequences: - 
Forward 5’ – CGATCCTTGACGTCTGGAAGGCCGGAACCGTGC – 3’ 
Reverse 5’ – GCACGGTTCCGGCCTTCCAGACGTCAAGGATGC – 3’ 
 
pLH4 
The mutant plasmid pLH4 harbours a gene which encodes the W72F mutant of the dI 
component of R. rubrum transhydrogenase. Again, it was produced using the 
Stratagene Quikchange kit following the manufacturer’s instructions. The template 
plasmid used was pCD1 (Diggle et al. 1995b) and the mutagenic primers were 
supplied by Alta Bioscience. They had the following nucleotide sequences: - 
 49 
 
Forward  5’ – CCAGGCCGATGTGGTCTTTAAGGTACAGCGCCCGATG – 3’ 
Reverse  5’ – CATCGGGCGCTGTACCTTAAAGACCACATCGGCCTGG – 3’. 
 
2.1.5 Purification and analysis of plasmids. 
 
Plasmids harbouring genes encoding wild-type and mutant recombinant proteins from 
R. rubrum transhydrogenase (see Table 2.1) were purified using a Qiagen QIAprep 
Spin Miniprep kit following the manufacturer’s instructions.  
 
plasmid protein encoded reference 
pNIC2 wild-type dIII (Diggle et al. 1996) 
pJDV1 dIII.E155W (Peake et al. 1999a) 
pLH1 dIII.R165A this work 
pLH2 dIII.E155W.R165A this work 
pLH3 truncated dIII.R165A this work (see Chapter 6) 
pCD1 wild-type dI (Diggle et al. 1995b) 
pLH4 dI.W72F this work 
 
Table 2.1 Table of plasmids used in this project. 
 
 
All plasmids were routinely checked by restriction-digest analysis following the 
manufacturer’s instructions (all restriction enzymes used were from New England 
Biolabs). In the plasmids pNIC2, pJDV1, pLH1 and pLH2, the dIII gene is harboured 
in the vector pET11c (Figure 2.1). The dIII gene is inserted in the pET11c vector 
between the BamHI restriction site (position 319) and the NdeI restriction site 
(position 359) such that the 3’ end of the forward strand of the dIII gene is located at 
the BamHI site and the 5’ end is located at the NdeI site.  
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Figure 2.1 Restriction map of the vector pET11c. 
The genes encoding wild-type dIII, dIII.E155W, dIII.R165A and dIII.E155W.R165A are harboured in 
the vector pET11c to produce the plasmids pNIC2, pJDV1, pLH1 and pLH2, respectively.  
 
 
The sequence of the dIII gene is shown in Figure 2.2. The mutation in pLH1 (to 
produce dIII.R165A) eliminated an AfeI restriction site from pNIC2 (see Table 2.1). 
Thus, pLH1 was selected by the loss of this site; the sequence of pLH1 was confirmed 
by DNA sequencing (Yorkshire Bioscience Ltd). To make the E155W mutation in 
dIII.R165A, the mutagenic primers were designed to introduce an AatII restriction site 
into pLH1. Thus, pLH2 was selected by the presence of this site; the fidelity of the 
PCR used in the mutagenesis was confirmed by DNA sequencing (Functional 
Genomics Laboratory at The University of Birmingham).  
In the plasmids pCD1 and pLH4, the dI gene was harboured in the vector 
pMS119.  To make the W72F mutation in wild-type dI, the mutagenic primer (see 
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previous section) was designed to eliminate an EagI restriction site from pCD1 (see 
Table 2.1). Thus, pLH4 was selected by the loss of this site; the fidelity of the PCR 
used in the mutagenesis was confirmed by sequencing (Functional Genomics 
Laboratory at The University of Birmingham). 
 
 
    1-CATATGAACCGCTCGATCTTCAACGTCATCCTGGGCGGCTTCGGCAGCGAGGGCGGCGTA-60 
 61-GCGGCGGCCGGTGGCGCGGCCGGCGATCGTTCGGTCAAGGCCGGCAGCGCCGAAGACGCG-120 
121-GCCTTCATCATGAAGAACGCCTCGAAGGTCATCATCGTGCCCGGCTATGGCATGGCGGTG-180 
181-GCCCAGGCCCAGCACGCCCTGCGCGAAATGGCCGATGTGCTCAAGAAGGAAGGCGTCGAG-240 
241-GTTTCCTACGCCATCCATCCGGTGGCCGGCCGTATGCCCGGGCACATGAACGTGCTGCTG-300 
301-GCCGAGGCCAATGTGCCCTATGACGAGGTCTTCGAGCTCGAAGAGATCAACAGCTCGTTC-360 
361-CAGACCGCCGATGTCGCCTTCGTCATCGGCGCCAACGACGTGACCAACCCGGCGGCCAAG-420 
421-ACCGATCCGTCGAGCCCGATCTACGGCATGCCGATCCTTGACGTTGAAAAGGCCGGAACC-480 
481-GTGCTGTTCATCAAGCGCTCGATGGCCTCGGGCTATGCCGGCGTCGAGAACGAACTGTTC-540 
541-TTCCGCAACAACACGATGATGCTGTTTGGCGACGCCAAGAAGATGACCGAGCAGATCGTC-600 
601-CAGGCGATGAACTGAAGCTCCGGATCC-628 
 
Figure 2.2 Sequence of the gene encoding wild-type dIII from R. rubrum transhydrogenase. 
Highlighted are the NdeI restriction site in yellow (including the start codon), the BamHI restriction site 
in cyan, the stop codon in grey, the bases encoding Glu155 in pink and the bases encoding Arg165 in 
green. 
 
 
Following digestion of the plasmid by restriction enzymes, the plasmid fragments 
were analysed on a 0.8% agarose gel in parallel with a DNA ladder (Bioline 
HyperLadder I). Samples were prepared by mixing 5 µL of the digested plasmid, 2 µL 
of “5 loading buffer” (supplied with the DNA ladder) and 3 µL water. To prepare 
the gel, 0.8% agarose (w/v) was dissolved in 100 mL warm TAE buffer (40 mM 
tris/HCl, 0.1% acetic acid (v/v), 1 mM EDTA). Ethidium bromide (5 µL) was added 
and the mixture was poured into a Horizon 58 (Life Technologies Inc.) gel 
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electrophoresis tank and left to solidify with a comb to create the loading wells. 
Plasmid samples were loaded into the wells and the gel was run for ~1 hour at 80V. 
The gel was then visualised using a UV illuminator. 
 
2.1.6 Transformation of E. coli cells. 
 
E. coli BL21(DE3) competent cells were transformed with the plasmids pNIC2 
(Diggle et al. 1996), pJDV1 (Peake et al. 1999a), pLH1 (see above) and pLH2 (see 
above) for over-expression of the genes encoding wild-type dIII of R. rubrum 
transhydrogenase, the E155W mutant of dIII, the R165A mutant of dIII and the 
E155W.R165A double mutant of dIII, respectively. E. coli C600 competent cells were 
transformed with the plasmid pCD1 (Diggle et al. 1995b) and pLH4 (see above) for 
over-expression of the gene encoding wild-type dI of R. rubrum transhydrogenase and 
the W72F mutant of dI, respectively. 
 The competent cells were thawed and 50 µL were added to the appropriate 
plasmid DNA (~20 ng). The mixture was incubated on ice for 30 minutes. It was then 
subjected to a heat shock at 42˚C for 45 seconds and returned to ice for a further 
1 minute. LB medium (500 µL) was then added to the mixture, which was incubated 
with shaking at 37˚C for 1 hour. Following this, 10 µL and 100 µL aliquots were 
plated onto LB agar plates containing 100 µg mL
-1
 ampicillin and incubated overnight 
at 37˚C.  
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2.1.7 Growth and over-expression of E. coli cells. 
 
Following transformation of host E. coli cells with plasmid DNA, a single colony was 
taken from the agar plate and added to 50 mL LB containing 100 µg mL
-1
 ampicillin, 
and incubated overnight in a shaking incubator at 37˚C. This was then split between 8 
flasks, each containing 400 mL fresh LB medium and 100 µg mL
-1
 ampicillin. The 
cells were grown in a shaking incubator at 37˚C until an optical density of 0.6 to 0.7 
was reached at 600 nm on a Unicam Helios γ spectrophotometer. Expression was 
induced by the addition of 1 mM isopropyl thiogalactoside. The cells were harvested 
by centrifugation in a Beckman Avanti
TM
 J-25 centrifuge using a JA-10 rotor at 
10,000 g at 4˚C for 10 minutes. The supernatants were discarded and the pellets were 
washed with TE buffer (50 mM tris-HCl, 1 mM EDTA, pH 8.0), combined into one 
tube, and centrifuged again at 10,000 g at 4˚C for 10 minutes using the same rotor. 
The supernatant was discarded and the pellets stored at -20˚C. Cell pellets were then 
thawed when required. Once thawed, the pellets were re-suspended in TE buffer 
supplemented with 1 mM DTT for dI and 100 μM NADP+ for dIII. The cells were 
broken by sonication (5  30 second sonications with 60 second intervals) in the 
presence of 0.5 mM phenylmethanesulfonyl fluoride (PMSF). The cell debris was 
removed by centrifugation in a Beckman XL-90 ultracentrifuge using a 70 Ti rotor at 
150,000 g at 4˚C for 1 hour. For the purification of wild-type dIII, dIII.E155W, 
wild-type dI and dI.W72F, which were predominantly found in the soluble fraction of 
the cell debris, the respective supernatant was next filtered using a 0.45 μm syringe 
filter. The isolated proteins were purified using column chromatography as described 
in following sections. Unlike wild-type dIII, dIII.R165A and dIII.E155W.R165A 
predominantly formed inclusion bodies, and were present in the pellet after the 
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centrifugation at 15,000 g (Figure 2.3). Thus, a new method of purification was 
needed for these mutant proteins; existing methods used for wild-type dIII (Diggle et 
al. 1996) were unsuitable. 
 
 
 
                                                    
  
 
Figure 2.3 SDS PAGE gel showing the expression of recombinant dIII.R165A. 
Following the growth and harvesting of the E. coli host cells, the cells were re-suspended in 50 mM 
tris-HCl, pH 8.0, 1 mM EDTA, 100 µM NADP+ and broken by sonication. The broken cells were then 
subjected to a high-speed centrifugation. The resulting supernatant (SN) and pellet (P) were analysed 
on a 12% SDS PAGE gel in parallel with a protein marker (M) (GE Healthcare low molecular weight 
marker), and the gel stained with PAGE blue. It is clear that dIII.R165A forms inclusion bodies and is 
present predominantly in the pellet.  
 
 
A method was developed for the purification of dIII.R165A and dIII.E155W.R165A 
from an existing protocol used for the purification of dI (Obiozo et al. 2007), 
dIII.R165A 
14.4 KDa 
20.1 KDa 
30 KDa 
45 KDa 
66 KDa 
97 KDa 
M P SN 
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involving the denaturation and refolding of the proteins. After centrifugation at 
150,000 g, the supernatant was discarded and the pellet was re-suspended in 20 mM 
tris-HCl, 40 μM NADP+, 6 M guanidine hydrochloride (GuHCl), pH 8.0. The re-
suspended pellet was incubated on ice for 30 minutes and centrifuged in a Beckman 
XL-90 ultracentrifuge using a 70 Ti rotor at 90,000 g at 4˚C for 1 hour. The resulting 
supernatant was stored at -20˚C. When required, the supernatant was thawed and used 
for the purification of either dIII.R165A or dIII.E155W.R165A (as described in 
Section 2.2.4). 
 
2.2 Purification and preparation of the dI and dIII components from R. 
rubrum transhydrogenase. 
 
2.2.1 SDS PAGE. 
 
SDS PAGE is a widely used technique, in which proteins are treated with SDS to 
denature and dissociate them into their individual subunits. When loaded onto a gel 
and subjected to an electric current the proteins separate according to their molecular 
weight; smaller proteins migrate further through the gel than larger proteins 
(Sambrook et al. 1989).  
SDS PAGE gels (12%) were prepared using a Bio-Rad Mini-Protean Tetra 
electrophoresis system. Liquid resolving-gel mixture (3.5 mL) (12% acrylamide (v/v), 
375 mM tris/HCl, pH 8.8, 2 mM EDTA, 0.16% SDS (w/v), 0.05% ammonium 
persulphate (w/v), 0.05% tetramethylethylenediamine (v/v)) was pipetted into the gel 
cassette, covered by water-saturated butanol to ensure that the top of the gel was level, 
and allowed to solidify for ~1 hour. The water-saturated butanol was discarded and 
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liquid stacking-gel mixture (5.5% acrylamide (v/v), 130 mM tris/HCl, pH 6.8, 2 mM 
EDTA, 0.1% SDS (w/v), 0.05% ammonium persulphate (w/v), 0.1% 
tetramethylethylenediamine (v/v)) was pipetted onto the resolving gel to fill the 
remaining space in the cassette. A comb was inserted into the liquid stacking gel to 
create the loading wells before the gel was allowed to solidify for ~30 minutes.  
Protein samples were prepared by adding 20 µL of “2 loading buffer” 
(125 mM tris/HCl, pH 6.8, 4 mM EDTA, 20% glycerol (v/v), 0.5% bromophenol blue 
(w/v), 0.5% xylene cyanol (w/v), 5% SDS (w/v), 2% β-mercaptoethanol (v/v)) to 
20 µL protein sample. The mixtures were heated to 60˚C for 10 minutes and loaded 
into the wells of the SDS PAGE gel. The gel was run for ~1 hour at 200 V in running 
buffer (250 mM tris/HCl, pH 8.3, 144 g L
-1
 glycine, 5 g L
-1
 SDS, 3.72 g L
-1
 EDTA). 
The gels were then stained by heating to 60˚C in a stain solution of 50% methanol 
(v/v), 10% acetic acid (v/v), 0.5% PAGE blue (w/v). The gels were then de-stained by 
heating to 60˚C in a de-stain solution of 10% methanol (v/v), 7% acetic acid (v/v).  
 
2.2.2 Purification of isolated wild-type dIII and dIII.E155W. 
 
The protocol for the purification of wild-type dIII in this work was adapted from an 
existing protocol (Diggle et al. 1996). The filtered supernatant obtained from E. coli 
cells expressing R. rubrum dIII (described in Section 2.1.7) was applied to a 300 mL 
Q-sepharose fast flow ion-exchange column (GE healthcare) pre-equilibrated with 
20 mM tris-HCl, 4 μM NADP+, pH 8.0. The column was washed with 50 mL of the 
same buffer, and then with 150 mL 20 mM tris-HCl, 4 μM NADP+, 200 mM NaCl, 
pH 8.0. The protein solution was then eluted with 600 mL 20 mM tris-HCl, 4 µM 
NADP
+
, 700 mM NaCl, pH 8.0. The presence of dIII was detected using assays 
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measuring the rate of the cyclic reaction in assays supplemented with purified dI 
(described in Section 2.3.4), and SDS PAGE. The appropriate fractions were collected 
and dialysed overnight in 2 L 20 mM tris-HCl, 4 µM NADP
+
, 0.5 mM PMSF, pH 8.0. 
The dialysed protein solution was filtered using a 0.45 μm syringe filter, and applied 
to a 300 mL Q-sepharose high performance ion-exchange column (GE healthcare) 
pre-equilibrated with 20 mM tris-HCl, 4 µM NADP
+
, pH 8.0. The column was 
washed with 40 mL 20 mM tris-HCl, 4 µM NADP
+
, pH 8.0, and then with 40 mL 
20 mM tris-HCl, 4 µM NADP
+
, 200 mM NaCl, pH 8.0. The protein was eluted with a 
600 mL gradient of 20 mM tris-HCl, 4 μM NADP+, 200-600 mM NaCl, pH 8.0. The 
appropriate fractions were collected and dialysed overnight in 2 L 20mM tris-HCl, 
4 μM NADP+, 0.5 mM PMSF, pH 8.0. Solid ammonium sulphate was added to the 
dialysed protein solution to give a final concentration of 55 g L
-1
. The protein solution 
was then filtered using a 0.45 μm syringe filter and was applied to a 300 mL butyl 
toyopearl hydrophobic interaction column (TOSOH) pre-equilibrated with 20 mM 
tris-HCl, 4 µM NADP
+
, 55 g L
-1 
ammonium sulphate, pH 8.0. The column was 
washed with 40 mL of the same buffer. The protein was eluted with a 600 mL 
gradient of 20 mM tris-HCl, 4 μM NADP+, 55-0 g L-1 ammonium sulphate, pH 8.0. 
The appropriate fractions were collected, pooled and stored at -20˚C in 25% glycerol 
(v/v). The procedure described typically produced ~60 mg dIII protein (wild-type dIII 
or dIII.E155W) from 3.2 L of bacterial culture. 
 
2.2.3 Purification of isolated wild-type dI and dI.W72F. 
 
The protocol for the purification of wild-type dI and dI.W72F in this work was 
adapted from an existing protocol for the purification of wild-type dI (Diggle et al. 
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1995b). The filtered supernatant obtained from E. coli cells expressing R. rubrum dI 
(described in Section 2.1.7) was applied to a 300 mL Q-sepharose fast flow 
ion-exchange column pre-equilibrated with 20 mM tris-HCl, 1 mM DTT, 1 mM 
EDTA, pH 8.0. The column was washed with 100 mL of the same buffer and then 
with 100 mL 20 mM tris-HCl, pH 8.0, 1 mM DTT, 1 mM EDTA, 200 mM NaCl. The 
protein was eluted with a 600 mL gradient of 20 mM tris-HCl, 1 mM DTT, 1 mM 
EDTA, 200-400 mM NaCl, pH 8.0. The presence of dI was detected by measuring the 
rate of the cyclic reaction in assays supplemented with purified dIII (described in 
Section 2.3.4), and SDS PAGE. The appropriate fractions were collected and dialysed 
overnight in 2 L 20 mM tris-HCl, 1 mM DTT, 1 mM EDTA, 0.5 mM PMSF, pH 8.0. 
The dialysed protein solution was filtered using a 0.45 μm syringe filter. Solid 
ammonium sulphate was added to the dialysed protein solution to give a final 
concentration of 1.5 M, which was then filtered using a 0.45 μm syringe filter. The 
protein solution was applied to a 300 mL butyl toyopearl hydrophobic interaction 
column pre-equilibrated with 20 mM tris-HCl, 1 mM DTT, 1 mM EDTA, 1.5 M 
ammonium sulphate, pH 8.0. The column was washed with 100 mL of the same 
buffer. The protein was eluted with a 600 mL gradient of 20 mM tris-HCl, 1 mM 
DTT, 1 mM EDTA, 1.5-0 M ammonium sulphate, pH 8.0. The appropriate fractions 
were collected and stored at -20˚C in 25% glycerol (v/v). The procedure described 
typically produced ~300 mg dI protein (wild-type dI or dI.W72F) from 3.2 L of 
bacterial culture. 
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2.2.4 Purification of isolated dIII.R165A and dIII.E155W.R165A. 
 
The protocol described here is for the denaturation and refolding of the protein. This 
method was adapted from an existing protocol for the purification of dI (Obiozo et al. 
2007), and developed for the purification of the dIII.R165A and dIII.E155W.R165A 
mutant proteins. Recall from Section 2.1.7, following centrifugation at 150,000 g, the 
resulting pellet was re-suspended and incubated in a buffer containing 6 M GuHCl, 
and subjected to another centrifugation step at 90,000 g. The resulting supernatant 
was stored at -20 ˚C. When required, the supernatant was thawed and diluted with 
20 mM tris-HCl, 40 µM NADP+, 6 M GuHCl to give a protein concentration of 
approximately 0.5 mg mL
-1
. A sample of this (40 mL) was then dialysed overnight in 
4 L 30 mM HEPES, 10 µM NADP+, 15% glycerol (v/v), 0.5 mM PMSF, pH 8.0. The 
dialysed protein solution was centrifuged in a Jouan CR3i centrifuge at 10,000 g at 
4˚C for 10 minutes to remove any precipitated protein. To concentrate the protein 
solution, this was applied to a 5 mL HiTrap Q-HP ion-exchange column (GE 
Healthcare) pre-equilibrated with 20 mM tris-HCl, 4 μM NADP+, pH 8.0. The column 
was washed with 40 mL of the same buffer, and then with 40 mL 20 mM tris-HCl, 
4 μM NADP+, 200 mM NaCl, pH 8.0. The protein was eluted in 1 mL fractions with 
20 mL 20mM tris-HCl, 4 μM NADP+, 600 mM NaCl, pH 8.0. The fractions 
containing the required purified protein were identified by SDS PAGE and pooled.  
 Following the HiTrap Q-HP ion-exchange column it was usually necessary to 
remove NADP
+
 from the protein solution. To this end, 3 mL of the pooled protein was 
applied using a syringe to two series-connected 5 mL HiTrap desalting columns (GE 
Healthcare) pre-equilibrated with 20 mM tris-HCl, pH 8.0. The protein was eluted in 
1 mL fractions with 10 mL 20 mM tris-HCl, pH 8.0. SDS PAGE showed that the 
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protein eluted in the first four fractions. These fractions were collected and pooled. 
The process was repeated, applying 3 mL of the pooled protein to two series-
connected HiTrap desalting columns. Again, the first four fractions were collected. 
The purified, desalted protein was used immediately without storage. The procedure 
described typically produced ~2 mg dIII.R165A or dIII.E155W.R165A from a 40 mL 
sample of unfolded protein. 
 
2.2.5 Determination of protein concentration. 
 
All protein concentrations were determined by the microtannin assay (Mejbaum-
Katzenellenbogen et al. 1959) using bovine serum albumin (BSA) as the standard.  
Samples of the purified protein were diluted 20 fold and 50 fold using water. 
Samples of BSA of known concentration (0-50 µg mL
-1
) were also prepared. To 1 mL 
of these samples, 1 mL tannin reagent A (see below) was added. The samples were 
incubated in a 30˚C water bath for 30 minutes. Tannin reagent B (1 mL) (see below) 
was then added to each sample and incubated at room temperature for 10 minutes. 
The absorbance of the samples at 500 nm was measured in a Unicam Helios γ 
spectrophotometer, which was set to zero using the 0 µg mL
-1
 BSA sample. A 
standard curve was constructed from the absorbance values of the BSA samples and 
used to calculate the concentration of the purified protein. 
 
Tannin reagent A 
805 mL deionised water 
75 mL concentrated HCl 
20 mL phenol 
90 g tannic acid 
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The water and tannic acid were heated to 80˚C before the other components were 
added. The solution was left to cool before filtering through Whatman #1 filter paper, 
and was stored at 4˚C. 
 
Tannin reagent B 
500 mL deionised water 
1 g gum Arabic (acacia) 
After combining, the mixture was heated to 80˚C until dissolved. The solution was 
left to cool before filtering through Whatman #1 filter paper, and was stored at 4˚C. 
 
2.2.6 Gel-filtration of wild-type dIII. 
 
In an attempt to remove bound-NADP
+
 from dIII, the purified protein solution was 
applied to two series-connected 5 mL HiTrap desalting columns pre-equilibrated with 
20 mM tris-HCl, pH 8.0. The protein was eluted in 1 mL fractions with 10 mL 20 mM 
tris-HCl, pH 8.0. SDS PAGE showed that the protein eluted in the first four fractions. 
These fractions were collected and pooled. The process was repeated, applying 3 mL 
of the pooled protein to two series-connected HiTrap desalting columns. Again, the 
first four fractions were collected. 
 
2.2.7 Phosphatase-treatment of dIII. 
 
The protocol for the phosphatase-treatment of R. rubrum dIII was adapted from a 
protocol used for the phosphatase-treatment of E. coli dIII (Pedersen et al. 2003). 
Prior to phosphatase-treatment, dIII (4 mL) was dialysed overnight against 2 L 
20 mM CHES-KOH, pH 9.0. To 50 µL aliquots of the dialysed protein, 10 U calf-
intestinal alkaline phosphatase (New England Biolabs) was added, and the solution 
was incubated at 37˚C for 10 minutes. The phosphatase-treated protein was then 
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plunged into ice and used within 30 minutes in enzyme assays (see Chapter 3) and 
fluorescence experiments (see Chapter 4). 
 Control fluorometric assay experiments were necessary to confirm that 
essentially all NADP
+
 and NADPH in the phosphatase-treated dIII had been 
converted to NAD
+
 and NADH, respectively. Fluorescence experiments were 
performed in parallel with untreated dIII, with an excitation wavelength of 340 nm, an 
emission wavelength of 460 nm and a half band width of 2 nm. To confirm the 
absence of NADP
+
, the phosphatase-treated dIII (0.2 mL) was added to 1.8 mL 
20 mM MOPS-KOH, pH 7.0, 5 mM MgCl2, 2 mM isocitrate. The reduction of 
NADP
+
 was recorded following the addition of 1 U NADP
+
-dependent isocitrate 
dehydrogenase (Sigma Life Science, from porcine heart). To confirm the generation 
of NAD
+
 from the phosphatase treatment of dIII, ethanol was added to give a 
concentration of 0.1% (v/v) and the reduction of NAD
+
 was recorded following the 
addition of 10 U alcohol dehydrogenase (Sigma Life Science, from baker’s yeast).  
 For the detection of NADPH, the phosphatase-treated dIII (0.2 mL) was added 
to 1.8 mL 20 mM MOPS-KOH, pH 7.0, 5 mM MgCl2, 2 mM oxidised glutathione 
before adding 1 U glutathione reductase (Sigma Life Science, from baker’s yeast). 
The oxidation of NADPH by the oxidised glutathione and glutathione reductase was 
recorded. 
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2.3 Biochemical methods. 
 
2.3.1 Determination of the NADP
+
-content of dIII. 
 
The NADP
+
 content of dIII was assayed using the method described (Klingenberg 
1974; Diggle et al. 1996). Solutions of known NADP
+
 concentration (0-50 µM) were 
used for calibration. To 0.6 mL of each sample of dIII containing approximately 
250 µg protein, 0.3 mL 14% perchloric acid (v/v) was added to precipitate the protein, 
and the mixture was incubated on ice for 10 minutes. The solutions were then 
neutralised by the addition of 0.45 mL 1 M KOH, 1 M KHCO3, and incubated on ice 
for 15 minutes before storing at -20˚C for at least an hour. Once thawed, the top clear 
layer from each sample (0.8 mL) was removed and centrifuged in a Hettich Mikro 20 
benchtop centrifuge for 5 minutes to remove any remaining protein precipitate.  
 The resulting solution (0.8 mL) was then added to 2.2 mL MOPS, pH 7.0, 
5 mM MgCl2, 2 mM isocitrate before adding 1 U NADP
+
-linked isocitrate 
dehydrogenase (Sigma Life Science, from porcine heart). The reduction of NADP
+
 by 
the isocitrate and NADP
+
-linked isocitrate dehydrogenase was measured at 25˚C as 
the amplitude of the fluorescence change with an excitation wavelength of 340 nm, an 
emission wavelength of 460 nm and a half band width of 2 nm. A calibration curve 
was constructed using the samples of known NADP
+
 concentration. 
 
2.3.2 Note on the preparation of dialysis tubing used in this project. 
 
In view of some unexpected properties of the dialysis tubing used in this project, it is 
emphasized that the tubing was routinely pre-prepared by standard procedures 
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(Bizouarn et al. 1996a). Thus, lengths of dialysis tubing (Visking or Spectra/Por, both 
Medicell) were incubated in 5% NaHCO3 (w/v), 1 mM EDTA at 80˚C for 30 minutes. 
The tubing was then either used immediately or stored in 20% ethanol (v/v) at 4˚C. 
 
2.3.3 Determination of nucleotide concentration of solutions. 
 
Prior to use, the concentration of nucleotide solutions used in experiments (e.g. 
enzyme assays and fluorescence experiments) was measured for reliable experimental 
analysis. Nucleotide concentrations were also measured to test passage through 
dialysis membranes (see Section 3.1.1). To this end, the absorbance of nucleotide 
solutions (1 mL) was measured on a Unicam Helios γ spectrophotometer at the 
wavelengths and extinction coefficients given in Table 2.2 using a 1 cm quartz 
cuvette.  
 
 wavelength 
(nm) 
extinction 
coefficient  
(mM
-1 
cm
-1
) 
reference 
NADP
+
 259 18.0 (Boehringer 1987) 
NADPH 340 6.2 (Boehringer 1987) 
NAD
+
 260 17.8 (Boehringer 1987) 
NADH 340 6.2 (Boehringer 1987) 
AcPdAD
+
 260 16.2 specification sheet (Sigma) 
ADP 259 15.4 (Bock et al. 1956) 
 
Table 2.2 Wavelengths and extinction coefficients used to spectroscopically measure the 
concentration of nucleotide solutions. 
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2.3.4 Enzyme assays: measurement of the cyclic and reverse 
transhydrogenation reactions. 
 
Cyclic transhydrogenation 
The cyclic reaction is defined (see Section 1.8.3) as the combined reduction of 
NADP
+
 by NADH and oxidation of NADPH by AcPdAD
+
, when both take place 
without either the NADP
+
 or the NADPH dissociating from the enzyme (Whitehead et 
al. 2009). The net reaction is the reduction of AcPdAD
+
 by NADH. The reduction of 
AcPdAD
+
 was measured by recording the formation of the product AcPdADH from 
its absorbance change at 375 nm using an extinction coefficient of 6.1 mM
-1
 cm
-1
 
(Palmer et al. 1992). The rate of the cyclic reaction was measured using a Shimadzu 
UV-2401 spectrophotometer at 25˚C. The assay solution for the cyclic reactions under 
standard conditions in a final volume of 1 mL contained 50 mM MOPS-KOH, pH 7.2, 
50 mM KCl, 2 mM MgCl2, 30 nM dIII, 1.0 µM dI and 100 µM NADH. When wild-
type dIII was used, no added NADP
+
 was required because the protein contained 
tightly bound NADP
+
; when dIII.R165A or dIII.E155W.R165A was used, the assay 
solution was supplemented with 100  µM NADP
+
. After a 2 minute incubation period 
the reaction was initiated by the addition of AcPdAD
+
 to give a final concentration of 
200 µM. 
 
Reverse transhydrogenation 
The reverse reaction was measured as the reduction of AcPdAD
+
 by NADPH (see 
Section 1.8.2). The reduction of AcPdAD
+
 was measured by recording the formation 
of the product AcPdADH from its absorbance change at 375 nm using an extinction 
coefficient of 6.1 mM
-1
 cm
-1
 (Palmer et al. 1992). Experiments were performed on a 
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Shimadzu UV-2401 spectrophotometer at 25˚C. The assay solution for the reverse 
reaction under standard conditions in a volume of 1 mL contained 50 mM MOPS-
KOH, pH 7.2, 50 mM KCl, 2 mM MgCl2, 150 nM dIII, 5.0 µM dI and 200 µM 
NADPH. The reaction was started by the addition of AcPdAD
+
 to give a final 
concentration of 200 µM. 
 
2.4 Biophysical methods. 
 
2.4.1 Fluorescence experiments. 
 
Fluorescence experiments were performed either on a Spex Fluoromax fluorimeter or 
a PTI Quantamaster fluorimeter. 
 The binding of nucleotides to either dIII.E155W or dIII.E155W.R165A (in 
complex with dI.W72F) was measured by recording the change in fluorescence at 
25˚C using 280 nm excitation, 340 nm emission and a half band width of 4 nm. The 
assay solution (final volume of 3 mL) contained 20 mM MOPS-KOH, pH 7.0, 0.4 µM 
dIII and 0.8 µM dI.W72F. The solution was incubated at 25˚C for 5 minutes before 
nucleotides were added (20 µM).  
 Fluorescence emission spectra of wild-type dI and dI.W72F were measured 
using either 275 nm or 290 nm excitation and a half band width of 2.8 nm. The 
mixture (final volume 3 mL) contained 20 mM MOPS-KOH, pH 7.0, 1.0 µM dI. 
Emission scans of the buffer solution containing no protein were subtracted to 
eliminate the water Raman peak. 
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2.4.2 X-ray crystallography: the crystallisation of dIII.R165A. 
 
Attempts were made to crystallise dIII.R165A. For further details see Chapter 6, 
where a detailed description is given. 
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Results and discussion: Part I 
 
CHAPTER 3 
 
The preparation of apo-dIII. 
Cyclic and aberrant cyclic reactions 
catalysed by dI2dIII complexes made with 
apo-dIII from R. rubrum transhydrogenase. 
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3.1 Removal of NADP(H) from dIII of R. rubrum transhydrogenase. 
 
Isolated purified wild-type dIII from R. rubrum transhydrogenase contains tightly 
bound NADP
+ 
(Diggle et al. 1996). For this reason, nucleotide-binding studies of the 
dIII component have been difficult. A method for the removal of NADP(H) from dIII 
would be useful in experiments designed to understand the binding of nucleotides into 
the dIII site. 
 
3.1.1 Dialysis of NADP
+
 from wild-type dIII of R. rubrum transhydrogenase. 
 
Attempts were made to remove the bound NADP
+
 from dIII by dialysis. After more 
than 3 days of dialysis NADP
+
 was still present in the dIII. However, it was 
discovered that NADP
+
 does not readily pass through dialysis membranes in the way 
that is expected. Dialysis membranes from Medicell (Visking and Spectra/Por) were 
prepared as described in Section 2.3.2. A 12-14 KDa cut off is reported (by the 
manufacturer) for both membranes. Thus, NADP
+
 with a molecular weight of 765 Da, 
would be expected to pass effectively through the two membranes. A 1 mL solution 
containing 1 mM NADP
+
 in 20 mM tris/HCl, pH 8.0 was dialysed overnight against 
1 L 20 mM tris/HCl, pH 8.0 at 4˚C, using Visking and Spectra/Por dialysis 
membranes. The NADP
+ 
concentrations of the solutions in the dialysis tubing were 
measured 18 hours later with a spectrophotometer as described in Section 2.3.3. If 
NADP
+
 effectively passed through the dialysis membranes (i.e. if equilibrium had 
been reached between the solution in the dialysis tubing and the dialysate), the 
NADP
+
 concentration would be 1 µM in both solutions, and 99.9% of the NADP
+
 in 
the dialysis tubing would have passed through the membrane. However, after dialysis 
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the concentration of NADP
+
 in the Visking dialysis tubing was 525 µM, and in the 
Spectra/Por dialysis tubing was 460 µM, showing that only about half of the NADP
+
 
had passed through the membranes. Kirkman et al. also reported NADP
+
 to be 
ineffective at passing through dialysis membranes (Kirkman et al. 1986). Similar 
experiments were set up to test the dialysis of other nucleotides (NADPH, NAD
+
, 
NADH, AcPdAD
+
 and ADP) through the Visking dialysis membrane. Solutions 
(1 mL) containing 1 mM nucleotide in 20 mM tris/HCl, pH 8.0 were dialysed 
separately overnight (18 hours) against 1 L 20 mM tris/HCl, pH8 at 4˚C. Following 
this, the nucleotide concentrations of the solutions in the dialysis tubing were 
measured with a spectrophotometer as described in Section 2.3.3. The nucleotide 
concentrations of the solutions in the dialysis tubing were 545 µM for NADPH, 
400 µM for NAD
+
, 350 µM for NADH, 150 µM for AcPdAD
+
 and 15 µM for ADP. 
These results show that, of the solutions in the dialysis tubing, 44.5% NADPH, 60% 
NAD
+
, 65% NADH, 85% AcPdAD
+
 and 98.5% ADP had passed through the 
membrane. Evidently, ADP was the only nucleotide of those tested to dialyse near to 
equilibrium. The chemical structure of ADP is similar to that of NAD(H), except it 
lacks the nicotinamide group and the adjacent ribose (see Figure 1.4). Since ADP was 
the only nucleotide to dialyse nearly to equilibrium, this suggests that properties of the 
nicotinamide mononucleotide moiety of the NADP
+
, NADPH, NAD
+
, NADH and 
AcPdAD
+
 prevent the effective passage of the nucleotides through the dialysis 
membranes.  
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3.1.2 Gel-filtration of wild-type dIII from R. rubrum transhydrogenase. 
 
It was evident that the removal of NADP
+
 from the dIII solution could not be 
achieved using dialysis and that another method was required. Isolated dIII, purified 
in buffer containing 4 µM NADP
+
 (as described in Section 2.2.2), contains 
~0.75 moles of NADP
+
 per mole of dIII (Table 3.1). Solutions of dIII were subjected 
to gel-filtration chromatography using procedures described in Section 2.2.6. After 
two passages through the gel-filtration columns, essentially all of the NADP
+
 
remained bound to the dIII. This confirms that wild-type dIII has a high affinity for 
the nucleotide (Diggle et al. 1996).  
 
 
Protein NADP
+
 before GF
 
(mol NADP
+
 mol
-1
 protein)
 
NADP
+
 after GF
 
(mol NADP
+
 mol
-1
 protein) 
wild-type dIII 0.71 
0.79 
0.73 
0.75 
0.78 
0.78 
 
dIII.R165A 0.28 
0.35 
0.12 
0.00 
0.01 
0.04 
 
Table 3.1 The NADP
+
 content of isolated wild-type dIII and dIII.R165A from R. rubrum 
transhydrogenase. 
Isolated wild-type dIII and dIII.R165A (samples from 3 separate preparations of each) were passed 
through a gel-filtration (GF) chromatography column as described in Section 2.2.6 (for more 
information on dIII.R165A see Section 3.1.4). The nucleotide-content of the proteins before and after 
gel-filtration was measured by a method involving the denaturation of the protein to extract the bound 
nucletide, and fluorometrically recording the extent of NADP+ reduction by isocitrate and the enzyme 
isocitrate dehydrogenase on a Spex Fluoromax fluorimater (as described in Section 2.3.1). 
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3.1.3 Removal of tightly bound NADP(H) by phosphatase treatment of wild-
type dIII from R. rubrum transhydrogenase. 
 
The removal of bound NADP(H) from wild-type dIII was achieved using a method 
adapted from Pedersen et al. (Pedersen et al. 2003). The dIII protein solution was 
incubated with calf-intestinal alkaline phosphatase as described in Section 2.2.7. 
Alkaline phosphatase cleaves the 2’-phosphate group from NADP+ producing NAD+. 
Control experiments were performed to detect NADP
+
 and NAD
+
 in untreated and 
phosphatase-treated solutions of dIII (Figure 3.1). NADP
+
-dependent isocitrate 
dehydrogenase (ICDH) catalyses the oxidative decarboxylation of isocitrate, whilst 
reducing NADP
+
 to NADPH. In the presence of untreated dIII, which contains bound 
NADP
+
, ICDH catalysed its reaction and the production of NADPH could be seen 
from the fluorescence increase at 340-460 nm (Figure 3.1a). This shows that NADP
+
 
was present in the solution; as the NADP
+
 slowly dissociated from dIII it was reduced 
by the ICDH. Alcohol dehydrogenase (ADH) catalyses the oxidation of ethanol whilst 
reducing NAD
+
 to NADH. No fluorescence change was seen when ADH and ethanol 
were added to the solution of untreated dIII, showing that NAD
+
 was not present in 
the solution. With phosphatase-treated dIII present, ICDH failed to catalyse any 
detectable oxidative decarboxylation of isocitrate but ADH did catalyse the oxidation 
of ethanol (Figure 3.1b). This is evidence that NADP
+
 in the solution had been 
converted to NAD
+
 during the treatment with phosphatase. A “blank” experiment was 
performed to detect the NADP
+
 concentration of a solution containing 20 mM MOPS-
KOH, pH 7.0, 5 mM MgCl2 (Figure 3.1c). As expected, no detectable reduction of 
NADP
+
 was seen, confirming the absence of the nucleotide. Control experiments were 
also performed to detect NADPH in the dIII solutions using the enzyme glutathione 
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reductase (also described in Section 2.2.7). Glutathione reductase catalyses the 
reduction of oxidised glutathione, whilst oxidising NADPH to NADP
+
. In the 
presence of untreated dIII, oxidised glutathione was reduced by glutathione reductase 
and the oxidation of NADPH could be seen (Figure 3.1d). With phosphatase-treated 
dIII present, no fluorescence change was seen showing that NADPH had been 
completely removed from the solution during treatment with phosphatase (Figure 
3.1e).  
  The ability of the alkaline phosphatase to cleave the 2’-phosphate from 
NADP(H) in the protein solution results in the formation of wild-type apo-dIII. 
 
 
Figure 3.1 (over page) Determination of NADP(H) and NAD
+
 levels in solutions of phosphatase-
treated wild-type dIII from R. rubrum transhydrogenase. 
Wild-type dIII was treated with alkaline phosphatase and control experiments were performed to 
ensure that essentially all NADP(H) had been removed from the protein solution. Fluorescence 
experiments were performed on a Spex Fluoromax fluorimeter as described in Section 2.2.7. Before 
recording, the experimental cuvettes contained (a) untreated wild-type dIII and isocitrate, (b) 
phosphatase-treated wild-type dIII and isocitrate, (c) buffer and isocitrate, (d) untreated wild-type dIII 
and oxidised glutathione and (e) phosphatase-treated wild-type dIII and oxidised glutathione. Figures 
(a), (b), and (c) show experiments to detect NADP+ and NAD+ using NADP+-linked isocitrate 
dehydrogenase (ICDH) and alcohol dehydrogenase (ADH), respectively. Figures (d) and (e) show 
experiments to detect NADPH using glutathione reductase (GR). In experiments (a), (b) and (c), the 
initial rapid fluorescence increase upon addition of ICDH is due to the intrinsic fluorescence of the 
enzyme. 
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3.1.4 Properties of the mutant dIII.R165A from R. rubrum transhydrogenase.  
 
A dIII.R165A mutant from R. rubrum transhydrogenase was isolated in which the 
arginine residue from the highly conserved K-R-S motif in the NADP(H)-binding site 
was substituted by an alanine. Unlike wild-type dIII, which was expressed mainly in 
the soluble fraction of the host E. coli cells (Diggle et al. 1996), dIII.R165A was 
predominantly expressed in inclusion bodies. Thus, the purification of this mutant 
protein required a new procedure. Following preliminary work, a successful 
procedure was developed in which the inclusion bodies containing dIII.R165A were 
denatured in GuHCl and the protein was subsequently refolded upon removal of the 
GuHCl by dialysis (see Section 2.2.4). The resulting dIII.R165A was >95% pure. In 
separate experiments, wild-type dIII was subjected to denaturation and refolding by 
an equivalent procedure; full activity was recovered with a rate of cyclic 
transhydrogenation, under standard conditions, of ~2600 mol AcPdAD
+
 reduced mol
-1
 
dIII min
-1
. This shows that the procedure did not cause inactivation of the wild-type 
protein, and thus the same was assumed to be true for the mutant. 
Previous studies on the equivalent mutation from E. coli transhydrogenase (Hu 
et al. 1999; Bergkvist et al. 2000) suggest that dIII.R165A from R. rubrum 
transhydrogenase would have a decreased affinity for NADP(H) compared to wild-
type dIII. The determination of nucleotide-content showed that dIII.R165A, purified 
as outlined above, was ~20% occupied by NADP
+
 (Table 3.1). Samples were 
subjected to gel-filtration chromatography and the NADP
+
 content was re-assayed 
(Table 3.1). The results show that essentially all the bound NADP
+
 had been removed 
by the gel-filtration, and suggest that dIII.R165A has a significantly decreased affinity 
for NADP
+
 relative to wild-type dIII. 
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 In dI2dIII complexes formed from R. rubrum dI and phosphatase-untreated 
wild-type dIII, the reverse reaction, as measured by the reduction of AcPdAD
+
 by 
NADPH, is limited by the slow dissociation of the product NADP
+ 
from the dIII (see 
Section 1.8.2). Under the standard conditions described in Section 2.3.4, the reverse 
reaction was measured in parallel in complexes of wild-type dI and either wild-type 
dIII (untreated with phosphatase) or dIII.R165A (Figure 3.2). In agreement with 
earlier results (Diggle et al. 1996), the steady-state rate of the reverse reaction was 
~1.4 mol AcPdAD
+
 reduced mol
-1
 dIII
 
min
-1
 in dI2dIII complexes made with wild-
type dIII. In complexes made with dIII.R165A, the rate was much higher (~13 mol 
AcPdAD
+
 reduced mol
-1
 dIII
 
min
-1
). This large increase in rate (~9 fold) is consistent 
with a faster rate of NADP
+
 release from dIII.R165A, and a decreased affinity for 
NADP
+
 relative to wild-type dIII. However, the rate of the reverse reaction in 
complexes made with dIII.R165A is still ~1000 fold lower than that of the cyclic 
reaction (see Section 3.2.5). Thus, the reverse reaction is probably still limited by the 
release of NADP
+
. 
The methods described above for the formation of the two forms of apo-dIII 
(phosphatase-treated wild-type dIII or dIII.R165A) are useful to more effectively 
study nucleotide-binding to dIII.  
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Figure 3.2 The reverse transhydrogenation reaction catalysed by dI2dIII complexes constructed 
with dI and either wild-type dIII or dIII.R165A from R. rubrum transhydrogenase. 
The reduction of AcPdAD+ by NADPH was measured as described in Section 2.3.4. The initial mixture 
(in curly brackets) was incubated for 5 minutes before recording was started. The reaction was initiated 
by the addition of AcPdAD+ (shown by the arrows). Disturbances from the mixing procedure have 
been replaced by dashed lines for clarity. 
 
 
 
 
 
 
100 s
 
∆A375=0.02 
dIII.R165A 
dI 
NADPH
 
wild-type dIII 
dI 
NADPH
 
AcPdAD
+ 
AcPdAD
+ 
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3.2 The cyclic and aberrant cyclic reactions catalysed by dI2dIII complexes 
made from dI and either wild-type apo-dIII or apo-dIII.R165A from R. rubrum 
transhydrogenase.  
 
As described in Section 1.8.3, dI2dIII complexes constructed with dI and dIII from R. 
rubrum transhydrogenase catalyse the cyclic transhydrogenation reaction. This 
reaction is defined as the combined reduction of NADP
+
 by NADH and oxidation of 
NADPH by NAD
+
, without NADP
+
 or NADPH dissociating from the enzyme 
(Whitehead et al. 2009). The net reaction is the reduction of AcPdAD
+
 by NADH, and 
is recorded by measuring the production of AcPdADH from its absorbance change at 
375 nm. 
 
3.2.1 The reduction of AcPdAD
+
 by NADH in the absence of NADP(H) 
catalysed by dI2dIII complexes constructed with dI and wild-type apo-dIII from 
R. rubrum transhydrogenase. 
 
Wild-type dIII from R. rubrum transhydrogenase was treated with alkaline 
phosphatase as described in Section 3.1.3. The phosphatase cleaved the 2’-phosphate 
from the nucleotide, resulting in the formation of the apo-form of dIII. Wild-type apo-
dIII was mixed with dI from R. rubrum transhydrogenase to form dI2dIII complexes, 
which were then used to measure the rate of AcPdAD
+
 reduction by NADH in the 
absence of added NADP(H). In the following experiments, the dI and dIII 
concentrations used (1.0 µM and 30 nM, respectively) were such that essentially all of 
the dIII was in complex with dI.  
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In Figure 3.3a, NADH and AcPdAD
+
 were added simultaneously to dI2dIII 
complexes made from dI and wild-type apo-dIII. The reduction of AcPdAD
+
 by 
NADH was recorded. The reaction started with a lag phase before reaching its 
maximum rate after ~30 seconds. In the scheme of the cyclic reaction shown in Figure 
1.6, dIII contains tightly bound NADP(H) throughout the reaction. The experiment in 
Figure 3.3a was conducted ostensibly in the absence of NADP(H). Assuming that 
both AcPdAD
+
 and NADH bind exclusively to dI, AcPdAD
+
 reduction by NADH 
would not take place without NADP
+
 or NADPH bound to dIII. However, previous 
work has suggested that NADH or AcPdAD
+
 can bind into the NADP
+
-binding site 
on dIII (Stilwell et al. 1997; Pedersen et al. 2003). In the experiment shown in Figure 
3.3a, if NADH or AcPdAD
+
 bound into the dIII site, hydride transfer could occur 
between the nucleotide bound to dIII and either NADH or AcPdAD
+
 bound to dI. 
Thus, a rate of AcPdAD
+
 reduction by NADH would be observed (a scheme for this 
reaction is shown in Figure 3.4). The conclusion can be drawn that either NADH or 
AcPdAD
+, or indeed both nucleotides, are binding into the dIII site (the “wrong” site). 
Since NADH and AcPdAD
+
 bind rapidly to dI (Venning et al. 1999; Venning et al. 
2000) and hydride transfer between bound nucleotides is fast (Pinheiro et al. 2001), 
the presence of the lag phase shows that the unspecific binding of NADH and/or 
AcPdAD
+
 to dIII is very slow. Moreover, the presence of the lag phase enables 
experiments to be performed to identify which nucleotide, NADH, AcPdAD
+
 or both 
can bind into the dIII site. To this end, the dI2dIII complexes formed with dI and wild-
type apo-dIII were incubated with AcPdAD
+
 for 2 minutes before the reaction was 
started by the addition of NADH (Figure 3.3b). The reaction started with a lag phase 
before reaching a maximum rate. From this result, it can be concluded that during the 
2 minute incubation period, the AcPdAD
+
 had not bound into the dIII site and that the 
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lag phase was probably due to the slow binding of NADH to dIII. If AcPdAD
+
 had 
bound to dIII during the incubation period, the dIII binding-sites would have been 
occupied by AcPdAD
+
 when the reaction was initiated, and the reaction would not 
have started with a lag phase, but with a prompt rate. The experiment shown in Figure 
3.3b was repeated, except the order of AcPdAD
+
 and NADH was switched (Figure 
3.3c). Thus, dI2dIII complexes formed from dI and wild-type apo-dIII were incubated 
for 2 minutes with NADH before the reaction was initiated by the addition of 
AcPdAD
+
. The reaction began with a prompt rate of ~2270 mol AcPdAD
+
 reduced 
mol
-1
 dIII
 
min
-1
; there was
 
no lag phase. The absence of a lag phase in this experiment 
shows that during the 2 minute incubation period NADH had fully occupied the dIII 
binding-sites and the reaction was able to proceed immediately at its maximum rate 
once initiated with AcPdAD
+
.  
The reduction of AcPdAD
+
 by NADH in the absence of NADP(H), where 
NADH binds into the dIII site (the “wrong” site), is here defined as the “aberrant” 
cyclic reaction, as shown by the scheme in Figure 3.4. It should be emphasised at this 
point that, when experiments similar to those shown in Figure 3.3 were performed 
with complexes of dI and wild-type dIII untreated with phosphatase (i.e. with bound 
NADP
+
) carrying  out the “normal” cyclic reaction, no lags were observed (data not 
shown). 
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Figure 3.3 Experiments showing the aberrant cyclic reaction catalysed by dI2dIII complexes 
formed with dI and wild-type apo-dIII from R. rubrum transhydrogenase. 
The aberrant cyclic reaction was measured as the reduction of AcPdAD+ by NADH (as described in 
Section 2.3.4) in the absence of NADP(H). In experiment (a), recording was started immediately after 
the initial mixture (in curly brackets) had been added to the cuvette. In experiments (b) and (c) the 
initial mixture was incubated in the cuvette for 2 minutes before recording was started. The reactions 
were initiated by the addition of nucleotides (shown by the arrows). Disturbances from mixing are 
replaced by dashed lines for clarity. Concentrations were 30 nM for dIII; 1.0 µM for dI; 200 µM for 
NADH and 200 µM for AcPdAD+. 
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Figure 3.4 Scheme of the aberrant cyclic reaction. 
In this scheme, the dotted lines indicate interactions between dI and dIII, and between the protein 
components and bound nucleotides. The dashed arrows show the two hydride transfer steps in the 
cyclic reaction. Only one of the two dI subunits is depicted. Overall, the aberrant cyclic reaction is the 
reduction of AcPdAD+ by NADH in the absence of NADP(H), where NAD+ and NADH remain bound 
to dIII. When dI and apo-dIII are mixed they spontaneously form dI2dIII complexes. NADH binds 
slowly to dIII in these complexes. When AcPdAD+ is added, it rapidly binds to dI and is reduced by the 
NADH bound to dIII. The resulting AcPdADH dissociates from dI whilst the NAD+ remains bound to 
dIII. NADH then binds to dI and reduces the NAD+ on dIII. The resulting NAD+ dissociates from dI 
whilst NADH remains bound to dIII. Another molecule of AcPdAD+ binds to dI and the cycle is 
repeated.  
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3.2.2 Binding properties of dI2dIII complexes constructed with dI and either 
wild-type dIII or dIII.R165A from R. rubrum transhydrogenase. 
 
Following the experiments described in the previous section (where the rate of the 
aberrant cyclic reaction, catalysed by dI2dIII complexes was measured), similar 
experiments were designed using apo-dIII.R165A instead of wild-type apo-dIII. When 
dI and wild-type dIII from R. rubrum transhydrogenase are mixed, they rapidly form 
dI2dIII complexes (Venning et al. 2001). The same cannot be assumed for dI and 
dIII.R165A. Prior to enzyme assays, it was necessary to ensure that the affinity of 
dIII.R165A for dI was not affected by the R165A mutation. To this end, the cyclic 
reaction (i.e. the reduction of AcPdAD
+
 by NADH in the presence of NADP
+
) 
catalysed by dI2dIII complexes formed with dI and either wild-type dIII (untreated 
with phosphatase) or dIII.R165A was measured under standard conditions (described 
in Section 2.3.4) as a function of dI concentration (Figure 3.5). The concentration of 
dIII was kept constant throughout and the concentration of dI was varied. The 
concentration of dI required to reach the half-maximal rate was ~40 nM for wild-type 
dIII and ~100 nM for dIII.R165A. The former value is consistent with previous results 
of calorimetry experiments where the Kd for the binding of dIII to dI2 was found to be 
≤60 nM (Venning et al. 2001). These results show that the affinity of dIII.R165A for 
dI has decreased ~2 fold relative to wild-type dIII. However, the concentrations of dI 
(1.0 µM) and dIII (30 nM) used in the experiments described in this project ensure 
that essentially all dIII, wild-type or dIII.R165A, will exist as dI2dIII complexes. 
  
 84 
 
 
 
 
 
 
       
 
 
 
 
   
 
 
 
 
 
 
Figure 3.5 Effect of dI concentration on the rate of the cyclic reaction catalysed by dI2dIII 
complexes constructed with dI and either wild-type dIII or dIII.R165A from R. rubrum 
transhydrogenase.  
The rate of AcPdAD+ reduction by NADH in the presence of NADP+ was measured under standard 
conditions (described in Section 2.3.4). The reactions were catalysed by dI2dIII complexes formed by 
mixing dI with either wild-type dIII (solid lines, circles) or dIII.R165A (dashed lines, triangles). The 
dIII concentration was kept constant (30 nM) while the dI concentration was varied. The data plotted 
are of single measurements. 
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3.2.3 The reduction of AcPdAD
+
 by NADH in the absence of NADP(H) 
catalysed by dI2dIII complexes constructed with dI and apo-dIII.R165A from R. 
rubrum transhydrogenase. 
 
The experiments shown in Figure 3.3, which revealed the aberrant cyclic reaction 
catalysed by dI2dIII with wild-type dIII, were repeated using dI2dIII complexes 
formed with dIII.R165A (Figure 3.6). The dIII.R165A used in these experiments had 
been passed through a gel-filtration chromatography column prior to use (see Section 
2.2.4) to remove bound NADP(H); thus it was in its apo-form. Overall, the results 
were very similar for dI2dIII complexes formed with apo-dIII.R165A compared with 
those formed with wild-type apo-dIII.  
Firstly, NADH and AcPdAD
+
 were simultaneously added to dI2dIII complexes 
made from dI and apo-dIII.R165A from R. rubrum transhydrogenase (Figure 3.6a). 
The reaction started with a lag phase similar to that seen with dI2dIII complexes 
formed with wild-type apo-dIII. The reaction reached a maximum rate only after ~30 
seconds. From this result, it can be concluded that NADH and/or AcPdAD
+
 binds into 
the NADP(H)-binding site on dIII.R165A. Since both NADH and AcPdAD
+
 bind 
rapidly to dI (Venning et al. 1999; Venning et al. 2000) and hydride transfer between 
bound nucleotides is fast (Pinheiro et al. 2001), the lag phase can be attributed to the 
very slow binding of either NADH or AcPdAD
+
 to dIII.R165A.  
Secondly, experiments were designed to determine which nucleotide (NADH 
and/or AcPdAD
+
) binds to dIII.R165A in the dI2dIII complexes. To this end, 
AcPdAD
+
 was incubated for 2 minutes with dI2dIII complexes formed with dI and 
apo-dIII.R165A, before the reaction was started by the addition of NADH (Figure 
3.6b). Again, the reaction started with a lag phase before reaching the maximum rate. 
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This shows that during the 2 minute incubation period, AcPdAD
+
 did not bind into the 
dIII.R165A site. If AcPdAD
+
 had bound to dIII.R165A during the incubation period, 
the dIII.R165A binding sites would have been occupied by AcPdAD
+
 when the 
NADH was added, causing the reaction to start promptly without a lag. Thus, it can be 
concluded that AcPdAD
+
 does not bind to dIII.R165A, and that the lag phase must be 
due to the slow binding of NADH to into the dIII.R165A sites. To confirm this, 
NADH was incubated with dI2dIII complexes formed with apo-dIII.R165A for 2 
minutes before the reaction was started by the addition of AcPdAD
+
 (Figure 3.6c). 
The reaction began promptly at a rate of ~1380 mol AcPdAD
+
 reduced mol
-1
 dIII 
min
-1
; there was no lag phase. This shows that during the 2 minute incubation period 
the dIII.R165A sites had been fully occupied with NADH, such that when AcPdAD
+
 
was added the reaction could proceed immediately at a maximum rate. The rate of the 
aberrant cyclic reaction observed using complexes with dIII.R165A was about 20% 
lower than that observed using complexes with wild-type dIII. 
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Figure 3.6 Experiments measuring the aberrant cyclic reaction catalysed by dI2dIII complexes 
constructed with dI and apo-dIII.R165A from R. rubrum transhydrogenase. 
The aberrant cyclic reaction was measured as the reduction of AcPdAD+ by NADH (as described in 
Section 2.3.4) in the absence of NADP(H). In experiment (a), recording was started immediately after 
the initial mixture (in curly brackets) was added to the cuvette. In experiments (b) and (c), the initial 
mixture was incubated for 2 minutes before recording was started. The reactions were initiated by the 
addition of nucleotides (shown by the arrows). Disturbances from mixing are replaced by dashed lines 
for clarity. Concentrations were 30 nM for apo-dIII.R165A; 1.0 µM for dI; 200 µM for NADH and 
200 µM for AcPdAD+. 
(b) 
(a) 
(c) 
20 s 
∆A375=0.2 dI 
apo-dIII.R165A 
dI 
apo-dIII.R165A 
AcPdAD
+ 
dI 
apo-dIII.R165A 
NADH
 
NADH 
AcPdAD
+ 
NADH
 
AcPdAD
+ 
 88 
 
3.2.4 The reduction of AcPdAD
+
 by NADH in the presence of NADP
+
 catalysed 
by dI2dIII complexes constructed with dI and wild-type apo-dIII from R. rubrum 
transhydrogenase. 
 
As explained in Section 3.1.3, treatment of wild-type dIII with alkaline phosphatase 
resulted in the formation of apo-dIII. Previously, it has proved difficult to study the 
binding of NADP
+
 and NADPH to dIII due to the very high affinity of the protein for 
the nucleotides. The formation of the apo-form of wild-type dIII enables experiments 
to observe NADP(H)-binding to dIII to be designed. To this end, the cyclic reaction, 
catalysed by dI2dIII complexes formed with dI and wild-type apo-dIII from R. rubrum 
transhydrogenase, was recorded as the reduction of AcPdAD
+
 by NADH with added 
NADP
+
.  
Firstly, NADH, AcPdAD
+
 and NADP
+
 were simultaneously added to dI2dIII 
complexes formed with dI and wild-type apo-dIII (Figure 3.7a). The reaction started 
with a lag phase and reached the maximum rate only after ~30 seconds. Since NADH 
and AcPdAD
+
 bind rapidly to dI (Venning et al. 1999; Venning et al. 2000) and 
hydride transfer between bound nucleotides is fast (Pinheiro et al. 2001), the presence 
of the lag phase in this experiment shows that nucleotide-binding to dIII in dI2dIII 
complexes is very slow. Recall from Section 3.2.1 that NADH is able to bind 
aberrantly into the dIII site. Thus, the lag phase can be attributed to either the slow 
binding of NADP
+
 and/or NADH to dIII. If NADP
+
 were binding to dIII, it would be 
rapidly reduced by NADH on dI during a “normal” cyclic reaction; if NADH were 
binding to dIII it would be rapidly oxidised by AcPdAD
+
 on dI during an aberrant 
cyclic reaction.  
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In a second experiment, dI was incubated with NADH, AcPdAD
+
 and NADP
+
 
for 1 minute before the reaction was started by the addition of wild-type apo-dIII 
(Figure 3.7b). The reaction again started with a lag phase before it reached its 
maximum rate. This confirms that the lag is not due to NADH or AcPdAD
+
 binding 
slowly to dI. The incubation period provided sufficient time for the nucleotides to 
bind to dI, yet the lag phase remained. This confirms that NADH and AcPdAD
+
 bind 
rapidly to dI (Venning et al. 1999; Venning et al. 2000).  
In the next experiment, dI2dIII complexes formed with dI and wild-type apo-
dIII, were incubated for 2 minutes with AcPdAD
+
 before the reaction was initiated by 
the simultaneous addition of NADH and NADP
+
 (Figure 3.7c). The reaction started 
with a lag phase and only after ~30 seconds reached its maximum rate. The incubation 
period provided sufficient time for dI and dIII to associate to form dI2dIII complexes 
(Venning et al. 2001), and also for AcPdAD
+
 to bind to the enzyme (Venning et al. 
1999), but the lag phase remained. This result confirms that the lag phase is due to the 
slow binding of either NADH or NADP
+
 to dIII.  
In the experiments described in this section, it has been assumed that NADP
+
 
can bind into the empty site on dIII. The experiment shown in Figure 3.7d strongly 
supports the assumption. Thus, dI2dIII complexes formed with dI and wild-type apo-
dIII were incubated with AcPdAD
+
 and NADP
+
 for 2 minutes before the reaction was 
initiated by the addition of NADH. The reaction began promptly at a rate of ~2360 
mol AcPdAD
+
 reduced mol
-1
 dIII
 
min
-1
; without any detectable lag. Recall from 
experiments described in Section 3.2.1, that AcPdAD
+
 is unable to bind into the dIII 
site. Thus, it can be concluded that during the incubation period the NADP
+
 bound 
into the empty sites of dIII. When NADH was added, the dIII sites were occupied by 
NADP
+
 and the reaction could proceed immediately at the maximum rate. If NADP
+
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had not bound to dIII, the reaction would have started with a lag phase. This confirms 
that the lag phase in the experiments described in this section was at least partly due 
to the slow binding of NADP
+
 to dIII. However, it cannot be ruled out in these 
experiments that the lag phase was also partly due to the slow binding of NADH into 
the dIII site. 
 
 
Figure 3.7 (over page) Experiments measuring the cyclic reaction catalysed by dI2dIII complexes 
formed with dI and wild-type apo-dIII from R. rubrum transhydrogenase. 
The cyclic reaction was recorded as the reduction of AcPdAD+ by NADH with added NADP+ as 
described in Section 2.3.4. In experiment (a), recording was started immediately after the initial 
mixture (in curly brackets) was added to the cuvette. In experiment (b), the initial mixture was 
incubated in the cuvette for 1 minute before recording was started, and in experiments (c) and (d) the 
initial mixture was incubated for 2 minutes before recording was started. The reactions were initiated in 
each experiment by the addition of nucleotides or proteins (shown by the arrows). Disturbances from 
mixing are replaced by dashed lines for clarity. Concentrations were 30 nM for phosphatase-treated 
dIII; 1.0 µM for dI; 200 µM for NADH; 200 µM NADP+ and 200 µM for AcPdAD+. 
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3.2.5 The reduction of AcPdAD
+
 by NADH in the presence of NADP
+
 catalysed 
by dI2dIII complexes constructed with dI and apo-dIII.R165A from R. rubrum 
transhydrogenase. 
 
The mutant dIII.R165A has been shown to have a significantly decreased affinity for 
NADP
+
 compared to wild-type dIII. Thus, experiments were designed to measure the 
binding of NADP
+
 to apo-dIII.R165A in dI2dIII complexes. The results of 
experiments to measure the reduction of AcPdAD
+
 by NADH in the presence of 
NADP
+
 with dI2dIII complexes formed with apo-dIII.R165A, were very similar to 
those with dI2dIII complexes formed with wild-type apo-dIII.  
Firstly, NADH, AcPdAD
+
 and NADP
+
 were simultaneously added to dI2dIII 
complexes formed with dI and apo-dIII.R165A (Figure 3.8a). The reaction started 
with a lag phase and reached its maximum rate only after ~30 seconds. Again, since 
NADH and AcPdAD
+
 bind rapidly to dI (Venning et al. 1999; Venning et al. 2000) 
and hydride transfer between bound nucleotides is fast (Pinheiro et al. 2001), the 
presence of the lag phase shows that the binding of nucleotides to apo-dIII in dI2dIII 
complexes is very slow. 
Next, NADH, AcPdAD
+
 and NADP
+
 were incubated for 1 minute with dI 
before the reaction was initiated by the addition of apo-dIII.R165A (Figure 3.8b). The 
reaction started with a lag phase and reached a maximum rate only after ~30 seconds. 
This shows that the lag cannot be attributed to nucleotides binding slowly to dI, since 
the incubation period provided sufficient time for binding, yet the lag phase remained. 
It can be concluded that the lag phase is due to the very slow binding of NADP
+
 
and/or NADH to the dIII.R165A. In another experiment, complexes of dI2dIII formed 
from dI and apo-dIII.R165A were incubated with AcPdAD
+
 for 2 minutes before the 
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reaction was initiated by the simultaneous addition of NADH and NADP
+
 (Figure 
3.8c). The reaction started with a lag phase before reaching a maximum rate only after 
~30 seconds. It was established that AcPdAD
+
 does not bind into the dIII site of 
dI2dIII formed with dI and either wild-type apo-dIII (in Section 3.2.1) or apo-
dIII.R165A (in Section 3.2.3). The result here supports the view that AcPdAD
+
 does 
not bind into the dIII site on dIII.R165A. If AcPdAD
+
 did bind, the reaction would 
have started immediately at a maximum rate with no lag phase; i.e. the AcPdAD
+
 
would have bound to dIII in the incubation period and hydride transfer would have 
begun immediately. However, this was not the case: the lag is due to the slow binding 
of NADP
+
 and/or NADH to dIII.  
In the experiments described in figures 3.7a, b and c, the lag phase could be 
attributed to the slow binding of either NADH or NADP
+
 to dIII. Given that 
dIII.R165A has a significantly decreased affinity for NADP
+
 relative to wild-type dIII 
it was investigated whether NADP
+
 is able to bind to dIII under the conditions of the 
experiments. To this end, dI2dIII complexes formed with dI and apo-dIII.R165A were 
incubated for 2 minutes with AcPdAD
+
 and NADP
+
 (Figure 3.8d). The reaction 
started immediately at a maximum rate of ~1420 mol AcPdAD
+
 reduced mol
-1
 dIII 
min
-1
. Recall that AcPdAD
+
 does not bind into the dIII site of dI2dIII formed with dI 
and either wild-type apo-dIII or apo-dIII.R165A. This result therefore shows that 
NADP
+
 does bind to dIII.R165A during the incubation period such that the 
dIII.R165A binding-sites were occupied by NADP
+
 when the reaction was initiated 
with NADH. The reaction could then proceed promptly at the maximum rate. If 
NADP
+
 had not bound to dIII.R165A, an initial lag phase would have been observed, 
attributable to the slow binding of NADH to dIII.R165A. The rate of the cyclic 
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reaction observed using dI2dIII complexes with dIII.R165A was about 35% lower 
than that observed in complexes with wild-type dIII. 
In summary, the results in this section show that the lag phase at the onset of 
the cyclic reaction can be attributed to the slow binding of NADP
+
 into the 
dIII.R165A site. Some slow binding of NADH probably also takes place in these 
experiments and leads to a contribution from an aberrant cyclic reaction. 
 
Figure 3.8 (over page) Experiments measuring the cyclic reaction catalysed by dI2dIII complexes 
formed with dI and apo-dIII.R165A from R. rubrum transhydrogenase. 
The cyclic reaction was recorded as the reduction of AcPdAD+ by NADH with added NADP+ as 
described in Section 2.3.4. In experiment (a), recording was started immediately after the initial 
mixture (in curly brackets) was added to the cuvette. In experiment (b) the initial mixture was 
incubated in the cuvette for 1 minute before recording was started, and in experiments (c) and (d) the 
initial mixture was incubated for 2 minutes before recording was started. The reactions were initiated in 
each experiment by the addition of nucleotides or proteins (shown by the arrows). Disturbances from 
mixing are replaced by dashed lines for clarity. Concentrations were 30 nM for dIII.R165A; 1.0 µM for 
dI; 200 µM for NADH; 200 µM NADP+ and 200 µM for AcPdAD+. 
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3.3 Analysis of the lag phase to determine the kinetics of nucleotide-binding 
to dIII in dI2dIII complexes from R. rubrum transhydrogenase. 
 
The lag phase at the onset of the cyclic and aberrant cyclic reactions was analysed to 
determine the kinetics of nucleotide-binding to dIII in dI2dIII complexes constructed 
with dI and either wild-type apo-dIII or apo-dIII.R165A. In the first set of 
experiments, a protocol similar to that shown in figures 3.3b and 3.5b, for the aberrant 
cyclic reaction was adopted. In this protocol dI2dIII complexes were incubated with 
AcPdAD
+
 before the reaction was initiated by the addition of NADH. The reactions 
started with a lag phase. The rate of AcPdAD
+
 reduction during this lag phase was 
plotted against time (Figure 3.9). Since the binding of NADH to dIII is slow, and the 
rates of other component reactions are fast, the rate of AcPdAD
+
 reduction during the 
lag phase is proportional to the degree of occupancy of the dIII site. The plots 
therefore show the filling of the dIII site with NADH. Assuming that all the sites are 
filled when the maximum rate of reaction is reached, the time taken to fill half the 
sites (t½) was ~10 s. In a second set of experiments, using a protocol similar to that 
shown in figures 3.6c and 3.7c, dI2dIII complexes were incubated with AcPdAD
+
 
before the reaction was initiated by the simultaneous addition of NADH and NADP
+
. 
Again, the reactions started with a lag phase and the rate of AcPdAD
+
 reduction 
during this lag phase was plotted against time (Figure 3.9A).  Here, the NADH and 
NADP
+
 compete for dIII binding sites to produce a population of complexes 
catalysing the cyclic reaction and a population catalysing the aberrant cyclic reaction. 
 The plots show that the kinetics of nucleotide-binding to dIII were similar in 
both sets of experiments. Thus, the kinetics of NADH-binding and of NADP
+
-binding 
to dIII in dI2dIII complexes are similar. The kinetics were also similar for the binding 
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of nucleotides to the dIII component of the complexes, whether using wild-type dIII 
or dIII.R165A. Further analysis of the data is consistent with nucleotide binding to 
dIII (wild-type dIII or dIII.R165A) being first-order in dI2dIII complexes (Figure 
3.9B). 
 
 
Figure 3.9 (over page) Kinetics of the lag phase in experiments measuring the cyclic and aberrant 
cyclic reactions catalysed by dI2dIII complexes constructed with dI and either wild-type apo-dIII 
or apo-dIII.R165A from R. rubrum transhydrogenase.   
The apo-form of wild-type dIII was prepared by phosphatase treatment (see Section 2.2.7), and of 
dIII.R165A, by two passages down a gel-filtration chromatography column (see Section 2.2.4). Rates 
of AcPdAD+ reduction were measured from experiments with complexes of wild-type dI and either 
wild-type apo-dIII (solid lines, closed symbols) or apo-dIII.R165A (dashed lines, open symbols). In the 
first set of experiments, using the protocol shown in figures 3.3b and 3.5b, the reaction was initiated by 
the addition of 200 M NADH (blue lines, circles). In a second set of experiments, using the protocol 
from figures 3.6c and 3.7c, the reaction was initiated by the simultaneous addition of  200 M NADP+ 
and 200 M NADH (red lines, triangles). Rates were calculated from tangents to the absorbance change 
at 375 nm, and were plotted as a function of time after initiating the reaction (Panel A). The  plots from 
the two sets of experiments were normalised to the same maximum rate (at the end of the lag phase). 
Results of duplicate experiments from each experimental condition are presented to illustrate scatter on 
the data. 
 The rate of AcPdAD+ reduction during the lag phase is proportional to the degree of 
occupancy of dIII. Points were taken from one data set of the graph shown in Panel A. From these data 
points the concentration of apo-dIII was calculated at various time intervals (assuming that the 
concentration of apo-dIII at 100% of the maximum rate of AcPdAD+ reduction was 0 nM, and at 0% of 
the rate was 30 nM, which is the total concentration of dIII added to the reaction). Plotting ln[apo-dIII] 
against time gave a straight line graph (Panel B); this is consistent with nucleotide binding to dIII being 
first-order in dI2dIII complexes (see Figure 5.2). 
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3.4 Estimation of nucleotide-binding affinities of wild-type dIII and 
dIII.R165A in dI2dIII complexes from R. rubrum transhydrogenase by 
measuring the rates of the cyclic and aberrant cyclic reactions.  
 
Experiments, in which the rates of the cyclic and aberrant cyclic reactions were 
measured, were extended in attempts to estimate Kd values of wild-type dIII and 
dIII.R165A in dI2dIII complexes for NADP
+
, NADPH and NADH.  
Firstly, to estimate binding affinities for NADP
+
 and NADPH, dI2dIII 
complexes constructed with dI and either wild-type apo-dIII or apo-dIII.R165A were 
incubated for 5 minutes with AcPdAD
+
 and varying concentrations of either NADP
+
 
or NADPH before the reaction was initiated by the addition of NADH. Recall that 
AcPdAD
+
 is unable to bind to the dIII in these complexes, thus the initial rate of 
reaction should be proportional to the amount of dIII occupied by either NADP
+
 or 
NADPH. The concentration required to reach the half-maximal rate in complexes 
with wild-type dIII was ~5 µM for NADP
+ 
(Figure 3.10A) and ~1 µM for NADPH 
(Figure 3.10B). In complexes with dIII.R165A the concentration required to reach the 
half-maximal rate was ~40 µM for NADP
+
 (Figure 3.10A) and ~1 µM for NADPH 
(Figure 3.10B). 
Secondly, experiments were performed to estimate the binding affinity of 
wild-type dIII and dIII.R165A in dI2dIII complexes for NADH. Complexes 
constructed with dI and either wild-type apo-dIII or apo-dIII.R165A were incubated 
for 5 minutes with varying concentrations of NADH before the reaction was initiated 
by the addition of AcPdAD
+
. In the incubation period the NADH bound to the dIII to 
an extent dependent on binding affinity. Thus, the initial rate of reaction should be 
proportional to the amount of dIII occupied by NADH when the reaction is initiated. 
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The concentration of NADH needed to reach the half-maximal rate in dI2dIII 
complexes was ~40 µM in complexes formed with wild-type dIII and with 
dIII.R165A (Figure 3.10C).  
There are a number of difficulties in relating the experimental values from 
Figure 3.10 to nucleotide-binding affinities. Firstly, the substrate concentration 
required to give a half-maximal rate of an enzyme-catalysed reaction (the Km when 
other substrates are saturating) is only a measure of the Kd for some kinetic schemes 
(Fersht 1999). Secondly, in both the cyclic and aberrant cyclic reactions, catalysed by 
dI2dIII complexes, NADH and AcPdAD
+
 compete for the same site on dI causing 
substrate inhibition (Bizouarn et al. 1995). This leads, for example, to the decrease in 
reaction rate at high concentrations of NADH in Figure 3.10C and will complicate the 
analysis. Thirdly, there is a problem in experiments shown in Figure 3.7 and 3.8 that 
NADH and NADP
+
 both compete for the same site on dIII, giving rise to a mixture of 
cyclic and aberrant cyclic reactions. It is concluded that the above estimates of the 
nucleotide concentrations which give half-maximal rates of reaction are only loosely 
indicative of the Kd values.  
 
 
 
 
 
 
 
 
 
 
 
 
 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10 continued over page  
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Figure 3.10 Effect of nucleotide concentration on the initial rate of the cyclic or aberrant cyclic 
reactions catalysed by dI2dIII complexes from R. rubrum transhydrogenase. 
To estimate binding affinities of wild-type dIII (solid lines, closed symbols) or dIII.R165A (dashed 
lines, open symbols) in dI2dIII complexes for NADP
+ and NADPH, the initial rate of the cyclic 
reaction (i.e. the rate of AcPdAD+ reduction by NADH in the presence of NADP(H)) was measured as 
a function of NADP+ concentration (A, triangles) or NADPH concentration (B, squares). To estimate 
binding affinities of wild-type dIII or dIII.R165A in dI2dIII complexes for NADH, the initial rate of the 
aberrant cyclic reaction (i.e. the rate of AcPdAD+ reduction by NADH in the absence of NADP(H)) 
was measured as a function of  NADH concentration (C, circles). The reaction conditions were as 
described in Section 2.3.4 except that the initial mixture was incubated for 5 minutes before the 
reaction was initiated. The data plotted are of single measurements. 
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CHAPTER 4 
 
 
The nucleotide-binding properties of the 
dIII component of dI2dIII complexes from 
R. rubrum transhydrogenase determined by 
fluorescence experiments. 
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4.1 Fluorescence properties of dIII.E155W from R. rubrum 
transhydrogenase. 
 
The fluorescence of the single tryptophan residue (βTrp415) in E. coli dIII is affected 
by the redox state of the bound nucleotide (Fjellstrom et al. 1997; Fjellstrom et al. 
1999b). The equivalent residue in R. rubrum dIII is Glu155 and it was replaced by a 
tryptophan (Peake et al. 1999a). Complexes of R. rubrum dI and dIII.E155W had 
rates of cyclic transhydrogenation that were undiminished from those of wild-type 
dI2dIII complexes. However, the fluorescence of the lone Trp155 was sensitive to the 
redox state of the bound nucleotide; it was greater when NADP
+
 was bound than 
when NADPH was bound (Peake et al. 1999a; Venning et al. 2000; Pinheiro et al. 
2001; Rodrigues et al. 2001; Venning et al. 2001). This provides a useful system for 
studying nucleotide binding.  
 In previous studies, when excess NADPH was added to a solution containing 
NADP
+
-bound dIII.E155W, a slow fluorescence quenching was observed (Rodrigues 
et al. 2001). It was reasoned that NADPH in excess would bind rapidly into the dIII 
site once the NADP
+
 had dissociated. This enabled the first-order rate constant for 
NADP
+
 release to be calculated. Conversely, when excess NADP
+
 was added to a 
solution containing NADPH-bound dIII.E155W, a very slow fluorescence increase 
was seen. The rate was attributed to the dissociation of NADPH and the first-order 
rate constant for NADPH release was calculated. At neutral pH, the first-order rate 
constants for NADP
+
 and NADPH release were 0.018 s
-1
 and 0.00045 s
-1
, respectively 
(Rodrigues et al. 2001). This was evidence not only that nucleotide release from dIII 
is very slow, but also indicated that isolated dIII binds NADPH with a higher affinity 
than NADP
+
.  
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4.2 Properties of dI.W72F, in which the single Trp of wild-type dI from R. 
rubrum transhydrogenase has been replaced by a Phe. 
 
Wild-type dI from R. rubrum transhydrogenase has a single tryptophan at position 72 
with an intense fluorescence at an unusually short wavelength (Broos et al. 2003; 
Tveen Jensen et al. 2008). The fluorescence from Trp72 is quenched when dI binds 
NADH. The objective of the work described in this chapter was to investigate the 
properties of nucleotide binding to the dIII component of dI2dIII complexes. To this 
end it was necessary to replace Trp72 of dI with a non-fluorescent amino acid residue. 
The fluorescence of dI2dIII complexes made of this protein and dIII.E155W would 
then arise only from the lone tryptophan in dIII.E155W. 
 The mutant dI.W72F was isolated as described in Section 2.1.4, and was 
purified by the same procedure as was effective for wild-type dI (see Section 2.2.3). 
Complexes made from dI.W72F and dIII.E155W catalysed cyclic transhydrogenation 
at a rate of ~3170 mol AcPdAD
+
 reduced mol
-1
 dIII min
-1
, which was comparable to 
rates of reaction catalysed by complexes made from wild-type dI and dIII.E155W 
(~2560 mol AcPdAD
+
 reduced mol
-1
 dIII min
-1
). This shows that the W72F mutation 
of the dI component has no inhibitory effect on catalysis. 
 In a set of experiments (Figure 4.1) it was found that the dependence of the 
rate of cyclic transhydrogenation on the dI.W72F concentration at a fixed 
concentration of dIII.E155W was similar to that observed with wild-type dI. The dI 
concentration required to reach the half-maximal rate was ~55 nM for complexes with 
dI.W72F and ~70 nM for complexes with wild-type dI. These results are comparable 
to equivalent experiments using complexes of wild-type dI and wild-type dIII (Diggle 
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et al. 1996). This indicates that dI.W72F forms complexes with dIII.E155W with a 
similar affinity to wild-type dI.  
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Figure 4.1 Effect of dI concentration on the rate of cyclic transhydrogenation catalysed by 
complexes constructed with dIII.E155W and either wild-type dI or dI.W72F from R. rubrum 
transhydrogenase.  
The initial rate of AcPdAD+ reduction by NADH in the presence of NADP+ was measured under 
standard conditions (described in Section 2.3.4). The reactions were catalysed by complexes 
constructed from dIII.E155W and either wild-type dI (solid line, circles) or dI.W72F (dashed line, 
triangles). The dIII concentration was kept constant (30 nM) while the dI concentration was varied. The 
data plotted are of single measurements. 
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4.2.1 Fluorescence properties of dI.W72F. 
 
The fluorescence emission spectra of wild-type dI and dI.W72F using excitation 
wavelengths of 275 nm and 290 nm are shown in Figure 4.2. At both excitation 
wavelengths the intense emission at 308 nm is considerably reduced by the mutation, 
consistent with the view that the fluorescence in the wild-type protein originates from 
Trp72.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Fluorescence emission spectra of isolated wild-type dI and dI.W72F from R. rubrum 
transhydrogenase. 
Fluorescence emission scans were performed on a PTI Quantamaster fluorimeter as described in 
Section 2.4.1. The experimental cuvette contained 20 mM MOPS-KOH, pH 7.0 and 1.0 µM of either 
isolated wild-type dI (solid lines) or dI.W72F (dashed lines) in a final volume of 3 mL. The excitation 
wavelength was 275 nm (black line) or 290 nm (red line). 
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Tryptophan emission is excited strongly by light at both 275 nm and 290 nm 
(Lakowicz 2004); thus, the fluorescence from the wild-type dI is only slightly less 
intense using 290 nm excitation. However, tyrosine emission is much reduced when 
excited at 290 nm (Lakowicz 2004). The fluorescence emission of dI.W72F at around 
300-310 nm when excited at 290 nm is rather less than when excited at 275 nm. This 
suggests that the low fluorescence in dI.W72F originates from the 8 tyrosine residues 
in the protein. This low fluorescence was unaffected by the addition of NADH to the 
protein (data not shown).  
  
4.3 The binding of nucleotides to the dIII.E155W component of dI2dIII 
complexes from R. rubrum transhydrogenase. 
 
4.3.1 The binding of nucleotides to dIII.E155W in complexes constructed with 
dI.W72F and apo-dIII.E155W from R. rubrum transhydrogenase. 
 
Experiments were designed to measure the binding of nucleotides to the dIII 
component of dI2dIII complexes constructed with dI.W72F and apo-dIII.E155W 
(Figure 4.3). The dIII.E155W used in these experiments had been treated with 
phosphatase to produce apo-dIII.E155W. In each experiment there was an initial rapid 
fluorescence quenching upon addition of nucleotides which was due to an inner-
filtering effect (the reabsorption of emission light and/or the absorption of excitation 
light by the nucleotide). It is assumed that the slow fluorescence changes following 
this inner-filtering effect were the result of the binding of nucleotides to dIII.E155W. 
The Trp155 fluorescence was then measured during the addition of various 
nucleotides, all at 20 µM. Following the inner-filtering effect, the addition of NADP
+
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gave rise to a slow increase in fluorescence (Figure 4.3a), and the addition of the 
reduced nucleotides NADPH (Figure 4.3b) and NADH (Figure 4.3c) gave rise to a 
slow decrease in fluorescence. These fluorescence changes can be attributed to the 
slow binding of the nucleotides to the dIII component of the complexes. It should be 
recalled that the addition of NADH to isolated dI.W72F did not cause any change in 
fluorescence. Replicate experiments showed that the addition of NAD
+
 (for example 
Figure 4.3d) led to a small but reproducible increase in fluorescence, but that the 
addition of AcPdAD
+
 (Figure 4.3e) did not cause any significant fluorescence change.  
 
 
Figure 4.3 (over page) Fluorescence experiments showing the binding of nucleotides to 
dIII.E155W in complexes formed with dI.W72F and apo-dIII.E155W from R. rubrum 
transhydrogenase. 
Fluorescence experiments were performed on a PTI Quantamaster fluorimeter as described in Section 
2.4.1. For each experiment, the initial mixture (3 mL), containing 20 mM MOPS-KOH, pH 7.0, 0.4 µM 
apo-dIII.E155W and 0.8 µM dI.W72F, was incubated for 5 minutes before recording was started. 
Nucleotides (20 µM) were added as shown by the arrows. The change in fluorescence intensity 
resulting from nucleotide-binding to dIII.E155W in the complexes was recorded. The initial rapid 
fluorescence quenching was due to the inner-filtering effect.  
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Figure 4.3 
 
 
4.3.2 Properties of the double mutant dIII.E155W.R165A from R. rubrum 
transhydrogenase. 
 
A double mutant of the dIII component of R. rubrum transhydrogenase, 
dIII.E155W.R165A, was isolated (as described in Section 2.1.4), in which Arg165 
from the K-R-S motif in the dIII binding-site was mutated to an alanine residue, and 
Glu155 was replaced by a tryptophan. The double mutant was purified by the same 
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procedure as was effective for dIII.R165A (see Section 2.2.4), and the apo-form of the 
protein was produced by subjecting the protein to gel-filtration. 
 Complexes made from dI and dIII.E155W.R165A catalysed cyclic 
transhydrogenation at a rate of 1750 ± 380 mol AcPdAD
+
 reduced mol
-1
 dIII min
-1
, 
which was comparable to rates of reaction catalysed by complexes made from dI and 
dIII.R165A (1770 ± 130 mol AcPdAD
+
 reduced mol
-1
 dIII min
-1
) (both values are the 
average of 3 preparations). This confirms earlier reports (Peake et al. 1999a) that the 
E155W mutation has no inhibitory effect on catalysis. In a set of experiments it was 
found that the dependence of the rate of the cyclic reaction on NADP
+
 (Figure 4.4A) 
or NADPH (Figure 4.4B) concentrations were similar to those observed with 
dIII.R165A (see Figure 3.5). The concentrations of NADP
+
 and NADPH needed to 
reach the half-maximal rate using complexes made with dI and dIII.E155W.R165A 
were ~20 µM and ~1 µM, respectively. This indicates that, when in complex with dI, 
dIII.E155W binds nucleotides with a similar affinity to dIII.R165A.  
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Figure 4.4 Effect of NADP(H) concentration on the rate of cyclic transhydrogenation catalysed 
by complexes made with dI and dIII.E155W.R165A from R. rubrum transhydrogenase.  
To estimate binding affinities of dIII.E155W.R165A in dI2dIII complexes for NADP
+ and NADPH, the 
initial rate of AcPdAD+ reduction by NADH was measured as a function of NADP+ concentration (A, 
triangles) or NADPH concentration (B, squares). The reaction conditions were as described in Section 
2.3.4. The data plotted are of single measurements. 
B. 
A. 
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4.3.3 The binding of nucleotides to dIII.E155W.R165A in complexes 
constructed with dI.W72F and apo-dIII.E155W.R165A from R. rubrum 
transhydrogenase. 
 
Fluorescence experiments, similar to those shown in Figure 4.3, were designed to 
observe the binding of nucleotides to the dIII component of complexes made with 
dI.W72F and apo-dIII.E155W.R165A (Figure 4.5). The Trp155 fluorescence was 
measured during the addition of various nucleotides (20 µM) to these complexes. The 
addition of NADP
+
 gave rise, following the inner-filtering effect, to a slow increase in 
fluorescence (Figure 4.5a). The addition of the reduced nucleotides NADPH (Figure 
4.5b) and NADH (Figure 4.5c) gave rise to a slow decrease in fluorescence. These 
fluorescence changes signify the binding of the nucleotides to the dIII component of 
the complexes. Replicate experiments showed that the addition of NAD
+
 (Figure 4.5d) 
led to a small but reproducible increase in fluorescence, but the addition of AcPdAD
+
 
(Figure 4.5e) did not cause any significant fluorescence change. 
 The fluorescence changes shown in these experiments are similar to those 
observed when nucleotides were added to complexes made with dI.W72F and apo-
dIII.E155W (see Figure 4.3). 
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Figure 4.5 Fluorescence experiments showing the binding of nucleotides to dIII.E155W.R165A in 
complexes formed with dI.W72F and apo-dIII.E155W.R165A from R. rubrum transhydrogenase. 
Fluorescence experiments were performed on a PTI Quantamaster fluorimeter as described in Section 
2.4.1. The initial mixture (3 mL) containing 20 mM MOPS-KOH, pH 7.0, 0.4 µM apo-
dIII.E155W.R165A and 0.8 µM dI.W72F was equilibrated for 5 minutes in the experimental cuvette. 
Nucleotides (20 µM) were then added (as shown by the arrows) while the fluorescence intensity was 
measured. The initial rapid fluorescence decrease was due to the inner-filtering effect.  
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4.4 Kinetics of nucleotide-binding to dIII.E155W and dIII.E155W.R165A in 
complexes with dI.W72F from the fluorescence experiments. 
  
The slow fluorescence changes produced by nucleotide addition to complexes made 
with dI.W72F and either dIII.E155W or dIII.E155W.R165A (see figures 4.3 and 4.5) 
can be attributed to nucleotide-binding into the dIII site. The amplitude of the 
fluorescence change was measured at various time intervals after the addition of the 
nucleotide and plotted as a function of time (Figure 4.6). The amplitude of the 
fluorescence change is assumed to be proportional to the degree of occupancy of dIII. 
Figure 4.6 and other experiments (not shown) establish that the kinetics of NADP
+
-
binding, NADPH-binding and NADH-binding to dIII.E155W or dIII.E155W.R165A, 
in complexes with dI.W72F, were similar within the scatter on the data (i.e. the rate of 
nucleotide-binding is not affected by the chemical nature of nicotinamide nucleotide 
or by its oxidation state). In previous work it was shown that the exchange of NADP
+
 
for NADPH bound to dIII.E155W (in complexes with wild-type dI) led to a decrease 
in fluorescence (Peake et al. 1999a; Rodrigues et al. 2001; Venning et al. 2001). The 
fluorescence decrease was attributed to resonance energy transfer from Trp155 to the 
NADPH. However, here we have shown that the binding of oxidised nucleotides 
(NADP
+
 and NAD
+
) to dIII.E155W in complexes with dI.W72F causes a fluorescence 
increase and the binding of reduced nucleotides (NADPH and NADH) causes a 
fluorescence decrease. This suggests that the environment around Trp155 is altered by 
the binding of nucleotides, and that the changes in the Trp155 environment caused by 
reduced nucleotides are different from those caused by oxidised nucleotides. 
The rate of the fluorescence change was also unaffected by varying the 
concentration of the added nucleotide. If the binding of nucleotides were a simple, 
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second-order reaction, the initial rate of the fluorescence change (following the inner-
filtering effect) would be directly proportional to the nucleotide concentration. 
However, at least with NADP
+
, NADPH and NADH in complexes formed with 
dI.W72F and dIII.E155W.R165A, and with NADH in complexes formed with 
dI.W72F and dIII.E155W, this was not the case. An increase in nucleotide 
concentration led to a less than proportionate increase in the initial rate. Because of its 
high affinity, this was most readily seen with NADPH. Thus, above 1 µM (where the 
binding-sites were fully occupied at equilibrium) and below 50 µM (where the inner-
filtering effect was still manageably small), the initial rate of fluorescence change was 
independent of nucleotide concentration. This suggests that the binding of nucleotides 
to dIII in dI2dIII complexes is not a simple, second-order process but that binding is 
likely to involve a conformational change of the protein. 
Within error, the kinetics of nucleotide-binding to the dIII component of 
dI2dIII complexes determined from the analyses of the lag phases of the cyclic and 
aberrant cyclic reactions (see Figure 3.9) are similar to those determined from the 
amplitudes of the fluorescence change. Although the scatter on the data is large, the 
half times (t½) for nucleotide-binding (Figures 3.9 and 4.6) were all in the order of 
25 s.  
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Figure 4.6 Kinetics of nucleotide-binding to either apo-dIII.E155W or apo-dIII.E155W.R165A in 
complexes with dI.W72F from R. rubrum transhydrogenase. 
Nucleotides were added to complexes constructed with dI.W72F and either apo-dIII.E155W (solid 
lines, closed symbols) or apo-dIII.E155W.R165A (dashed lines, open symbols). The amplitude of the 
resulting fluorescence change (following the inner-filtering effect) was measured as a function of time. 
Experiments are shown using two concentrations of each nucleotide; the concentrations were 1 µM and 
40 µM for NADPH (green lines, squares) and 5 µM and 50 µM for both NADP+ (red lines, triangles) 
and NADH (blue lines, circles).  
 
 
 
4.5 Nucleotide-binding affinities of dIII.E155W and dIII.E155W.R165A from 
R. rubrum transhydrogenase estimated from fluorescence experiments. 
 
A set of experiments was designed to estimate Kd values of dIII.E155W and 
dIII.E155W.R165A for nucleotides when in complex with dI.W72F. Complexes were 
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generated from dI.W72F and either apo-dIII.E155W or apo-dIII.E155W.R165A, and 
the Trp155 fluorescence was measured during the addition of nucleotides (varying 
concentrations). Following the inner-filtering effect, slow fluorescence changes were 
observed (similar to those shown in Figures 4.3 and 4.5) that can be attributed to the 
slow binding of nucleotides to the dIII component of the complexes. The amplitude of 
this fluorescence change was assumed to be proportional to the occupation of the dIII 
component and was plotted as a function of nucleotide concentration (Figure 4.7).  
 
 
Figure 4.7 (over page) The dependence of the Trp fluorescence change on nucleotide 
concentration in complexes constructed with dI.W72F and either apo-dIII.E155W or apo-
dIII.E155W.R165A from R. rubrum transhydrogenase. 
Fluorescence experiments were performed on a PTI Quantamaster fluorimeter as described in Section 
2.4.1.  Nucleotide at the concentrations shown was added to solutions containing complexes generated 
with 0.8 µM dI.W72F and either 0.4 µM apo-dIII.E155W (solid lines, closed symbols) or 0.4 µM apo-
dIII.E155W.R165A (dashed lines, open symbols). The amplitude of the Trp fluorescence change was 
assumed to be proportional to the occupancy of the dIII component in the complexes. Thus, the 
amplitude was measured as a function of NADP+ concentration (A, triangles), NADPH concentration 
(B, squares) or NADH concentration (C, circles). The data plotted are of single measurements. 
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Figure 4.7 continued over page 
 
A. 
B. 
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Figure 4.7 continued 
 
 
Since the concentration of the dIII component in these experiments is in the 
same order as the nucleotide concentrations, the Kd values could not simply be 
calculated from the graphs in Figure 4.7 as the nucleotide concentration needed to 
reach the half-maximal fluorescence change. The equation                      
(where [E.nuc] is the concentration of enzyme with bound nucleotide, [nuc] is the 
concentration of free nucleotide and [E] is the concentration of unbound enzyme) can 
be expanded to                                where      is the total  enzyme 
concentration) and then to              
      
     
   (Fersht 1999). Plotting [E.nuc] 
vs               gave straight line graphs (Figure 4.8), of which the gradients were 
equal to –Kd. Thus, the Kd of dIII.E155W in complex with dI.W72F for NADH was 
~4 µM (Figure 4.8D). The Kd of dIII.E155W.R165A in complex with dI.W72F for 
NADPH was ~0.1 µM (Figure 4.8B), for NADP
+
 was ~12 µM (Figure 4.8A) and for 
C. 
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NADH was ~8 µM (Figure 4.8C). The Kd values of dIII.E155W in the complexes for 
NADP
+
 or NADPH could not be reliably estimated in this way due to carry-over of 
phosphatase into the fluorescence cuvette. The concentration of the carried-over 
phosphatase was such that the 2’-phosphate of a significant fraction of the added 
NADP
+
 or NADPH would have been cleaved during the assay. 
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Figure 4.8 continued over page 
B. 
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Figure 4.8 Plots to estimate the Kd values of either dIII.E155W or dIII.E155W.R165A in complex 
with dI.W72F for nucleotides. 
Using various data points from the graphs in Figure 4.7, [E.nuc] and [nuc] were calculated. Plots of 
[E.nuc] vs [E.nuc]/[nuc] gave straight line graphs with a gradient of –Kd. Thus, the Kd values for either 
dIII.E155W (solid lines, closed symbols) or dIII.E155W.R165A (dashes lines, open symbols) in 
complex with dI.W72F for NADP+ (A, triangles), NADPH (B, squares) and NADH (C and D, circles) 
were calculated. 
 
D. 
C. 
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CHAPTER 5 
 
Discussion 
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5.1 Nucleotide-binding affinities of the dIII component of R. rubrum 
transhydrogenase: overall conclusions. 
 
The nucleotide-binding affinities of the dIII component in dI2dIII complexes were 
estimated either by measuring the rates of the cyclic and aberrant cyclic reactions 
(Chapter 3), or by measuring the amplitude of fluorescence changes caused by 
nucleotide addition (Chapter 4). A summary of the results is given in Table 5.1. The 
indications are that in dI2dIII complexes wild-type dIII has nucleotide-binding 
affinities in the order NADPH > NADP
+ 
> NADH > NAD
+
 > AcPdAD
+
, and 
dIII.R165A has nucleotide-binding affinities in the order NADPH > NADP
+ ≈ NADH 
> NAD
+
 > AcPdAD
+
. 
 Wild-type dIII binds its reduced substrate NADPH with a higher affinity than 
that of its oxidised substrate NADP
+
. NMR experiments have shown that there are 
structural differences between dIII in its NADPH-bound form and in its NADP
+
-
bound form (Quirk et al. 1999). However, these structural differences have not been 
observed in any of the published crystal structures that include the dIII component 
(Prasad et al. 1999; White et al. 2000; Cotton et al. 2001; Sundaresan et al. 2003; 
Mather et al. 2004; Bhakta et al. 2007). Wild-type dIII also binds the reduced 
nucleotide NADH with a higher affinity than that of the oxidised nucleotide NAD
+
. 
The weaker binding of NADH than NADPH, and of NAD
+
 than NADP
+
, to wild-type 
dIII is probably due to the replacement of the 2’-phosphate group of NADP(H) for the 
2’-hydroxyl group of NAD(H). The absence of the 2’-phosphate group will lead to the 
elimination of hydrogen bonds between the residues in the NADP(H)-binding site 
(e.g. the K-R-S motif) and the nucleotide. Interestingly, dIII.R165A was found to bind 
NADH and NADP
+
 with a similar affinity. As well as decreasing the affinity for 
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NADP
+
, the R165A mutation also eliminated some specificity of dIII for NADP
+
. 
Clearly, Arg165 (together with Lys164 and Ser166 of the K-R-S motif) and the set of 
interactions involving the 2’-phosphate moiety of the NADP(H), play important roles 
in both nucleotide-binding and nucleotide-specificity.  
 
experiment type protein apparent Kd 
a
 (µM) 
NADPH NADP
+ 
NADH 
enzyme assays 
 
enzyme assays 
wild-type dIII 1 5 40 
 
dIII.R165A 
 
1 
 
40 
 
40 
 
enzyme assays 
 
dIII.E155W.R165A 1 20 ND
b 
fluorescence  
 
fluorescence 
dIII.E155W ND
b 
ND
b 
4 
 
dIII.E155W.R165A 
 
0.1 
 
12 
 
8 
 
Table 5.1 Summary of apparent Kd values of dIII components in dI2dIII complexes for 
nucleotides.  
a Apparent Kd values were either estimated from enzyme assays as the nucleotide concentration 
required to reach the half-maximal rate (see Chapter 3), or calculated from fluorescence experiments 
(see Chapter 4).  
b ND = not determined. 
 
 
The NAD
+
 analogue, AcPdAD
+
, was unable to bind to the dIII component of 
dI2dIII complexes under the conditions of the experiments described in this thesis. 
AcPdAD
+
 has an acetyl group in place of the carboxamide at the C3 position of the 
nicotinamide ring of NAD
+
. The crystal structure of R. rubrum dIII with bound 
NADP
+ 
(Sundaresan et al. 2003), shows that the NH2 group of the carboxamide forms 
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hydrogen bonds with the highly conserved residues Val87, Ala88 and Met91 (Figure 
5.1). There are also potential hydrogen bonds between these residues and the NH2 
group of the carboxamide in the crystal structures of dIII from H. sapiens (White et al. 
2000) and B. taurus (Prasad et al. 1999). These hydrogen bonds will clearly be lost 
when AcPdAD
+
 binds into the site in place of NADP
+
. This will account for the 
failure to observe a significant degree of binding of AcPdAD
+
 in the experiments 
described in Chapters 3 and 4.  
 
 
 
Figure 5.1 Crystal structure showing the importance of the carboxamide group of the 
nicotinamide moiety of NADP
+
 in binding to dIII.  
Hydrogen bonds between the NH2 of the carboxamide group and residues Val87, Ala88 and Met91 of 
R. rubrum dIII are shown as dashed green lines. This figure was produced using Swiss-PDB Viewer 
and Povray using PDB ID 1PNO. 
 
 
 
 
 
V 
A 
M 
NH2 
NADP+ 
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5.2 The mechanistic significance of the slow binding of nucleotides to the dIII 
component of dI2dIII complexes from R. rubrum transhydrogenase. 
 
As described in Section 1.11, transhydrogenase is thought to function by way of a 
binding-change mechanism involving open and occluded conformations of the 
enzyme. Nucleotides can bind to or dissociate from dI in either conformation. 
However, nucleotides can only bind to or dissociate from dIII when in the open 
conformation. In the occluded conformation, the (dihydro)nicotinamide rings of the 
nucleotides are brought together and  hydride transfer is permitted. The switch 
between the open and occluded conformations is thought to be central in the coupling 
mechanism of hydride transfer and proton translocation. Loop E of dIII has been 
identified as an important structural element involved in this switch. Crystal structures 
show loop E closed over the bound nucleotide when dIII adopts an occluded 
conformation (White et al. 2000; Sundaresan et al. 2003; Bhakta et al. 2007). 
Although no crystal structures of dIII in the open conformation have been solved, it is 
thought that loop E retracts to allow the conversion from the occluded to the open 
state (Rodrigues et al. 2002). Analyses of the results presented in this thesis not only 
support the proposed binding-change mechanism of transhydrogenase, but also give a 
kinetic and structural insight into the conversion between the open and occluded 
conformations. 
It was shown by enzyme assays (Chapter 3) and fluorescence experiments 
(Chapter 4) that nucleotide-binding to the dIII component of dI2dIII complexes is very 
slow. Furthermore, the initial rates of fluorescence changes caused by nucleotide-
binding to dIII in the complexes were independent of the concentration of the 
nucleotide. This led to the suggestion that the binding of nucleotides to the dIII 
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component of dI2dIII complexes is not a simple, second-order process but that binding 
is likely to involve a conformational change of the protein (see Section 4.4). The new 
data can be readily explained by the model for nucleotide-binding in Figure 5.2. This 
model is consistent with the finding that the rate of nucleotide binding is governed by 
a step (i.e. that described by k1), which is first-order in dI2dIII complexes (see Figure 
3.9B). 
 
                  
 
 
 
 
 
Figure 5.2 Model of nucleotide-binding to wild-type apo-dIII or apo-dIII.R165A in dI2dIII 
complexes from R. rubrum transhydrogenase.  
The dIII component of dI2dIII complexes can adopt an open (op) or occluded (occ) conformation. In 
solution, it predominantly adopts the occluded conformation (i.e. K’ is small and K’’’ is large). In the 
open conformation, nucleotide (Nuc)-binding to dIII can occur readily. The protein can then switch to 
the occluded conformation where hydride transfer can take place. For clarity, the binding of nucleotides 
to dI is not shown. Rate constants for each step are represented by k1 through k6.  
 
 
In the model, apo-dIII in the dI2dIII complex exists predominantly in its 
occluded conformation; K’ is small. For nucleotide binding to take place, dIII must 
k6 
k2 
k4 
k5 
k3 
k1 
dI2dIII
occ
 dI2dIII
op
 K’ = k1 / k2 
dI2dIII
op
 + Nuc dI2dIII
op
-Nuc K’’ = k3 / k4 
K’’’ = k5 / k6 dI2dIII
op
-Nuc dI2dIII
occ
-Nuc 
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adopt its open conformation. The switch from the occluded to the open conformation 
is slow; thus k1 is small. Typically, the second-order rate constants for the binding of 
substrates to enzymes are large and in the order of 10
7
 M
-1
 s
-1
 (Fersht 1999). Thus, 
once in its open conformation, dIII is expected to bind nucleotides rapidly; k3 in the 
model is large (perhaps ≈ 107 M-1 s-1). The nucleotide-bound form of dIII also favours 
the occluded conformation; K’’’ is large.  
Within the context of the model, the rate of nucleotide-binding to dIII is 
limited by the conversion of apo-dIII from the occluded to the open conformation (the 
first-order rate constant k1). Since t½ ≈ 25 s for nucleotide-binding to dIII in dI2dIII 
complexes (see Chapters 3 and 4), the value of k1 can be calculated as ~0.03 s
-1
 (using 
the first-order rate equation t½ = ln2/k).  
Rodrigues et al. (Rodrigues et al. 2001) calculated first-order rate constants for 
NADP
+
 and NADPH release from isolated dIII. The rate constant for NADPH release 
(0.00045 s
-1
) was significantly slower than that for NADP
+
 release (0.018 s
-1
) 
suggesting a higher affinity of dIII for the reduced nucleotide. In the experiments of 
Rodrigues et al., excess NADP
+
 was added to solutions of NADPH-bound 
dIII.E155W and the rate of the fluorescence increase was measured.  The rate of 
NADP
+
 binding was thought to be limited by the rate of NADPH release from the 
protein. In other experiments, NADPH was added to a solution of NADP
+
-bound 
dIII.E155W and the rate of the fluorescence decrease was measured. The rate of 
NADPH binding was thought to be limited by the rate of release of NADP
+
. In light 
of the model proposed in this thesis (Figure 5.1) the results of Rodrigues et al. need to 
be re-interpreted.  There are two possibilities. Firstly, the conversion from the 
occluded to the open conformation of nucleotide-bound dIII (k6) limits the binding 
reaction, and is dependent on the chemical nature of the bound nucleotide (i.e. k6 is 
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smaller with NADPH-bound dIII than with NADP
+
-bound dIII). Recall that, in 
contrast, the rate of nucleotide binding to apo-dIII was similar for both NADP
+
 and 
NADPH because it was limited in both cases by the conversion of the occluded apo-
form to the open apo-form (see Chapter 4). An alternative explanation for the results 
of Rodrigues et al. is that the rate constants k4 and k6 are in the same order, and 
therefore the rate of nucleotide release is limited both by the conversion from the 
occluded to open conformation of the protein (k6), and by the dissociation of the 
protein-nucleotide complex when in the open conformation (k4) - NADPH dissociates 
more slowly from dIII than NADP
+
 (i.e. k4 is smaller with NADPH-bound dIII than 
with NADP
+
-bound dIII). 
 The kinetics of nucleotide binding to apo-dIII.R165A in dI2dIII complexes 
were similar to those of wild-type apo-dIII. It was shown that NADP
+
 dissociates 
from dIII.R165A much more readily than from wild-type dIII (see Table 3.1). In 
terms of the model shown in Figure 5.2, this could result from an increase in k4. That 
the kinetics of nucleotide binding to dIII.R165A and wild-type dIII are similar is 
consistent with the view that the R165A mutation had no effect on the rate constant 
(k1) for the conversion from the occluded to the open conformation. The residues of 
the K-R-S motif (including Arg165) are located at the N-terminus of loop E. The 
unchanged value of k1 perhaps therefore indicates that the R165A mutation does not 
greatly affect the rate of opening of loop E during the switch between the occluded to 
the open conformations.  
Crystal structures of dIII, bound to either NADP
+
 or NADPH, show the 
protein in its occluded conformation where loop E is closed over the bound nucleotide 
(Prasad et al. 1999; White et al. 2000; Sundaresan et al. 2003; Bhakta et al. 2007). 
There are numerous interactions between the bound nucleotide and the protein that 
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were thought to be important in stabilising dIII in its occluded conformation. 
Although no structural data of dIII in its apo-form currently exists, it was thought that 
loop E might adopt an open conformation in the absence of bound nucleotide. 
However, the results presented in this thesis suggest that like NADP(H)-bound dIII, 
apo-dIII predominantly adopts its occluded conformation, in which loop E is expected 
to be closed over the nucleotide-binding site. Obviously, in the absence of bound 
nucleotide, interactions between the nucleotide and the protein would be lost. These 
interactions are clearly not as important for stabilising dIII in its occluded state as 
once thought. The question then arises: what stabilises loop E in its occluded 
conformation in the absence of bound nucleotide? The crystal structures of dIII in its 
occluded state also show several intramolecular hydrogen bonds between residues of 
loop E and helix D/loop D of dIII. These residues include Asp132 (via its side chain), 
Glu155 (side chain), Thr134 (peptide carbonyl) and Asn135 (side chain) in helix 
D/loop D, and Ala172 (peptide amine), Arg181 (side chain), Asn176 (side chain) and 
Glu175 (peptide carbonyl) in loop E. Most of these residues are at least partially 
conserved, and Asp132 has previously been identified as being important for 
nucleotide binding (Meuller et al. 1996; Fjellstrom et al. 1999a). Even in the absence 
of bound nucleotide, these hydrogen bond interactions between residues of helix 
D/loop D and loop E may be essential for stabilising dIII in its occluded 
conformation. A crystal structure of apo-dIII would determine the intramolecular 
interactions that stabilise the protein, and indeed loop E, in an occluded conformation. 
Crystallisation trials were attempted with apo-dIII.R165A but were unsuccessful (see 
Chapter 6).  
It remains unclear how the conversion between the occluded and open 
conformations, and thus coupling between hydride transfer and proton translocation in 
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the intact enzyme, is modulated. Further structural information of dIII in its open 
conformation would be particularly revealing and would give an insight into the 
expected conformational change of loop E relative to dIII in its occluded 
conformation. Indeed a crystal structure of the intact enzyme (including the 
membrane-spanning dII components) would answer many unresolved issues 
regarding the coupling mechanism of transhydrogenase. For example, identifying the 
interactions between the dII and dIII components would give us a better 
understanding of how the switch between the open and occluded conformations of the 
protein is modulated during proton translocation, and what interactions cause loop E 
of dIII to favour either its open or occluded conformation. 
 
5.3 The metabolic significance of NADH binding in the “wrong” site of 
transhydrogenase. 
 
Wild-type dIII in dI2dIII complexes binds NADH with a surprisingly high affinity. 
Furthermore, the occurrence of the aberrant cyclic reaction shows that NADH binds to 
dIII in the correct orientation to undergo hydride transfer with nucleotide bound to dI. 
The cyclic and aberrant cyclic reactions are only observed experimentally with the 
non-physiological nucleotide, AcPdAD
+
. The equivalent reactions in the intact 
enzyme with physiological nucleotides would involve the reduction of NAD
+
 by 
NADH; thus resulting in no net change of redox state of the nucleotides and no net 
proton translocation. These equivalent reactions would probably not occur at any 
significant rate in the living cell because turnover of the intact enzyme is driven by ∆p 
and involves switching between the occluded and open states. When dIII is converted 
into the open state it can rapidly release its product nucleotides and bind substrate 
 133 
 
nucleotides; thus breaking the cycling. This said, the phenomenon of NAD(H) binding 
to the dIII site (the “wrong” site) brings into question the efficiency of 
transhydrogenase. If NAD(H) were able to bind to dIII in the intact enzyme in the 
living cell, hydride transfer would occur between NAD
+
 and NADH causing the 
enzyme to slip. There are two possible scenarios for the aberrant binding of NAD(H) 
to dIII in the living cell. Firstly, if NADH bound to dIII and NAD
+
 bound to dI, then 
hydride transfer (not resulting in any overall change of redox state of the nucleotides) 
would lead to outward proton translocation from the n-phase to the p-phase. Since 
there is no free energy available from the redox reaction, this would only take place if 
the proton electrochemical potential was greater inside the bacterial cell compared to 
outside (i.e. ∆p > 0) to drive the reaction. This would be an unlikely occurrence under 
physiological conditions. A more likely scenario (Figure 5.3) would be, if NAD
+
 
bound to dIII and NADH bound to dI. Hydride transfer (again not resulting in any 
overall change in redox state of the nucleotides) would lead to inward proton 
translocation from the p-phase to the n-phase. For this to occur, the proton 
electrochemical potential would need to be greater outside the bacterial cell relative to 
the inside (i.e. ∆p < 0). In this situation, transhydrogenase would dissipate ∆p, 
uncoupling the respiratory chain from ATP-synthesis. For NAD
+
 to bind to dIII in the 
cell, the NAD(H) pool would need to be predominantly in its oxidised form, and the 
free NADP(H) concentration would need to be very low compared to that of NAD
+
. 
Measuring the concentrations of nicotinamide nucleotides in the cell is difficult 
(Krebs et al. 1969) and knowledge of NAD(P)
+
/NAD(P)H ratios and concentrations is 
limited. Therefore, it is difficult to predict whether the conditions, resulting in NAD
+
 
binding to dIII, would ever be met. 
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It cannot be ruled out that, in the living cell, the concentrations and redox 
states of the nicotinamide nucleotides are such that transhydrogenase does not slip. 
NADP(H) concentrations may be too high ever to allow the binding of NAD(H) to 
dIII. In the experiments described in this thesis, NAD(H) was shown to bind to the 
dIII component of dI2dIII complexes; in the intact enzyme with functional dII 
components, the affinity of dIII for NAD(H) may be too low for NAD(H) to bind to a 
significant degree. Thus, it is possible that the aberrant binding of NAD(H) to dIII 
may not occur at any significant rate in the cell and impinge on metabolism.  
 
      
   
 
 
 
Figure 5.3 Cartoon of the chemiosmotic proton circuit showing the transhydrogenation reaction 
that would occur if NAD
+
 bound to dIII in the living cell. 
If NAD+ bound to dIII in the living cell, proton translocation would be coupled to the hydride transfer 
reaction producing NAD+ and NADH from NADH bound to dI and NAD+ bound to dIII. This would 
dissipate ∆p, decreasing the energy available to ATP-synthase to produce ATP. However, the rate of 
electron transport through the electron transport chain, and hence proton pumping into the p-phase, 
would continue at a high rate. This would uncouple the electron transport chain from ATP synthesis. 
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Results and discussion: Part II 
 
CHAPTER 6 
 
Crystallisation of R. rubrum dIII.R165A. 
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6.1 Introduction 
 
Several high-resolution structures of various components of transhydrogenase have 
been determined previously (Table 6.1). However, because of the tight binding of 
NADP(H) to dIII, a structure of apo-dIII is not available. In light of the results 
presented earlier in this work, the crystal structure of apo-dIII would be invaluable to 
provide information about the conformation of apo-dIII. The results predict that apo-
dIII would adopt an occluded conformation, in which loop E is closed over the empty 
nucleotide-binding site. Thus, a crystal structure would give an insight into the 
interactions between residues surrounding the NADP(H)-binding site which may 
stabilise dIII, and indeed loop E, in its occluded conformation.  
Previous work on transhydrogenase (Hu et al. 1999; Bergkvist et al. 2000) has 
shown that mutating residues in the highly conserved K-R-S motif decreases the 
affinity of the protein for NADP(H) (see Section 1.10.2.2). As described earlier in this 
work (Chapter 3), a mutant of the dIII component from R. rubrum transhydrogenase, 
dIII.R165A, was isolated in which the arginine from the highly conserved K-R-S 
motif was substituted for an alanine residue. Enzyme and fluorescence assays as well 
as direct nucleotide-content determination experiments confirmed that dIII.R165A did 
indeed have a significantly decreased affinity for NADP
+
 relative to wild-type dIII. 
Moreover, the apo-form of dIII.R165A was produced by subjecting the protein to gel-
filtration. Following these results, it was considered possible to crystallise apo-
dIII.R165A. To this end, crystallisation trials were prepared as described in this 
chapter. 
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Table 6.1 Table of published crystal structures of transhydrogenase. 
 
protein complex organism resolution 
(Å) 
space 
group 
unit cell parameters 
abc (Å) 
α, β,  (˚) 
(reference) 
PDB ID 
dI-NAD+ R. rubrum 2.0 P21 65.9116.6102.0 
90.0, 104.2, 90.0 
(Buckley et al. 2000) 
1F8G 
 
dI-NADH R. rubrum 1.9 P21 64.1116.792.6 
90.0, 106.3, 90.0 
(Prasad et al. 2002) 
1L7E 
 
apo-dI  
 
R. rubrum 1.8 P21 67.0117.194.2 
90.0, 108.3, 90.0 
(Prasad et al. 2002) 
1L7D 
 
dI-NAD+ E. coli 1.9 P1 38.867.076.6 
67.1, 80.7, 81.0 
(Johansson et al. 2005) 
1X14 
 
dI-NADH E. coli 2.0 P1 38.767.176.8 
67.2, 80.2, 81.6 
(Johansson et al. 2005) 
1X15 
 
apo-dI  
 
E. coli 1.9 P1 38.866.976.3 
67.1, 80.7, 81.2 
(Johansson et al. 2005) 
1X13 
 
dIII-NADP+ R. rubrum 2.1 P6122 117.9117.9211.3 
90.0, 90.0, 120.0 
(Sundaresan et al. 2003) 
1PNO 
 
dIII-NADP+ H. sapiens 2.0 P4122 58.158.1250.8 
90.0, 90.0, 90.0 
(White et al. 2000)  
1DJL 
 
dIII-NADP+ B. taurus 1.2 P1 33.736.738.5 
68.4, 88.0, 74.8 
(Prasad et al. 1999) 
1D4O 
 
dIII-NADPH H. sapiens 2.2 P4122 57.857.8250.9 
90.0, 90.0, 90.0 
(Mather et al. 2004) 
1U31 
 
dIII-NADPH R. rubrum 2.4 P6122 118.3118.3212.8 
90.0, 90.0, 120.0 
(Sundaresan et al. 2003) 
1PNQ 
 
dI2dIII 
(NAD+/NADP+) 
 
 
R. rubrum 
 
 
 
2.5 
 
 
 
P212121 
 
 
 
71.574.2205.1 
90.0, 90.0, 90.0 
 
 
(Cotton et al. 2001) 
1HZZ 
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dI2dIII 
(NAD+/NADP+) 
R. rubrum 2.3 P212121 71.774.0204.2 
90.0, 90.0, 90.0 
(Mather et al. 2004) 
1U28 
 
dI2dIII 
(NADH/NADPH) 
R. rubrum 3.0 P212121 72.374.6204.2 
90.0, 90.0, 90.0 
(Mather et al. 2004) 
1U2D 
 
dI2dIII 
(NAD+/H2NADPH) 
R. rubrum 2.3 P212121 72.274.4204.8 
90.0, 90.0, 90.0 
(Bhakta et al. 2007) 
2OOR 
 
dI2dIII 
(H2NADH/NADP
+) 
R. rubrum 2.6 P212121 71.2101.0131.7 
90.0, 90.0, 90.0 
(Bhakta et al. 2007) 
2OO5 
 
 
 
6.2 A brief overview of protein x-ray crystallography. 
 
X-ray crystallography is a widely used technique to determine the secondary and 
tertiary structure of proteins at high resolution. To begin with, the protein to be 
crystallised must be highly purified and concentrated; the required protein 
concentration depends on the individual protein but is typically around 10-
20 mg mL
-1
.  
 The crystallisation of the protein is often the most difficult part of the 
crystallographic process. A diagrammatic summary of the process is given in Figure 
6.1. Once crystallised, the protein crystal is placed in an x-ray beam where it diffracts 
the x-rays onto a detector to produce a diffraction pattern. From this diffraction 
pattern an electron density map can be calculated and subsequently the three-
dimensional structure of the protein can be determined. 
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Figure 6.1 A diagrammatic overview of x-ray crystallography. 
A protein crystal is placed in a beam of x-rays. The x-rays are diffracted onto a detector to produce a 
diffraction pattern. From this, via Fourier transform, an electron density map can be produced. Once 
refined, this electron density map will show the crystal structure of the protein. 
 
 
6.2.1 Preparation of protein crystals for x-ray crystallography. 
 
There are several methods for the crystallisation of proteins. The most popular 
method, and the one used in this work, is the vapour diffusion method. It consists of a 
sealed well containing a reservoir solution (the mother liquor) and a drop of protein 
either hanging above it (hanging drop) or sitting on a ledge next to it (sitting drop) 
(Figure 6.2).  
diffracted 
beams 
protein 
crystal 
x-ray beam 
detector 
crystal structure 
electron density map 
diffraction pattern 
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 The mother liquor contains a precipitant, for example polyethylene glycol 
(PEG) or ammonium sulphate, as well as a buffer at a suitable pH, and occasionally 
additives. The protein drop consists of both the protein solution and the reservoir 
solution; typically a 1:1 ratio of protein to reservoir solution is used but this can be 
varied to optimise crystallisation. Water from the protein drop diffuses into the 
reservoir solution causing the concentration of the protein and precipitant in the drop 
to slowly increase. This may result in the precipitation of the protein. For the 
precipitation to be such that the protein forms crystals, various properties must be 
explored. For example, temperature, pH, protein concentration and precipitant 
concentration can be varied.  
Once high quality crystals have been grown, the crystals must be mounted to 
be used for data collection. Typically, the crystals are mounted onto a nylon loop, 
although fine capillary tubes can also be used. Data collection takes place at a 
temperature of 100 K to reduce radiation damage caused by the x-rays. There are two 
types of radiation damage. Primary radical formation is where x-rays hit atoms in the 
crystal producing radicals. These radicals then diffuse through the crystal and collide 
with other atoms causing secondary radical formation. Freezing eliminates the ability 
of the radicals to diffuse within the crystal, and thus reduces secondary radical 
formation. In order to prevent the formation of ice crystals, the protein crystals must 
be cryoprotected. Examples of cryoprotectants are glycerol, ethylene glycol and some 
sugars. The protein crystals must be soaked in solutions similar to the mother liquor 
but containing the chosen cryoprotectant, typically at a concentration of 15-25%. It is 
often necessary to soak protein crystals step-wise in solutions containing increasing 
concentrations of the cryoprotectant to avoid crystal damage. The protein (surrounded 
by mother liquor containing the cryoprotectant) is picked up using a nylon loop. It is 
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then flash frozen by plunging the loop containing the crystal into liquid nitrogen. The 
protein crystal is now ready for data collection. 
 
 
 
 
 
 
Figure 6.2 Diagram of a sitting drop crystallisation well. 
Sitting drop crystallisation plates consist of a number of wells, which house the reservoir solution, and 
a ledge where the protein drop is placed. The plate is sealed with either a cover slip or clear tape. Each 
well is a sealed chamber, such that water diffuses from the protein drop to the reservoir solution, 
increasing both the protein and precipitant concentrations in the protein drop. If the conditions are 
correct, the protein will precipitate and form protein crystals.  
 
 
6.2.2 The unit cell of crystals. 
 
Crystals contain unit cells. The unit cell is the building block of a crystal and is 
repeated infinitely in three dimensions. The molecules, within and between unit cells, 
are held together by hydrogen bonds, usually via water molecules. The unit cell is 
defined by the vectors a, b, c, which form the cell edges (measured in angstroms), and 
cover slip or 
tape sealing 
the well 
reservoir 
solution 
protein drop 
H2O 
 142 
 
the angles between them: α is the angle between b and c, β is the angle between a and 
c, and  is the angle between a and b (see cell parameters in Table 6.1). 
 
6.3 Crystallisation trials of R. rubrum dIII.R165A. 
 
First attempts at the crystallisation of the purified and concentrated isolated R. rubrum 
dIII.R165A were set up using commercial crystallisation screens (JCSG-plus
TM
 by 
Molecular Dimensions Ltd. and Index
TM
 by Hampton Research), sitting drop 
crystallisation plates (MRC crystallisation plate
TM
 by Molecular Dimensions Ltd.) and 
a crystallisation robot (mosquito
®
 by TTP LabTech). This was done in parallel with 
isolated wild-type R. rubrum dIII. No crystals formed of either the wild-type or 
mutant proteins. 
A successful protocol for the crystallisation of wild-type dIII in complex with 
R. rubrum wild-type dI (dI2dIII) is available (Cotton et al. 2001; Mather et al. 2004; 
Bhakta et al. 2007). A second set of crystallisation trials was then set up using the two 
commercial screens above to crystallise dIII.R165A in complex with dI. The protein 
drop contained 300 µM R. rubrum dI, 300 µM R. rubrum dIII.R165A, 50 µM NADH, 
pH 8.0. Crystals were obtained in wells with a 1:1 ratio of protein solution to reservoir 
solution (100 mM imidazole, pH 7.0, 20-26% PEG 6000 (w/v), 100 mM ammonium 
sulphate). The crystals were cryoprotected by soaking in solutions containing 
increasing concentrations of ethylene glycol (5-25% (v/v)). A number of crystals were 
exposed to a home x-ray source (Rigaku MicroMax007HF) and diffracted to ~3.2 Å. 
Data processing using the program XDS (Kabsch 1993) identified the space group of 
a typical crystal (LXH_01) as P21 with unit cell parameters a=73.4 Å, b=119.5 Å, 
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c=96.6 Å, α=90.0˚, β=105.8˚, =90.0˚. The data processing statistics are shown in 
Table 6.2. 
 
resolution 
(Å) 
no. of 
observations 
no. of 
unique 
reflections 
no. of 
reflections 
possible 
completeness Rsym
 
I/SIGMA Rmeas 
9.43 2933 955 1081 88.3% 2.0% 46.92 2.4% 
6.74 5549 1740 1821 95.6% 3.0% 31.02 3.6% 
5.52 7185 2280 2359 96.7% 5.8% 18.27 6.9% 
4.79 8446 2673 2747 97.3% 6.8% 15.63 8.2% 
4.29 9537 3044 3106 98.0% 7.1% 14.94 8.5% 
3.92 10566 3392 3450 98.3% 11.0% 9.94 13.3% 
3.63 11333 3655 3711 98.5% 15.8% 7.34 19.0% 
3.39 12206 3962 4004 99.0% 23.3% 5.13 28.2% 
3.20 12727 4162 4243 98.1% 40.3% 3.02 48.9% 
total 80482 25863 26522 97.5% 9.4% 12.42 11.3% 
 
Table 6.2 Data processing statistics for crystal LXH_01. 
Rsym = Σ|Iav-In|/ Σ Iav where In is the intensity of the n
th reflection and Iav is the average intensity. 
 
 
The unit cell parameters are similar to those of either a dI dimer (PDB ID 1F8G) or of 
a dI2dIII complex (PDB ID 2OO5) (see Table 6.1); therefore it is not possible to 
predict, from the cell parameters alone, whether the crystal contains dIII.R165A or 
whether it contains only dI. Molecular replacement using PHASER (McCoy et al. 
2007) was done with the known structure of the wild-type dI dimer (the dI portion 
taken from PDB ID 2OO5) as a search model. The statistics for the molecular 
replacement solution are shown in Table 6.3. 
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search 
molecule 
α β γ Tx Ty Tz RFZ TFZ 
1st dI dimer 
 
50.105 56.394 318.863 0.02808 0.00162 0.04574 18.5 14.3 
2nd dI dimer 77.470 40.079 117.611 0.45045 -0.37611 0.46475 20.5 37.3 
 
Table 6.3 Molecular replacement statistics for crystal LXH_01. 
The rotation function is presented as the Eulerian angles α, β and γ. The translation function is 
expressed as the fractional unit cell coordinates Tx, Ty and Tz. The rotation function z-score and the 
translation function z-score are represented as RFZ and TFZ, respectively. 
 
 
 The molecular replacement solution was subjected to partial rigid-body and 
positional refinement using REFMAC5 (Murshudov et al. 1997) resulting in a model 
with two dimers of dI in the asymmetric unit with R/Rfree values of 0.229/0.330. This 
convincing molecular replacement solution showed that there were no intermolecular 
spaces large enough to accommodate a molecule of dIII.R165A. Thus, the crystal 
LXH_01 contained only dimers of dI and not complexes of dI and dIII.R165A. 
In an attempt to incorporate dIII.R165A into the crystals, trials were set up in 
which the protein solution contained a higher concentration of dIII.R165A to 
compensate for a weaker affinity (~2 fold) of dIII.R165A for dI than wild-type dIII 
(see Figure 3.5). Thus, the protein solution contained 300 µM R. rubrum dI, 600 µM 
R. rubrum dIII.R165A and 5 mM NADH at pH 8.0. Plate-like crystals were obtained 
in wells with a 1:1 ratio of protein solution to reservoir solution (100 mM bis-tris 
pH 6.0, 50-200 mM ammonium acetate and 20-30% PEG 4000 (w/v)). The crystals 
were cryoprotected by soaking in solutions containing increasing concentrations of 
ethylene glycol (5-25% (v/v)). A number of crystals were exposed to either the home 
x-ray source, or the x-ray beamline ID14-1 at the European Synchrotron Radiation 
Facility, and diffracted to a maximum resolution of ~4.5 Å. The data collected from a 
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typical crystal (LXH_02) were processed using XDS (Kabsch 1993); the space group 
was identified as P21 with unit cell parameters of a=71.6 Å, b=120.0 Å, c=97.1 Å, 
α=90.0˚, β=108.1˚, =90.0˚. The data processing statistics are shown in Table 6.4.  
 
 
resolution 
(Å) 
no. of 
observations 
no. of 
unique 
reflections 
no. of 
possible 
reflections 
completeness Rsym I/SIGMA Rmeas 
12.74 1369 396 438 90.4% 4.8% 20.91 5.7% 
9.28 2441 658 661 99.5% 5.2% 21.54 6.1% 
7.66 3208 851 857 99.3% 9.4% 13.21 10.9% 
6.66 3676 971 967 100.4% 19.9% 6.54 23.2% 
5.98 4182 1099 1102 99.7% 26.9% 5.10 31.3% 
5.47 4632 1223 1226 99.8% 39.6% 3.52 46.2% 
5.07 5001 1322 1328 99.5% 44.2% 3.17 51.6% 
4.75 5341 1421 1422 99.9% 44.8% 3.08 52.3% 
4.48 5415 1469 1493 98.4% 42.2% 3.20 49.4% 
total 35265 9410 9494 99.1% 21.7% 6.72 25.4% 
 
Table 6.4 Data processing statistics for crystal LXH_02. 
Rsym = Σ|Iav-In|/ Σ Iav where In is the intensity of the n
th reflection and Iav is the average intensity. 
 
 
Again, these cell parameters are similar to those of either a dI dimer (PDB ID 
1F8G) or of a dI2dIII complex (PDB ID 2OO5) (see Table 6.1). Molecular 
replacement was done using the program PHASER (McCoy et al. 2007) and the 
known structure of wild-type dI (the dI portion taken from PDB ID 2OO5), but this 
time with an α-helix removed from the search model. When the x-ray data are of 
lower resolution, one way of confirming that a molecular replacement solution is 
correct, is to remove a fragment of the search model. If the solution is correct, 
difference electron density will show the missing fragment of the search model, 
giving electron density maps that show electron density for the missing fragment. The 
resulting molecular replacement solution for crystal LXH_02 showed electron density 
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for the missing helix (data not shown) confirming that the solution is correct. The 
molecular replacement statistics are shown in Table 6.5. Partial rigid-body refinement 
using REFMAC5 (Murshudov et al. 1997) gave an R/Rfree value of 0.391/0.384 
further confirming that the crystal LXH_02 contained only dI dimers; there were no 
intermolecular spaces large enough to accommodate a molecule of dIII. 
 
search 
molecule 
α β γ Tx Ty Tz RFZ TFZ 
1st dI dimer 
 
49.514 55.797 322.569 0.02623 0.00096 0.05266 14.1 9.1 
2nd dI dimer 260.812 140.374 73.97 0.4360 -0.37684 0.46462 12.9 21.7 
 
Table 6.5 Molecular replacement statistics for crystal LXH_02. 
The rotation function is presented as the angles α, β and γ. The translation function is expressed as the 
fractional unit cell coordinates Tx, Ty and Tz. The rotation function z-score and the translation function 
z-score are represented as RFZ and TFZ, respectively. 
 
 
6.3.1 Preparation of a truncated form of R. rubrum dIII.R165A. 
 
The crystal structures of isolated R. rubrum dIII with NADP
+
 or NADPH bound 
(Sundaresan et al. 2003) were solved using a dIII construct that was 31 amino acids 
shorter at the N-terminal compared to that used in the unsuccessful crystallisation 
trials described above. It was reasoned that the extra amino acids may be disordered 
and disrupt interactions between protein molecules that are needed to form protein 
crystals. Thus, the next logical step was to produce a truncated form of the 
dIII.R165A used previously in this work and set up a third round of crystallisation 
trials. 
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The mutant plasmid pLH3 harbours the gene that encodes the truncated form 
of the dIII.R165A mutant protein from R. rubrum transhydrogenase. For the 
preparation of pLH3, the primers used were supplied by Alta Bioscience and were 
designed with the following sequences: - 
Forward 5’ – CGTGGTGGCATATGTCGGTCAAGGCCGGCAGCGC – 3’  
Reverse 5’ – GCACGGTTCCGGCCTTCCAGACGTCAAGGATGC – 3’ 
                                                
The forward primer incorporates an NdeI restriction site into the 5’ end of the forward 
strand of the dIII.R165A gene. Part of the truncated gene was amplified by the 
polymerase chain reaction (PCR); a diagrammatic summary of the PCR reaction is 
shown in Figure 6.3.  
A mixture (final volume 100 µL) containing approximately 10 ng of the 
template plasmid pLH1 (see Section 2.1.4), 10 µL “10 reaction buffer” (supplied 
with the polymerase), 1 mM dNTP mixture, 0.4 µM of each primer, 1.5 mM MgCl2, 
5% DMSO (v/v) and 8 U BIO-X-ACT Short DNA polymerase (Bioline) was split into 
four tubes each containing 25 µL. The following program was carried out in a Bio-
Rad My Cycler Thermal Cycler: - 
 
 
95˚C   5 minutes                                         
50-70˚C 1 minute                       
95˚C  30 seconds 
50-70˚C 30 seconds                               
70˚C  1 minute 
70˚C  10 minutes       1     
4˚C  Hold 
 
1 
30 
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Figure 6.3 Diagram of the PCR reaction performed to produce a fragment of the gene encoding 
truncated dIII.R165A. 
The plasmid pLH1 harbours the gene that encodes the full-length dIII.R165A. In this diagram, part of 
this plasmid is enlarged showing the NdeI and BamHI restriction sites, between which the dIII.R165A 
gene is housed. Also shown are the primers (red arrows); the forward primer includes an NdeI 
restriction site. The direction of the arrows shows the direction of transcription. Following the PCR 
reaction, the resulting gene fragment and the intact pLH1 plasmid were digested with NdeI and SacI; 
the position of the SacI restriction site is shown. The digested fragment and vector were then ligated to 
produce pLH3. 
 
 
Following the PCR experiment, the samples were analysed on a 0.8% agarose 
gel in parallel with a 1000 bp DNA ladder (Bioline HyperLadder I) (Figure 6.4), and 
BamHI 
SacI 
pLH1 
NdeI 
NdeI 
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the appropriate band was extracted using a Qiagen QIAquick Gel Extraction Kit 
following the manufacturer’s instructions. 
The purified gene fragment (~40 ng) and the pLH1 plasmid were separately 
digested in a final volume of 15 µL by 20 U of the restriction enzyme NdeI (New 
England Biolabs) at 37˚C overnight and then by 20 U of the restriction enzyme SacI 
(New England Biolabs) at 37˚C for 3 hours. The digested gene fragment (insert) was 
analysed on a 2% agarose gel in parallel with a 100 bp DNA ladder (New England 
Biolabs), and the digested plasmid (vector) was analysed on a 0.8% agarose gel using 
a 1000 bp ladder (Bioline HyperLadder I). The appropriate bands were extracted from 
the gels using a Qiagen QIAquick Gel Extraction Kit.  
   
    
 
 
 
 
Figure 6.4 Agarose gel showing the dIII.R165A gene fragment following PCR. 
A PCR experiment was performed to amplify a fragment of the gene encoding full-length dIII.R165A, 
which is harboured in the plasmid pLH1. The samples from the PCR experiment were analysed on a 
0.8% agarose gel containing ethidium bromide (as described in Section 2.1.5). The gel was visualised 
and photographed using a UV illuminator. The gene fragment (~400 bp) resulting from the PCR 
experiment was extracted from the gel, digested with restriction enzymes and used as the insert for the 
subsequent ligation step with digested pLH1. This ligation experiment resulted in the production of the 
plasmid pLH3, which harbours the gene encoding truncated dIII.R165A. 
dIII.R165A gene 
fragment 
400 bp  
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For the ligation of the insert and the vector, 50 ng of the vector and 6 ng of the 
insert were mixed with 1 µl “10 T4 DNA ligase buffer” (supplied with the T4 DNA 
ligase) to achieve a final volume of 9 µL. The mixture was incubated for 2 minutes at 
42˚C before adding 1 µl T4 DNA ligase (Bioline). The mixture was incubated at 16˚C 
for 16 hours in a Bio-Rad My Cycler Thermal Cycler. To deactivate the ligase, the 
mixture was incubated at 65˚C for 10 minutes. The resulting plasmid was used to 
transform E. coli BL21(DE3) competent cells as described in Section 2.1.6.  
The fidelity of pLH3 was confirmed by sequencing by the Functional 
Genomics Laboratory at The University of Birmingham.  
The growth of the cells and the over-expression (at either 25˚C or 37˚C) of the 
truncated dIII.R165A were performed in parallel with the full-length dIII.R165A as 
described for pNIC2 in Section 2.1.7. After the cells were harvested and broken by 
sonication, they were subjected to a high-speed centrifugation (150,000 g). Following 
this high-speed centrifugation, the resulting supernatants and pellets were analysed by 
SDS PAGE (Figure 6.5). Recall from Section 2.1.7, that the full-length dIII.R165A 
forms inclusion bodies and is mostly present in the pellet after the high-speed 
centrifugation. Thus, the full-length protein was visible on the SDS PAGE gel in the 
pellet samples, showing that it had formed inclusion bodies when expressed at both 
temperatures. However, the truncated protein was not visible on the SDS PAGE gel in 
either the supernatants or the pellets after expression at either 25˚C or 37˚C.  
Due to time restraints, I was unable to express pLH3 to sufficient levels to 
produce a purified truncated form of dIII.R165A. Crystallisation trials of this protein 
were therefore not possible. 
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Figure 6.5 SDS PAGE gel showing the lack of expression of the truncated dIII.R165A compared 
with the full-length dIII.R165A. 
After the growth and expression of the full-length dIII.R165A or the truncated dIII.R165A at either 
25˚C or 37˚C, the cells were broken by sonication and subjected to a high-speed centrifugation 
(described in Section 2.1.7). The resulting pellets and supernatants were analysed on a 12% SDS PAGE 
gel, which was stained with PAGE blue. The full-length dIII.R165A is encoded by the gene harboured 
in the plasmid pLH1, and the truncated dIII.R165A is encoded by the gene harboured in the plasmid 
pLH3. The plasmid expressed, the temperature of the expression and the fraction following the high-
speed spin analysed by SDS PAGE in the numbered lanes were: 1) pLH1, 37˚C, pellet; 2) pLH1, 25˚C, 
pellet; 3) pLH3, 37˚C, pellet; 4) pLH3, 25˚C, pellet; 5) pLH1, 37˚C, supernatant; 6) pLH1, 25˚C, 
supernatant; 7) pLH3, 37˚C, supernatant; 8) pLH3, 25˚C, supernatant; M = protein marker (GE 
Healthcare low molecular weight marker). 
 
6.4 Future directions of the project. 
 
All published crystal structures of the dIII component are of the protein in its 
occluded conformation with bound nucleotide. Nucleotide binding to and release from 
dIII is thought to be central in the coupling mechanism between hydride transfer and 
proton translocation. Thus, a crystal structure of dIII in either its open conformation or 
full-length 
dIII.R165A 
66 KDa 
30 KDa 
20.1 KDa 
45 KDa 
14.4 KDa 
M 1 2 3 4 5 6 7 8 
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in its apo-form would be beneficial in understanding the role of loop E in the coupling 
mechanism. For this reason, if more time was available for this project, I would 
continue with the crystallisation trials of dIII.R165A. From the results described in 
this thesis it would be expected that dIII.R165A would crystallise in an occluded 
conformation. However, since dIII.R165A has a decreased affinity for NADP(H) 
compared to wild-type dIII, it is thought possible to crystallise the protein in its apo-
form.  
 To this end, the expression of the truncated form of dIII.R165A would need to 
be explored in an attempt to produce a concentrated, pure preparation of the protein 
that would be suitable for crystallisation trials. The full-length dIII.R165A was 
expressed in large quantities in inclusion bodies (see Section 3.1.4). Thus, the 
unsuccessful expression of the truncated form of dIII.R165A is thought to be due to 
the “missing” part of the N-terminal and not the R165A mutation. Examples of 
parameters to vary in the expression of the protein are temperature, isopropyl 
thiogalactoside concentration and incubation period. If the expression of the truncated 
dIII.R165A was still not successful, the construct of the plasmid containing the gene 
would need to be reviewed. 
 The successful crystallisation of the dIII component from R. rubrum 
(Sundaresan et al. 2003) was achieved using a construct of wild-type dIII that was 31 
amino acids shorter at the N-terminal compared to the full-length dIII used in this 
project. In the work of Sundaresan et al., the dIII component contained a poly-
histidine tag sequence at the N-terminal. This was not cleaved before crystallisation. 
Thus, the gene encoding the truncated form of dIII.R165A (described in Section 
6.3.1) could be inserted into a pET16b vector, which would incorporate an identical 
poly-histidine tag sequence onto the N-terminal of dIII.R165A as was used by 
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Sundaresan et al. The protocol for the expression of the truncated wild-type dIII 
(Sundaresan et al. 2003) could then be adopted for the truncated dIII.R165A. If the 
expression was successful, the protein could be purified by affinity chromatography 
using a medium containing nickel. Crystallisation trials could then be set up to 
crystallise the truncated dIII.R165A. 
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